{"matching_results": 31005, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1518, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1175}, {"key": "negative", "matching_results": 331}, {"key": "neutral", "matching_results": 12}]}]}, {"key": "watchlistnews.com", "matching_results": 747, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 559}, {"key": "negative", "matching_results": 186}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "dailypolitical.com", "matching_results": 703, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 580}, {"key": "negative", "matching_results": 122}]}]}, {"key": "tickerreport.com", "matching_results": 690, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 597}, {"key": "negative", "matching_results": 93}]}]}, {"key": "thelincolnianonline.com", "matching_results": 676, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 505}, {"key": "negative", "matching_results": 170}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 632, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 487}, {"key": "negative", "matching_results": 145}]}]}, {"key": "theolympiareport.com", "matching_results": 622, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 458}, {"key": "negative", "matching_results": 163}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "wkrb13.com", "matching_results": 611, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 490}, {"key": "negative", "matching_results": 121}]}]}, {"key": "freelancer.com.co", "matching_results": 605, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 567}, {"key": "negative", "matching_results": 37}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "marketscreener.com", "matching_results": 407, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 279}, {"key": "negative", "matching_results": 126}, {"key": "neutral", "matching_results": 2}]}]}]}], "results": [{"id": "r9SyFsn0hSSyODAPpOZMyBZtjKDR_w5ayw5ENNbG050TeLcp7gqi3NqgScgf-FoZ", "result_metadata": {"score": 37.72705}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.905149, "label": "/finance/investing"}, {"score": 0.905149, "label": "/finance/investing/beginning investing"}, {"score": 0.720287, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "managerOf", "sentence": "Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire", "score": 0.536213, "arguments": [{"text": "Investor", "location": [24, 32], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "firms", "location": [42, 47], "entities": [{"type": "Organization", "text": "firms", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999665, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.994254, "count": 1}, {"text": "Investor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.914592, "count": 1}, {"text": "advisory firms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.667014, "count": 1}, {"text": "deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.596218, "count": 1}, {"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.579672, "count": 1}]}, "crawl_date": "2018-11-20T19:52:56Z", "url": "http://www.4-traders.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-Investor-advisory-firms-back-Takeda-s-62-billion-deal-for-Shire-27638752/", "host": "4-traders.com", "text": "(Reporting by Ben Martin, editing by Louise Heavens) By Ben Martin Stocks treated in this article : Takeda Pharmaceutical Co Ltd , Shire", "main_image_url": "https://img.zonebourse.com/reuters/2018-11-20T140433Z_2_LYNXNPEEAJ0WF_RTROPTP_3_TAKEDA-PHARMA-SHIRE.JPG", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T00:00:00+01:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0.183675, "label": "positive"}, "text": "Takeda", "relevance": 0.928414, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.608995, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.523028, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "London-listed Shire", "relevance": 0.521036, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Institutional Shareholder Services", "relevance": 0.417139, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glass Lewis", "relevance": 0.397167, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "drugmaker Shire", "relevance": 0.329207, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.47335, "label": "positive"}, "text": "Ben Martin", "relevance": 0.32581, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ISS", "relevance": 0.272228, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.26617, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.236949, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.224544, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0.426036, "label": "positive"}, "text": "Louise Heavens", "relevance": 0.185822, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.170487, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "48.20 billion pounds", "relevance": 0.170487, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.170487, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.4 percent", "relevance": 0.170487, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.6 percent", "relevance": 0.170487, "type": "Quantity"}], "sentiment": {"document": {"score": 0.39118, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Two shareholder advisory firms", "keywords": [{"text": "shareholder advisory firms"}]}, "sentence": "LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion (48.20 billion pounds) takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "object": {"text": "Takeda Pharmaceutical's $62 billion (48.20 billion pounds) takeover offer for drugmaker Shire", "keywords": [{"text": "Takeda Pharmaceutical"}, {"text": "takeover offer"}, {"text": "drugmaker Shire"}, {"text": "pounds"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "drugmaker Shire"}, {"type": "Quantity", "text": "48.20 billion pounds"}, {"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "back", "tense": "past"}, "text": "have backed", "normalized": "have back"}}, {"subject": {"text": "investors", "keywords": [{"text": "investors"}]}, "sentence": "LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion (48.20 billion pounds) takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "object": {"text": "to block the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "hope", "tense": "present"}, "text": "hope", "normalized": "hope"}}, {"subject": {"text": "Glass Lewis both", "keywords": [{"text": "Glass Lewis"}], "entities": [{"type": "Company", "text": "Glass Lewis"}]}, "sentence": " Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "object": {"text": "that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support", "keywords": [{"text": "Takeda vote"}, {"text": "two-thirds support"}, {"text": "pharmaceuticals company"}, {"text": "investor meeting"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "recommend", "tense": "past"}, "text": "recommended", "normalized": "recommend"}}, {"subject": {"text": "the pharmaceuticals company", "keywords": [{"text": "pharmaceuticals company"}]}, "sentence": " Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "object": {"text": "Dec. 5", "keywords": [{"text": "Dec."}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs to secure", "normalized": "need to secure"}}, {"subject": {"text": "It"}, "sentence": " It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.", "object": {"text": "a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "retail investors"}, {"text": "small group"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "former employees to derail the takeover of London-listed Shire", "keywords": [{"text": "London-listed Shire"}, {"text": "takeover"}, {"text": "employees"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.", "object": {"text": "a small group of about 130 retail investors", "keywords": [{"text": "retail investors"}, {"text": "small group"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "object": {"text": "the significant debt", "keywords": [{"text": "significant debt"}]}, "action": {"verb": {"text": "take", "tense": "present"}, "text": "is taking", "normalized": "be take"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "complete", "tense": "future"}, "text": "to complete", "normalized": "to complete"}}, {"subject": {"text": "by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company", "keywords": [{"text": "largest-ever overseas acquisition"}, {"text": "Japanese company"}, {"text": "scale"}]}, "sentence": " Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "object": {"text": "the risks", "keywords": [{"text": "risks"}]}, "action": {"verb": {"text": "pose", "tense": "past"}, "text": "posed", "normalized": "pose"}}, {"subject": {"text": "the largest-ever overseas acquisition", "keywords": [{"text": "largest-ever overseas acquisition"}]}, "sentence": " Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "object": {"text": "by a Japanese company", "keywords": [{"text": "Japanese company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "ISS and Glass Lewis", "keywords": [{"text": "Glass Lewis"}, {"text": "ISS"}], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, "sentence": " But ISS and Glass Lewis said that investor support for the cash-and-shares transaction was warranted.", "object": {"text": "that investor support for the cash-and-shares transaction was warranted", "keywords": [{"text": "cash-and-shares transaction"}, {"text": "investor support"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "the company", "keywords": [{"text": "company"}]}, "action": {"verb": {"text": "diversify", "tense": "present"}, "text": "diversifies", "normalized": "diversify"}}, {"subject": {"text": "The deal diversifies the company", "keywords": [{"text": "deal"}, {"text": "company"}], "entities": []}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "strong cash flow generation", "keywords": [{"text": "strong cash flow"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "strong cash flow generation", "keywords": [{"text": "strong cash flow"}], "entities": []}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "with divestments", "keywords": [{"text": "divestments"}]}, "action": {"verb": {"text": "combine", "tense": "past"}, "text": "combined", "normalized": "combine"}}, {"subject": {"text": "strong cash flow generation", "keywords": [{"text": "strong cash flow"}], "entities": []}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "for relatively rapid deleveraging", "keywords": [{"text": "relatively rapid deleveraging"}]}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allows", "normalized": "allow"}}, {"subject": {"text": "top of the range leverage", "keywords": [{"text": "leverage"}, {"text": "range"}]}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "action": {"verb": {"text": "maintain", "tense": "present"}, "text": "maintaining", "normalized": "maintain"}}, {"subject": {"text": "ISS", "keywords": [{"text": "ISS"}], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, "sentence": " \"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "object": {"text": "The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term", "keywords": [{"text": "relatively rapid deleveraging"}, {"text": "strong cash flow"}, {"text": "range leverage"}, {"text": "geographies"}], "entities": []}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Glass Lewis", "keywords": [{"text": "Glass Lewis"}], "entities": [{"type": "Company", "text": "Glass Lewis"}]}, "sentence": " Glass Lewis said in a separate report that \"the strategic case is compelling for Takeda.\"", "object": {"text": "that \"the strategic case is compelling for Takeda", "keywords": [{"text": "Takeda"}, {"text": "strategic case"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "a separate report that \"the strategic case", "keywords": [{"text": "separate report"}, {"text": "strategic case"}]}, "sentence": " Glass Lewis said in a separate report that \"the strategic case is compelling for Takeda.\"", "object": {"text": "compelling for Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Shares in Shire", "keywords": [{"text": "Shire"}, {"text": "Shares"}], "entities": [{"type": "Location", "text": "London-listed Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " Shares in Shire were up 0.4 percent in London while Takeda closed up 0.6 percent in Tokyo.", "object": {"text": "0.4 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "0.4 percent"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Shares in Shire were up 0.4 percent in London while Takeda closed up 0.6 percent in Tokyo.", "action": {"verb": {"text": "close", "tense": "past"}, "text": "closed", "normalized": "close"}}, {"subject": {"text": "by Ben Martin", "keywords": [{"text": "Ben Martin"}], "entities": [{"type": "Person", "text": "Ben Martin"}]}, "sentence": " (Reporting by Ben Martin, editing by Louise Heavens)", "object": {"text": "editing by Louise Heavens)", "keywords": [{"text": "Louise Heavens"}, {"text": "editing"}], "entities": [{"type": "Person", "text": "Louise Heavens"}]}, "action": {"verb": {"text": "Reporting", "tense": "present"}, "text": "Reporting", "normalized": "Reporting"}}, {"subject": {"text": "Stocks", "keywords": [{"text": "Stocks"}]}, "sentence": " Stocks treated in this article : Takeda Pharmaceutical Co Ltd , Shire", "object": {"text": "in this article", "keywords": [{"text": "article"}]}, "action": {"verb": {"text": "treat", "tense": "past"}, "text": "treated", "normalized": "treat"}}], "concepts": [{"text": "Stock", "relevance": 0.980322, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock market", "relevance": 0.72185, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Share", "relevance": 0.703124, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "Debt", "relevance": 0.702462, "dbpedia_resource": "http://dbpedia.org/resource/Debt"}, {"text": "Derivative", "relevance": 0.680523, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Corporate finance", "relevance": 0.676781, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "Leverage", "relevance": 0.654587, "dbpedia_resource": "http://dbpedia.org/resource/Leverage_(finance)"}, {"text": "Shareholder", "relevance": 0.636952, "dbpedia_resource": "http://dbpedia.org/resource/Shareholder"}, {"text": "Mergers and acquisitions", "relevance": 0.556638, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Finance", "relevance": 0.539247, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.520828, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pharmaceutical drug", "relevance": 0.518048, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Takeover", "relevance": 0.506783, "dbpedia_resource": "http://dbpedia.org/resource/Takeover"}, {"text": "Investor", "relevance": 0.505167, "dbpedia_resource": "http://dbpedia.org/resource/Investor"}, {"text": "Stakeholder", "relevance": 0.492738, "dbpedia_resource": "http://dbpedia.org/resource/Stakeholder_(corporate)"}], "categories": [{"score": 0.92696, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.914409, "label": "/finance/investing"}, {"score": 0.914409, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "hasAttribute", "sentence": "LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion (48.20 billion pounds) takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "score": 0.593121, "arguments": [{"text": "Takeda Pharmaceutical", "location": [62, 83], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$62 billion", "location": [86, 97], "entities": [{"type": "Money", "text": "$62 billion"}]}]}, {"type": "basedIn", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.817805, "arguments": [{"text": "Takeda", "location": [339, 345], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [331, 336], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.592184, "arguments": [{"text": "Takeda", "location": [339, 345], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [359, 370], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.497807, "arguments": [{"text": "Dec. 5", "location": [408, 414], "entities": [{"type": "Date", "text": "Dec. 5"}]}, {"text": "acquisition", "location": [359, 370], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.493241, "arguments": [{"text": "investor", "location": [377, 385], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "meeting", "location": [386, 393], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "timeOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.94429, "arguments": [{"text": "Dec. 5", "location": [408, 414], "entities": [{"type": "Date", "text": "Dec. 5"}]}, {"text": "meeting", "location": [386, 393], "entities": [{"type": "EventMeeting", "text": "meeting"}]}]}, {"type": "agentOf", "sentence": "It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.", "score": 0.838826, "arguments": [{"text": "Shire", "location": [660, 665], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "takeover", "location": [634, 642], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "agentOf", "sentence": "Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "score": 0.473375, "arguments": [{"text": "Takeda", "location": [730, 736], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [811, 822], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "score": 0.561392, "arguments": [{"text": "company", "location": [885, 892], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, {"text": "acquisition", "location": [859, 870], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "Those shareholders are worried about the significant debt that Takeda is taking on to complete the deal and the risks posed by the scale of the acquisition, which is the largest-ever overseas acquisition by a Japanese company.", "score": 0.991265, "arguments": [{"text": "company", "location": [885, 892], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, {"text": "Japanese", "location": [876, 884], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "But ISS and Glass Lewis said that investor support for the cash-and-shares transaction was warranted.", "score": 0.998091, "arguments": [{"text": "Glass Lewis", "location": [906, 917], "entities": [{"type": "Person", "text": "Glass Lewis"}]}, {"text": "said", "location": [918, 922], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Glass Lewis said in a separate report that \"the strategic case is compelling for Takeda.", "score": 0.995972, "arguments": [{"text": "Glass Lewis", "location": [1281, 1292], "entities": [{"type": "Person", "text": "Glass Lewis"}]}, {"text": "said", "location": [1293, 1297], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "hasAttribute", "sentence": "LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion (48.20 billion pounds) takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "score": 0.630283, "arguments": [{"text": "Takeda Pharmaceutical", "location": [62, 83], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "48.20 billion pounds", "location": [99, 119], "entities": [{"type": "Money", "text": "48.20 billion pounds"}]}]}, {"type": "affectedBy", "sentence": "\"The deal diversifies the company in terms of products and geographies, and provides strong cash flow generation that, combined with divestments, allows for relatively rapid deleveraging, despite maintaining top of the range leverage in the mid-term,\" ISS said in a report to clients.", "score": 0.512031, "arguments": [{"text": "clients", "location": [1272, 1279], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "said", "location": [1252, 1256], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "basedIn", "sentence": "\" Shares in Shire were up 0.4 percent in London while Takeda closed up 0.6 percent in Tokyo.", "score": 0.682993, "arguments": [{"text": "Takeda", "location": [1423, 1429], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "London", "location": [1410, 1416], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "agentOf", "sentence": "(Reporting by Ben Martin, editing by Louise Heavens) By Ben Martin Stocks treated in this article : Takeda Pharmaceutical Co Ltd , Shire", "score": 0.756554, "arguments": [{"text": "Ben Martin", "location": [1476, 1486], "entities": [{"type": "Person", "text": "Ben Martin\nStocks"}]}, {"text": "Reporting", "location": [1463, 1472], "entities": [{"type": "EventCommunication", "text": "Reporting"}]}]}, {"type": "agentOf", "sentence": "(Reporting by Ben Martin, editing by Louise Heavens) By Ben Martin Stocks treated in this article : Takeda Pharmaceutical Co Ltd , Shire", "score": 0.551914, "arguments": [{"text": "Louise Heavens", "location": [1499, 1513], "entities": [{"type": "Person", "text": "Louise Heavens"}]}, {"text": "Reporting", "location": [1463, 1472], "entities": [{"type": "EventCommunication", "text": "Reporting"}]}]}, {"type": "partOfMany", "sentence": "LONDON (Reuters) - Two shareholder advisory firms have backed Takeda Pharmaceutical's $62 billion (48.20 billion pounds) takeover offer for drugmaker Shire , dealing a blow to a group of investors who hope to block the deal.", "score": 0.41131, "arguments": [{"text": "group", "location": [178, 183], "entities": [{"type": "Person", "text": "group"}]}, {"text": "investors", "location": [187, 196], "entities": [{"type": "Person", "text": "investors"}]}]}, {"type": "partOfMany", "sentence": "It is a boost for Takeda, which has faced a campaign by a small group of about 130 retail investors that includes former employees to derail the takeover of London-listed Shire.", "score": 0.425426, "arguments": [{"text": "group", "location": [553, 558], "entities": [{"type": "Person", "text": "group"}]}, {"text": "investors", "location": [579, 588], "entities": [{"type": "Person", "text": "investors"}]}]}, {"type": "locatedAt", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.643466, "arguments": [{"text": "Institutional Shareholder Services", "location": [225, 259], "entities": [{"type": "Organization", "text": "Institutional Shareholder Services"}]}, {"text": "ISS", "location": [261, 264], "entities": [{"type": "Facility", "text": "ISS"}]}]}, {"type": "agentOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.919245, "arguments": [{"text": "Glass Lewis", "location": [270, 281], "entities": [{"type": "Person", "text": "Glass Lewis"}]}, {"text": "recommended", "location": [287, 298], "entities": [{"type": "EventCommunication", "text": "recommended"}]}]}, {"type": "timeOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.975255, "arguments": [{"text": "Tuesday", "location": [302, 309], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "recommended", "location": [287, 298], "entities": [{"type": "EventCommunication", "text": "recommended"}]}]}, {"type": "affectedBy", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.483489, "arguments": [{"text": "shareholders", "location": [315, 327], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "recommended", "location": [287, 298], "entities": [{"type": "EventCommunication", "text": "recommended"}]}]}, {"type": "partOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.491164, "arguments": [{"text": "shareholders", "location": [315, 327], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda", "location": [339, 345], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Institutional Shareholder Services (ISS) and Glass Lewis both recommended on Tuesday that shareholders in Japan's Takeda vote for the acquisition at an investor meeting scheduled for Dec. 5, at which the pharmaceuticals company needs to secure two-thirds support.", "score": 0.473969, "arguments": [{"text": "shareholders", "location": [315, 327], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [359, 370], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Glass Lewis", "sentiment": {"score": 0.574175, "label": "positive"}, "relevance": 0.692497, "count": 3}, {"text": "Institutional Shareholder Services", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.683985, "count": 1}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.784099, "label": "negative"}, "relevance": 0.682241, "count": 1}, {"text": "shareholder", "sentiment": {"score": -0.784099, "label": "negative"}, "relevance": 0.672768, "count": 1}, {"text": "shareholders", "sentiment": {"score": 0.456584, "mixed": "1", "label": "positive"}, "relevance": 0.617863, "count": 2}, {"text": "group of investors", "sentiment": {"score": -0.784099, "label": "negative"}, "relevance": 0.613388, "count": 1}, {"text": "ISS", "sentiment": {"score": 0.57217, "label": "positive"}, "relevance": 0.606403, "count": 3}, {"text": "LONDON", "sentiment": {"score": -0.784099, "label": "negative"}, "relevance": 0.601051, "count": 1}, {"text": "deal", "sentiment": {"score": -0.318581, "mixed": "1", "label": "negative"}, "relevance": 0.594692, "count": 3}, {"text": "retail investors", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.58807, "count": 1}, {"text": "Takeda", "sentiment": {"score": -0.249179, "mixed": "1", "label": "negative"}, "relevance": 0.584694, "count": 4}, {"text": "small group", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.581534, "count": 1}, {"text": "strong cash flow generation", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.575715, "count": 1}, {"text": "terms of products", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.568975, "count": 1}, {"text": "London", "sentiment": {"score": -0.46681, "label": "negative"}, "relevance": 0.567886, "count": 1}, {"text": "term", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.566051, "count": 1}, {"text": "Japan's Takeda vote", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.561237, "count": 1}, {"text": "top of the range leverage", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.56013, "count": 1}, {"text": "Japanese company", "sentiment": {"score": 0.243367, "mixed": "1", "label": "positive"}, "relevance": 0.555768, "count": 1}, {"text": "cash", "sentiment": {"score": 0.373244, "label": "positive"}, "relevance": 0.555648, "count": 1}, {"text": "Shire", "sentiment": {"score": 0.306305, "mixed": "1", "label": "positive"}, "relevance": 0.553486, "count": 3}, {"text": "report", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.549053, "count": 1}, {"text": "Reuters", "sentiment": {"score": -0.784099, "label": "negative"}, "relevance": 0.547762, "count": 1}, {"text": "acquisition", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.546634, "count": 1}, {"text": "boost", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.542393, "count": 1}, {"text": "geographies", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.540084, "count": 1}, {"text": "rapid deleveraging", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.537332, "count": 1}, {"text": "drugmaker Shire", "sentiment": {"score": -0.784099, "label": "negative"}, "relevance": 0.536286, "count": 1}, {"text": "Shares", "sentiment": {"score": -0.46681, "label": "negative"}, "relevance": 0.535721, "count": 1}, {"text": "company", "sentiment": {"score": 0.583199, "label": "positive"}, "relevance": 0.533969, "count": 1}, {"text": "campaign", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.531258, "count": 1}, {"text": "pharmaceuticals company", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.529079, "count": 1}, {"text": "takeover of London", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.528152, "count": 1}, {"text": "pounds", "sentiment": {"score": -0.784099, "label": "negative"}, "relevance": 0.527785, "count": 1}, {"text": "takeover offer", "sentiment": {"score": -0.784099, "label": "negative"}, "relevance": 0.526374, "count": 1}, {"text": "risks", "sentiment": {"score": -0.372454, "label": "negative"}, "relevance": 0.524556, "count": 1}, {"text": "article", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520349, "count": 1}, {"text": "former employees", "sentiment": {"score": 0.78421, "label": "positive"}, "relevance": 0.51684, "count": 1}, {"text": "investor meeting", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.513419, "count": 1}, {"text": "clients", "sentiment": {"score": 0.589343, "label": "positive"}, "relevance": 0.507192, "count": 1}, {"text": "Tokyo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507192, "count": 1}, {"text": "significant debt", "sentiment": {"score": -0.372454, "label": "negative"}, "relevance": 0.505952, "count": 1}, {"text": "advisory firms", "sentiment": {"score": -0.784099, "label": "negative"}, "relevance": 0.490732, "count": 1}, {"text": "shares transaction", "sentiment": {"score": 0.373244, "label": "positive"}, "relevance": 0.488798, "count": 1}, {"text": "separate report", "sentiment": {"score": 0.589343, "label": "positive"}, "relevance": 0.480636, "count": 1}, {"text": "scale of the acquisition", "sentiment": {"score": -0.372454, "label": "negative"}, "relevance": 0.479292, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.475313, "count": 1}, {"text": "two-thirds support", "sentiment": {"score": 0.726087, "label": "positive"}, "relevance": 0.467211, "count": 1}, {"text": "Ben Martin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.465633, "count": 1}, {"text": "investor support", "sentiment": {"score": 0.373244, "label": "positive"}, "relevance": 0.464242, "count": 1}]}, "extracted_metadata": {"sha1": "fd9b3bb2695a8094bb1482ae4405285469e534d9", "filename": "1542743576160.zip-c431b5861cf4a81d083f5e96350eef57.xml", "file_type": "json"}, "title": "Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire", "forum_title": "Markets : News, Companies, New Contracts - Marketscreener.com"}, {"id": "8Ptp7Um0Wjn9tnSjgt_LyrHgbMpJkJMh2SvEdLKJDLPLTnQCA_w77vevPUs1d5C6", "result_metadata": {"score": 37.494576}, "author": "Bloomberg News", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.747573, "label": "positive"}, "text": "London", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["City"]}}], "sentiment": {"document": {"score": 0.816948, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Health care", "relevance": 0.932431, "dbpedia_resource": "http://dbpedia.org/resource/Health_care"}, {"text": "Health", "relevance": 0.615825, "dbpedia_resource": "http://dbpedia.org/resource/Health"}], "categories": [{"score": 0.999884, "label": "/finance/investing/stocks"}, {"score": 0.996807, "label": "/real estate/buying and selling homes"}], "relations": [{"type": "residesIn", "sentence": "Health Care Stocks Dwindle in London as Buyers Swoop on Bargains", "score": 0.454081, "arguments": [{"text": "Buyers", "location": [40, 46], "entities": [{"type": "Person", "text": "Buyers"}]}, {"text": "London", "location": [30, 36], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}], "keywords": [{"text": "Health Care Stocks Dwindle", "sentiment": {"score": 0.816948, "label": "positive"}, "relevance": 0.999461, "count": 1}, {"text": "London", "sentiment": {"score": 0.816948, "label": "positive"}, "relevance": 0.797087, "count": 1}, {"text": "Bargains", "sentiment": {"score": 0.816948, "label": "positive"}, "relevance": 0.682989, "count": 1}, {"text": "Buyers Swoop", "sentiment": {"score": 0.816948, "label": "positive"}, "relevance": 0.219244, "count": 1}]}, "crawl_date": "2018-11-20T21:00:37Z", "url": "https://www.bnn.ca/health-care-stocks-dwindle-in-london-as-buyers-swoop-on-bargains-1.1171055", "host": "bnn.ca", "text": "Ltd.", "main_image_url": "https://www.bnnbloomberg.ca/polopoly_fs/1.1171056!/fileimage/httpImage/image.png_gen/derivatives/landscape_620/bc-health-care-stocks-dwindle-in-london-as-buyers-swoop-on-bargains.png", "country": "CA", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T00:00:00-06:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.628197, "label": "negative"}, "text": "BTG Plc", "relevance": 0.973518, "type": "Company", "disambiguation": {"subtype": [], "name": "BTG", "dbpedia_resource": "http://dbpedia.org/resource/BTG"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biotech Abzena Plc", "relevance": 0.429833, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vernalis Plc", "relevance": 0.420597, "type": "Company", "disambiguation": {"subtype": [], "name": "Vernalis plc", "dbpedia_resource": "http://dbpedia.org/resource/Vernalis_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sinclair Pharma Plc", "relevance": 0.41464, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.403847, "label": "negative"}, "text": "Shire Plc", "relevance": 0.410803, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cambian Group Plc", "relevance": 0.406086, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CareTech Holdings Plc", "relevance": 0.403518, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.394874, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 2, "sentiment": {"score": -0.831904, "label": "negative"}, "text": "Julie Simmonds", "relevance": 0.390029, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Touchstone Innovations Plc", "relevance": 0.389701, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clinigen Group Plc", "relevance": 0.383713, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "IP Group Plc", "relevance": 0.36345, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.32962, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Panmure Gordon", "relevance": 0.293925, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Quantum Pharma Holdings Ltd", "relevance": 0.277269, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bloomberg", "relevance": 0.26776, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Beth Mellor", "relevance": 0.253325, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "John Viljoen", "relevance": 0.234053, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Joe Easton", "relevance": 0.233553, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston Scientific Corp.", "relevance": 0.232489, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.403847, "label": "negative"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.231308, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "reporter", "relevance": 0.22927, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Welsh Carson Anderson", "relevance": 0.228582, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Stowe", "relevance": 0.227123, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "EnglishCivilParish", "City"], "name": "Stowe, Buckinghamshire", "dbpedia_resource": "http://dbpedia.org/resource/Stowe,_Buckinghamshire"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "analyst", "relevance": 0.22544, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.578948, "label": "positive"}, "text": "John Lauerman", "relevance": 0.212127, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Monica Houston-Waesch", "relevance": 0.212007, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Huadong Medicine Co.", "relevance": 0.204202, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ligand Pharmaceuticals Inc.", "relevance": 0.203319, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "18 months", "relevance": 0.203319, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "jeaston7@bloomberg.net", "relevance": 0.203319, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "bmellor@bloomberg.net", "relevance": 0.203319, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "20 percent", "relevance": 0.203319, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "35 percent", "relevance": 0.203319, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12 months", "relevance": 0.203319, "type": "Quantity"}], "sentiment": {"document": {"score": -0.505505, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "The takeover of BTG Plc by Boston Scientific Corp.", "keywords": [{"text": "BTG Plc"}, {"text": "Boston Scientific Corp"}, {"text": "takeover"}], "entities": [{"type": "Company", "text": "BTG Plc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "BTG", "dbpedia_resource": "http://dbpedia.org/resource/BTG"}}, {"type": "Company", "text": "Boston Scientific Corp."}]}, "sentence": "(Bloomberg) -- The takeover of BTG Plc by Boston Scientific Corp. announced Tuesday confirms a clear pattern: U.K. health care companies keep getting gobbled up.", "object": {"text": "a clear pattern: U.K. health care companies keep getting gobbled up", "keywords": [{"text": "clear pattern"}, {"text": "U.K. health care"}, {"text": "companies"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "The takeover of BTG Plc by Boston Scientific Corp. announced Tuesday", "keywords": [{"text": "BTG Plc"}, {"text": "Boston Scientific Corp."}, {"text": "takeover"}, {"text": "Tuesday"}], "entities": [{"type": "Company", "text": "BTG Plc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "BTG", "dbpedia_resource": "http://dbpedia.org/resource/BTG"}}, {"type": "Company", "text": "Boston Scientific Corp."}]}, "sentence": "(Bloomberg) -- The takeover of BTG Plc by Boston Scientific Corp. announced Tuesday confirms a clear pattern: U.K. health care companies keep getting gobbled up.", "object": {"text": "a clear pattern: U.K. health care companies keep getting gobbled up", "keywords": [{"text": "clear pattern"}, {"text": "U.K. health care"}, {"text": "companies"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}]}, "action": {"verb": {"text": "confirm", "tense": "present"}, "text": "confirms", "normalized": "confirm"}}, {"subject": {"text": "The maker of both radiotherapy treatments and snake venom antidotes", "keywords": [{"text": "snake venom antidotes"}, {"text": "radiotherapy treatments"}, {"text": "maker"}]}, "sentence": " The maker of both radiotherapy treatments and snake venom antidotes is the eighth target in the sector to be acquired over the past 18 months, according to broker Panmure Gordon, which says the trend reflects the cheapness of British pharmaceutical stocks.", "object": {"text": "the eighth target in the sector", "keywords": [{"text": "target"}, {"text": "sector"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the eighth target in the sector", "keywords": [{"text": "target"}, {"text": "sector"}]}, "sentence": " The maker of both radiotherapy treatments and snake venom antidotes is the eighth target in the sector to be acquired over the past 18 months, according to broker Panmure Gordon, which says the trend reflects the cheapness of British pharmaceutical stocks.", "action": {"verb": {"text": "acquire", "tense": "past"}, "text": "to be acquired", "normalized": "to be acquire"}}, {"subject": {"text": "The maker of both radiotherapy treatments and snake venom antidotes is the eighth target in the sector to be acquired over the past 18 months", "keywords": [{"text": "snake venom antidotes"}, {"text": "radiotherapy treatments"}, {"text": "target"}, {"text": "sector"}], "entities": [{"type": "Quantity", "text": "18 months"}]}, "sentence": " The maker of both radiotherapy treatments and snake venom antidotes is the eighth target in the sector to be acquired over the past 18 months, according to broker Panmure Gordon, which says the trend reflects the cheapness of British pharmaceutical stocks.", "object": {"text": "to broker Panmure Gordon, which says the trend reflects the cheapness of British pharmaceutical stocks", "keywords": [{"text": "broker Panmure Gordon"}, {"text": "British pharmaceutical stocks"}, {"text": "trend"}, {"text": "cheapness"}], "entities": [{"type": "Person", "text": "Panmure Gordon"}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "broker Panmure Gordon", "keywords": [{"text": "broker Panmure"}, {"text": "Gordon"}], "entities": [{"type": "Person", "text": "Panmure Gordon"}]}, "sentence": " The maker of both radiotherapy treatments and snake venom antidotes is the eighth target in the sector to be acquired over the past 18 months, according to broker Panmure Gordon, which says the trend reflects the cheapness of British pharmaceutical stocks.", "object": {"text": "the trend reflects the cheapness of British pharmaceutical stocks", "keywords": [{"text": "British pharmaceutical stocks"}, {"text": "trend"}, {"text": "cheapness"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "says", "normalized": "say"}}, {"subject": {"text": "the cheapness of British pharmaceutical stocks", "keywords": [{"text": "British pharmaceutical stocks"}, {"text": "cheapness"}]}, "sentence": " The maker of both radiotherapy treatments and snake venom antidotes is the eighth target in the sector to be acquired over the past 18 months, according to broker Panmure Gordon, which says the trend reflects the cheapness of British pharmaceutical stocks.", "object": {"text": "the trend", "keywords": [{"text": "trend"}]}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflects", "normalized": "reflect"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe believe this rush of takeovers of U.K. companies highlights the general undervaluation\u201d in the sector, analyst Julie Simmonds wrote in a note to clients after the BTG announcement sent its stock soaring by as much as 35 percent.", "object": {"text": "this rush of takeovers of U.K. companies highlights the general undervaluation\u201d in the sector", "keywords": [{"text": "takeovers"}, {"text": "U.K. companies"}, {"text": "general undervaluation"}, {"text": "rush"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believe", "normalized": "believe"}}, {"subject": {"text": "analyst Julie Simmonds", "keywords": [{"text": "analyst Julie Simmonds"}], "entities": [{"type": "JobTitle", "text": "analyst"}, {"type": "Person", "text": "Julie Simmonds"}]}, "sentence": " \u201cWe believe this rush of takeovers of U.K. companies highlights the general undervaluation\u201d in the sector, analyst Julie Simmonds wrote in a note to clients after the BTG announcement sent its stock soaring by as much as 35 percent.", "object": {"text": "to clients", "keywords": [{"text": "clients"}]}, "action": {"verb": {"text": "write", "tense": "past"}, "text": "wrote", "normalized": "write"}}, {"subject": {"text": "the BTG announcement", "keywords": [{"text": "BTG announcement"}], "entities": [{"type": "Company", "text": "BTG Plc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "BTG", "dbpedia_resource": "http://dbpedia.org/resource/BTG"}}]}, "sentence": " \u201cWe believe this rush of takeovers of U.K. companies highlights the general undervaluation\u201d in the sector, analyst Julie Simmonds wrote in a note to clients after the BTG announcement sent its stock soaring by as much as 35 percent.", "object": {"text": "its stock", "keywords": [{"text": "stock"}]}, "action": {"verb": {"text": "send", "tense": "past"}, "text": "sent", "normalized": "send"}}, {"subject": {"text": "Simmonds", "keywords": [{"text": "Simmonds"}], "entities": [{"type": "Person", "text": "Julie Simmonds"}]}, "sentence": " Simmonds said that rivals appear to be pursuing companies whose share prices have remained depressed following earnings disappointments.", "object": {"text": "that rivals appear to be pursuing companies whose share prices have remained depressed following earnings disappointments", "keywords": [{"text": "earnings disappointments"}, {"text": "share prices"}, {"text": "companies"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "rivals", "keywords": [{"text": "rivals"}]}, "sentence": " Simmonds said that rivals appear to be pursuing companies whose share prices have remained depressed following earnings disappointments.", "object": {"text": "pursuing companies whose share prices have remained depressed following earnings disappointments", "keywords": [{"text": "earnings disappointments"}, {"text": "share prices"}, {"text": "companies"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "BTG shares", "keywords": [{"text": "BTG shares"}], "entities": [{"type": "Company", "text": "BTG Plc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "BTG", "dbpedia_resource": "http://dbpedia.org/resource/BTG"}}]}, "sentence": " Prior to Tuesday\u2019s announcement, BTG shares had fallen about 20 percent in 12 months as uncertainty over licensing revenue and development delays caused analysts to re-think profit estimates.", "object": {"text": "fallen about 20 percent in 12 months", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "20 percent"}, {"type": "Quantity", "text": "12 months"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "BTG shares", "keywords": [{"text": "BTG shares"}], "entities": [{"type": "Company", "text": "BTG Plc", "disambiguation": {"subtype": ["Organization", "Company"], "name": "BTG", "dbpedia_resource": "http://dbpedia.org/resource/BTG"}}]}, "sentence": " Prior to Tuesday\u2019s announcement, BTG shares had fallen about 20 percent in 12 months as uncertainty over licensing revenue and development delays caused analysts to re-think profit estimates.", "object": {"text": "about 20 percent", "keywords": [{"text": "percent"}], "entities": [{"type": "Quantity", "text": "20 percent"}]}, "action": {"verb": {"text": "fall", "tense": "past"}, "text": "had fallen", "normalized": "have fall"}}, {"subject": {"text": "uncertainty over licensing revenue and development delays", "keywords": [{"text": "licensing revenue"}, {"text": "development delays"}, {"text": "uncertainty"}]}, "sentence": " Prior to Tuesday\u2019s announcement, BTG shares had fallen about 20 percent in 12 months as uncertainty over licensing revenue and development delays caused analysts to re-think profit estimates.", "object": {"text": "analysts to re-think profit estimates", "keywords": [{"text": "re-think profit estimates"}, {"text": "analysts"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "caused", "normalized": "cause"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company, headquartered near London\u2019s Fleet Street, later reassured markets by upgrading its 2019 growth forecast in October, and once again just a week prior to the news it would be acquired.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "headquartered", "normalized": "headquarter"}}, {"subject": {"text": "The company, headquartered near London\u2019s Fleet Street,", "keywords": [{"text": "Fleet Street"}, {"text": "company"}, {"text": "London"}], "entities": [{"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}]}, "sentence": " The company, headquartered near London\u2019s Fleet Street, later reassured markets by upgrading its 2019 growth forecast in October, and once again just a week prior to the news it would be acquired.", "object": {"text": "markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "reassure", "tense": "past"}, "text": "reassured", "normalized": "reassure"}}, {"subject": {"text": "The company, headquartered near London\u2019s Fleet Street", "keywords": [{"text": "Fleet Street"}, {"text": "company"}, {"text": "London"}], "entities": [{"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}]}, "sentence": " The company, headquartered near London\u2019s Fleet Street, later reassured markets by upgrading its 2019 growth forecast in October, and once again just a week prior to the news it would be acquired.", "object": {"text": "its 2019 growth", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "upgrade", "tense": "present"}, "text": "upgrading", "normalized": "upgrade"}}, {"subject": {"text": "it"}, "sentence": " The company, headquartered near London\u2019s Fleet Street, later reassured markets by upgrading its 2019 growth forecast in October, and once again just a week prior to the news it would be acquired.", "object": {"text": "acquired"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " The company, headquartered near London\u2019s Fleet Street, later reassured markets by upgrading its 2019 growth forecast in October, and once again just a week prior to the news it would be acquired.", "action": {"verb": {"text": "acquire", "tense": "future"}, "text": "would be acquired", "normalized": "would be acquire"}}, {"subject": {"text": "the reporter", "keywords": [{"text": "reporter"}], "entities": [{"type": "JobTitle", "text": "reporter"}]}, "sentence": " To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net", "object": {"text": "on this story: Joe Easton in London at jeaston7@bloomberg.net", "keywords": [{"text": "Joe Easton"}, {"text": "story"}, {"text": "London"}, {"text": "jeaston7"}], "entities": [{"type": "Person", "text": "Joe Easton"}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"type": "EmailAddress", "text": "jeaston7@bloomberg.net"}]}, "action": {"verb": {"text": "contact", "tense": "future"}, "text": "To contact", "normalized": "To contact"}}, {"subject": {"text": "Monica Houston-Waesch", "keywords": [{"text": "Monica Houston-Waesch"}], "entities": [{"type": "Person", "text": "Monica Houston-Waesch"}]}, "sentence": " To contact the editors Beth Mellor at bmellor@bloomberg.net, John Viljoen, Monica Houston-Waesch", "object": {"text": "the editors Beth Mellor at bmellor@bloomberg.net", "keywords": [{"text": "editors Beth Mellor"}, {"text": "bmellor"}], "entities": [{"type": "Person", "text": "Beth Mellor"}, {"type": "EmailAddress", "text": "bmellor@bloomberg.net"}]}, "action": {"verb": {"text": "contact", "tense": "future"}, "text": "To contact", "normalized": "To contact"}}], "concepts": [{"text": "Attention-deficit hyperactivity disorder", "relevance": 0.973308, "dbpedia_resource": "http://dbpedia.org/resource/Attention-deficit_hyperactivity_disorder"}, {"text": "Medicine", "relevance": 0.709842, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmacy", "relevance": 0.567488, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmacology", "relevance": 0.536005, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Hyperactivity", "relevance": 0.520215, "dbpedia_resource": "http://dbpedia.org/resource/Hyperactivity"}, {"text": "Attention", "relevance": 0.518223, "dbpedia_resource": "http://dbpedia.org/resource/Attention"}, {"text": "Pharmaceutical drug", "relevance": 0.476168, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "2010s", "relevance": 0.469755, "dbpedia_resource": "http://dbpedia.org/resource/2010s"}, {"text": "Leveraged buyout", "relevance": 0.427614, "dbpedia_resource": "http://dbpedia.org/resource/Leveraged_buyout"}, {"text": "Stock", "relevance": 0.425652, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}], "categories": [{"score": 0.994198, "label": "/health and fitness/disorders/mental disorder/a.d.d."}], "relations": [{"type": "affectedBy", "sentence": "(Bloomberg) -- The takeover of BTG Plc by Boston Scientific Corp. announced Tuesday confirms a clear pattern: U.K. health care companies keep getting gobbled up.", "score": 0.321966, "arguments": [{"text": "BTG Plc", "location": [31, 38], "entities": [{"type": "Organization", "text": "IP Group Plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "takeover", "location": [19, 27], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "affectedBy", "sentence": "\"We believe this rush of takeovers of U.K. companies highlights the general undervaluation\" in the sector, analyst Julie Simmonds wrote in a note to clients after the BTG announcement sent its stock soaring by as much as 35 percent.", "score": 0.590448, "arguments": [{"text": "clients", "location": [568, 575], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "wrote", "location": [549, 554], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "\"We believe this rush of takeovers of U.K. companies highlights the general undervaluation\" in the sector, analyst Julie Simmonds wrote in a note to clients after the BTG announcement sent its stock soaring by as much as 35 percent.", "score": 0.962737, "arguments": [{"text": "BTG", "location": [586, 589], "entities": [{"type": "Organization", "text": "IP Group Plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announcement", "location": [590, 602], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "agentOf", "sentence": "Simmonds said that rivals appear to be pursuing companies whose share prices have remained depressed following earnings disappointments.", "score": 0.988633, "arguments": [{"text": "Simmonds", "location": [652, 660], "entities": [{"type": "Person", "text": "Julie Simmonds"}]}, {"text": "said", "location": [661, 665], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "Prior to Tuesday's announcement, BTG shares had fallen about 20 percent in 12 months as uncertainty over licensing revenue and development delays caused analysts to re-think profit estimates.", "score": 0.829525, "arguments": [{"text": "Tuesday", "location": [798, 805], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "announcement", "location": [808, 820], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "locatedAt", "sentence": "The company, headquartered near London's Fleet Street, later reassured markets by upgrading its 2019 growth forecast in October, and once again just a week prior to the news it would be acquired.", "score": 0.943294, "arguments": [{"text": "Fleet Street", "location": [1022, 1034], "entities": [{"type": "Facility", "text": "Fleet Street"}]}, {"text": "London", "location": [1013, 1019], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "agentOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.691881, "arguments": [{"text": "Biotech Abzena Plc", "location": [1265, 1283], "entities": [{"type": "Organization", "text": "Biotech Abzena Plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "bought", "location": [1284, 1290], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "affectedBy", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.491551, "arguments": [{"text": "private equity firm", "location": [1294, 1313], "entities": [{"type": "Organization", "text": "Welsh Carson Anderson & Stowe LP"}]}, {"text": "bought", "location": [1284, 1290], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "timeOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.806671, "arguments": [{"text": "August 2018", "location": [1348, 1359], "entities": [{"type": "Date", "text": "August 2018"}]}, {"text": "bought", "location": [1284, 1290], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "agentOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.689302, "arguments": [{"text": "Cambian Group Plc", "location": [1411, 1428], "entities": [{"type": "Organization", "text": "Cambian Group Plc"}]}, {"text": "bought", "location": [1429, 1435], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "affectedBy", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.62139, "arguments": [{"text": "CareTech Holdings Plc", "location": [1439, 1460], "entities": [{"type": "Organization", "text": "CareTech Holdings Plc"}]}, {"text": "bought", "location": [1429, 1435], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "partOf", "sentence": "(Bloomberg) -- The takeover of BTG Plc by Boston Scientific Corp. announced Tuesday confirms a clear pattern: U.K. health care companies keep getting gobbled up.", "score": 0.675662, "arguments": [{"text": "BTG Plc", "location": [31, 38], "entities": [{"type": "Organization", "text": "IP Group Plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Boston Scientific Corp.", "location": [42, 65], "entities": [{"type": "Organization", "text": "Boston Scientific Corp.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.897207, "arguments": [{"text": "August 2018", "location": [1462, 1473], "entities": [{"type": "Date", "text": "August 2018"}]}, {"text": "bought", "location": [1429, 1435], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "agentOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.786258, "arguments": [{"text": "Shire Plc", "location": [1527, 1536], "entities": [{"type": "Organization", "text": "Shire Plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "bought", "location": [1537, 1543], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "agentOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.598652, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [1547, 1577], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "bought", "location": [1537, 1543], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "agentOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.649377, "arguments": [{"text": "Quantum Pharma Holdings Ltd", "location": [1626, 1653], "entities": [{"type": "Organization", "text": "Quantum Pharma Holdings Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "bought", "location": [1654, 1660], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "affectedBy", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.508734, "arguments": [{"text": "Clinigen Group Plc", "location": [1664, 1682], "entities": [{"type": "Organization", "text": "Clinigen Group Plc"}]}, {"text": "bought", "location": [1654, 1660], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "timeOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.843589, "arguments": [{"text": "September 2017", "location": [1684, 1698], "entities": [{"type": "Date", "text": "September 2017"}]}, {"text": "bought", "location": [1654, 1660], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "employedBy", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.374919, "arguments": [{"text": "Anti", "location": [1700, 1704], "entities": [{"type": "Person", "text": "Anti"}]}, {"text": "Sinclair Pharma Plc", "location": [1736, 1755], "entities": [{"type": "Organization", "text": "Sinclair Pharma Plc"}]}]}, {"type": "agentOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.668301, "arguments": [{"text": "Sinclair Pharma Plc", "location": [1736, 1755], "entities": [{"type": "Organization", "text": "Sinclair Pharma Plc"}]}, {"text": "bought", "location": [1756, 1762], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "partOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.229751, "arguments": [{"text": "Sinclair Pharma Plc", "location": [1736, 1755], "entities": [{"type": "Organization", "text": "Sinclair Pharma Plc"}]}, {"text": "Huadong Medicine Co.", "location": [1766, 1786], "entities": [{"type": "Organization", "text": "Huadong Medicine Co.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.555993, "arguments": [{"text": "Huadong Medicine Co.", "location": [1766, 1786], "entities": [{"type": "Organization", "text": "Huadong Medicine Co.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "bought", "location": [1756, 1762], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "agentOf", "sentence": "(Bloomberg) -- The takeover of BTG Plc by Boston Scientific Corp. announced Tuesday confirms a clear pattern: U.K. health care companies keep getting gobbled up.", "score": 0.983456, "arguments": [{"text": "Boston Scientific Corp.", "location": [42, 65], "entities": [{"type": "Organization", "text": "Boston Scientific Corp.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [66, 75], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "timeOf", "sentence": "Buyout Spree Here are the other seven U.K. health care takeovers of the past 18 months: Biotech Abzena Plc bought by private equity firm Welsh Carson Anderson & Stowe LP (August 2018) Child specialist education and mental health firm Cambian Group Plc bought by CareTech Holdings Plc (August 2018) Attention deficit hyperactivity disorder drug-maker Shire Plc bought by Takeda Pharmaceutical Co. Ltd. (completion ongoing) Unlicensed medicines-maker Quantum Pharma Holdings Ltd bought by Clinigen Group Plc (September 2017) Anti-ageing cosmetic treatment firm Sinclair Pharma Plc bought by Huadong Medicine Co. (October 2018) Pharmaceutical technology and research firm Touchstone Innovations Plc bought by IP Group Plc (October 2017) Molecular research and drug discovery firm Vernalis Plc bought by Ligand Pharmaceuticals Inc. (October 2018) --With assistance from John Lauerman.", "score": 0.823429, "arguments": [{"text": "October 2018", "location": [1788, 1800], "entities": [{"type": "Date", "text": "October 2018"}]}, {"text": "bought", "location": [1756, 1762], "entities": [{"type": "EventBusiness", "text": "bought"}]}]}, {"type": "locatedAt", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors Beth Mellor at bmellor@bloomberg.net, John Viljoen, Monica Houston-Waesch", "score": 0.419341, "arguments": [{"text": "Joe Easton", "location": [2097, 2107], "entities": [{"type": "Person", "text": "Joe Easton"}]}, {"text": "London", "location": [2111, 2117], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "locatedAt", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors Beth Mellor at bmellor@bloomberg.net, John Viljoen, Monica Houston-Waesch", "score": 0.441099, "arguments": [{"text": "editors", "location": [2159, 2166], "entities": [{"type": "Person", "text": "editors"}]}, {"text": "London", "location": [2111, 2117], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors Beth Mellor at bmellor@bloomberg.net, John Viljoen, Monica Houston-Waesch", "score": 0.955561, "arguments": [{"text": "Beth Mellor", "location": [2167, 2178], "entities": [{"type": "Person", "text": "Beth Mellor"}]}, {"text": "editors", "location": [2159, 2166], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors Beth Mellor at bmellor@bloomberg.net, John Viljoen, Monica Houston-Waesch", "score": 0.809892, "arguments": [{"text": "John Viljoen", "location": [2205, 2217], "entities": [{"type": "Person", "text": "John Viljoen"}]}, {"text": "editors", "location": [2159, 2166], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors Beth Mellor at bmellor@bloomberg.net, John Viljoen, Monica Houston-Waesch", "score": 0.685051, "arguments": [{"text": "Monica Houston", "location": [2219, 2233], "entities": [{"type": "Person", "text": "Monica Houston"}]}, {"text": "editors", "location": [2159, 2166], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "hasAttribute", "sentence": "To contact the reporter on this story: Joe Easton in London at jeaston7@bloomberg.net To contact the editors Beth Mellor at bmellor@bloomberg.net, John Viljoen, Monica Houston-Waesch", "score": 0.935437, "arguments": [{"text": "Beth Mellor", "location": [2167, 2178], "entities": [{"type": "Person", "text": "Beth Mellor"}]}, {"text": "bmellor@bloomberg.net", "location": [2182, 2203], "entities": [{"type": "Age", "text": "bmellor@bloomberg.net"}]}]}, {"type": "timeOf", "sentence": "(Bloomberg) -- The takeover of BTG Plc by Boston Scientific Corp. announced Tuesday confirms a clear pattern: U.K. health care companies keep getting gobbled up.", "score": 0.526992, "arguments": [{"text": "Tuesday", "location": [76, 83], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "announced", "location": [66, 75], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "timeOf", "sentence": "(Bloomberg) -- The takeover of BTG Plc by Boston Scientific Corp. announced Tuesday confirms a clear pattern: U.K. health care companies keep getting gobbled up.", "score": 0.845947, "arguments": [{"text": "Tuesday", "location": [76, 83], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "confirms", "location": [84, 92], "entities": [{"type": "EventCommunication", "text": "confirms"}]}]}, {"type": "agentOf", "sentence": "The maker of both radiotherapy treatments and snake venom antidotes is the eighth target in the sector to be acquired over the past 18 months, according to broker Panmure Gordon, which says the trend reflects the cheapness of British pharmaceutical stocks.", "score": 0.934159, "arguments": [{"text": "which", "location": [341, 346], "entities": [{"type": "Organization", "text": "Panmure Gordon"}]}, {"text": "says", "location": [347, 351], "entities": [{"type": "EventCommunication", "text": "says"}]}]}, {"type": "basedIn", "sentence": "The maker of both radiotherapy treatments and snake venom antidotes is the eighth target in the sector to be acquired over the past 18 months, according to broker Panmure Gordon, which says the trend reflects the cheapness of British pharmaceutical stocks.", "score": 0.983043, "arguments": [{"text": "pharmaceutical", "location": [396, 410], "entities": [{"type": "Organization", "text": "pharmaceutical", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "British", "location": [388, 395], "entities": [{"type": "GeopoliticalEntity", "text": "British", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "\"We believe this rush of takeovers of U.K. companies highlights the general undervaluation\" in the sector, analyst Julie Simmonds wrote in a note to clients after the BTG announcement sent its stock soaring by as much as 35 percent.", "score": 0.950534, "arguments": [{"text": "companies", "location": [462, 471], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "U.K.", "location": [457, 461], "entities": [{"type": "GeopoliticalEntity", "text": "U.K.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "\"We believe this rush of takeovers of U.K. companies highlights the general undervaluation\" in the sector, analyst Julie Simmonds wrote in a note to clients after the BTG announcement sent its stock soaring by as much as 35 percent.", "score": 0.990717, "arguments": [{"text": "Julie Simmonds", "location": [534, 548], "entities": [{"type": "Person", "text": "Julie Simmonds"}]}, {"text": "wrote", "location": [549, 554], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}], "keywords": [{"text": "takeover of BTG Plc", "sentiment": {"score": 0.562993, "label": "positive"}, "relevance": 0.762095, "count": 1}, {"text": "U.K. health care companies", "sentiment": {"score": 0.562993, "label": "positive"}, "relevance": 0.646338, "count": 1}, {"text": "Biotech Abzena Plc", "sentiment": {"score": -0.893656, "label": "negative"}, "relevance": 0.622897, "count": 1}, {"text": "maker of both radiotherapy treatments", "sentiment": {"score": -0.606476, "label": "negative"}, "relevance": 0.601759, "count": 1}, {"text": "Cambian Group Plc", "sentiment": {"score": -0.893656, "label": "negative"}, "relevance": 0.599498, "count": 1}, {"text": "analyst Julie Simmonds", "sentiment": {"score": 0.68686, "label": "positive"}, "relevance": 0.56553, "count": 1}, {"text": "CareTech Holdings Plc", "sentiment": {"score": -0.893656, "label": "negative"}, "relevance": 0.563511, "count": 1}, {"text": "rush of takeovers of U.K. companies", "sentiment": {"score": 0.68686, "label": "positive"}, "relevance": 0.56112, "count": 1}, {"text": "share prices", "sentiment": {"score": -0.895835, "label": "negative"}, "relevance": 0.553155, "count": 1}, {"text": "drug discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551221, "count": 1}, {"text": "completion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549915, "count": 1}, {"text": "October", "sentiment": {"score": 0.78211, "label": "positive"}, "relevance": 0.548964, "count": 4}, {"text": "companies", "sentiment": {"score": -0.895835, "label": "negative"}, "relevance": 0.546518, "count": 1}, {"text": "Simmonds", "sentiment": {"score": -0.895835, "label": "negative"}, "relevance": 0.543698, "count": 1}, {"text": "mental health firm", "sentiment": {"score": -0.893656, "label": "negative"}, "relevance": 0.542642, "count": 1}, {"text": "Boston Scientific Corp.", "sentiment": {"score": 0.562993, "label": "positive"}, "relevance": 0.541376, "count": 1}, {"text": "sector", "sentiment": {"score": 0.31625, "mixed": "1", "label": "positive"}, "relevance": 0.538802, "count": 2}, {"text": "months", "sentiment": {"score": -0.81761, "label": "negative"}, "relevance": 0.536226, "count": 3}, {"text": "company", "sentiment": {"score": 0.78211, "label": "positive"}, "relevance": 0.534932, "count": 1}, {"text": "Clinigen Group Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53333, "count": 1}, {"text": "analysts", "sentiment": {"score": -0.898236, "label": "negative"}, "relevance": 0.53083, "count": 1}, {"text": "Molecular research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526894, "count": 1}, {"text": "firm Touchstone Innovations Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526323, "count": 1}, {"text": "Bloomberg", "sentiment": {"score": 0.562993, "label": "positive"}, "relevance": 0.52448, "count": 1}, {"text": "London", "sentiment": {"score": -0.742675, "label": "negative"}, "relevance": 0.524273, "count": 1}, {"text": "London\u2019s Fleet Street", "sentiment": {"score": 0.78211, "label": "positive"}, "relevance": 0.524029, "count": 1}, {"text": "September", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523483, "count": 1}, {"text": "rivals", "sentiment": {"score": -0.895835, "label": "negative"}, "relevance": 0.520909, "count": 1}, {"text": "reporter", "sentiment": {"score": -0.742675, "label": "negative"}, "relevance": 0.519221, "count": 1}, {"text": "Child specialist education", "sentiment": {"score": -0.893656, "label": "negative"}, "relevance": 0.519196, "count": 1}, {"text": "growth", "sentiment": {"score": 0.78211, "label": "positive"}, "relevance": 0.51898, "count": 1}, {"text": "markets", "sentiment": {"score": 0.78211, "label": "positive"}, "relevance": 0.518675, "count": 1}, {"text": "general undervaluation", "sentiment": {"score": 0.68686, "label": "positive"}, "relevance": 0.518228, "count": 1}, {"text": "U.K. health care takeovers", "sentiment": {"score": -0.893656, "label": "negative"}, "relevance": 0.517758, "count": 1}, {"text": "uncertainty", "sentiment": {"score": -0.898236, "label": "negative"}, "relevance": 0.517571, "count": 1}, {"text": "revenue", "sentiment": {"score": -0.898236, "label": "negative"}, "relevance": 0.516337, "count": 1}, {"text": "Takeda Pharmaceutical Co. Ltd", "sentiment": {"score": -0.893656, "label": "negative"}, "relevance": 0.515536, "count": 1}, {"text": "clients", "sentiment": {"score": 0.68686, "label": "positive"}, "relevance": 0.515484, "count": 1}, {"text": "development", "sentiment": {"score": -0.898236, "label": "negative"}, "relevance": 0.514681, "count": 1}, {"text": "story", "sentiment": {"score": -0.742675, "label": "negative"}, "relevance": 0.514189, "count": 1}, {"text": "week", "sentiment": {"score": 0.78211, "label": "positive"}, "relevance": 0.513437, "count": 1}, {"text": "snake venom antidotes", "sentiment": {"score": -0.606476, "label": "negative"}, "relevance": 0.513397, "count": 1}, {"text": "trend", "sentiment": {"score": -0.606476, "label": "negative"}, "relevance": 0.513176, "count": 1}, {"text": "BTG announcement", "sentiment": {"score": 0.68686, "label": "positive"}, "relevance": 0.511853, "count": 1}, {"text": "Stowe LP", "sentiment": {"score": -0.893656, "label": "negative"}, "relevance": 0.511338, "count": 1}, {"text": "stock", "sentiment": {"score": 0.68686, "label": "positive"}, "relevance": 0.509694, "count": 1}, {"text": "clear pattern", "sentiment": {"score": 0.562993, "label": "positive"}, "relevance": 0.509547, "count": 1}, {"text": "IP Group Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509528, "count": 1}, {"text": "assistance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50686, "count": 1}, {"text": "news", "sentiment": {"score": 0.78211, "label": "positive"}, "relevance": 0.506747, "count": 1}]}, "extracted_metadata": {"sha1": "73ccbc51e93dea7faabc37bb88ed7dffef047134", "filename": "1542747637809.zip-66be918a97c13a1dd8b750957a0f9aaa.xml", "file_type": "json"}, "title": "Health Care Stocks Dwindle in London as Buyers Swoop on Bargains", "forum_title": "News Wire"}, {"id": "P3YN_dUI9--5OBiESx4PmkddXD5sE7oTGZ73T_bsxBB4Ek2e9vfiS7dCttarRWE6", "result_metadata": {"score": 36.657433}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": -0.337592, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "EU", "keywords": [{"text": "EU"}], "entities": [{"type": "Organization", "text": "EU"}]}, "sentence": "Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition", "object": {"text": "Takeda", "keywords": [{"text": "Takeda"}]}, "action": {"verb": {"text": "approve", "tense": "present"}, "text": "approves", "normalized": "approve"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}]}, "sentence": "Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition", "object": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "buy", "tense": "present"}, "text": "buying", "normalized": "buy"}}], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.826037, "label": "/real estate/buying and selling homes"}, {"score": 0.810536, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "agentOf", "sentence": "Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition", "score": 0.956277, "arguments": [{"text": "EU", "location": [24, 26], "entities": [{"type": "GeopoliticalEntity", "text": "EU", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "approves", "location": [27, 35], "entities": [{"type": "EventCommunication", "text": "approves"}]}]}, {"type": "affectedBy", "sentence": "Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition", "score": 0.452908, "arguments": [{"text": "Takeda", "location": [36, 42], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "approves", "location": [27, 35], "entities": [{"type": "EventCommunication", "text": "approves"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": -0.337592, "label": "negative"}, "relevance": 0.999889, "count": 1}, {"text": "Takeda", "sentiment": {"score": -0.337592, "label": "negative"}, "relevance": 0.997812, "count": 1}, {"text": "Shire", "sentiment": {"score": -0.337592, "label": "negative"}, "relevance": 0.601922, "count": 1}, {"text": "EU", "sentiment": {"score": -0.337592, "label": "negative"}, "relevance": 0.082782, "count": 1}, {"text": "divestment condition", "sentiment": {"score": -0.337592, "label": "negative"}, "relevance": 0.021422, "count": 1}]}, "crawl_date": "2018-11-20T19:02:52Z", "url": "http://www.4-traders.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-EU-approves-Takeda-buying-Shire-on-divestment-condition-27639210/", "host": "4-traders.com", "text": "(Reporting by Alastair Macdonald) Stocks treated in this article : Takeda Pharmaceutical Co Ltd , Shire", "main_image_url": "https://img.zonebourse.com/reuters/2018-11-20T141142Z_1_LYNXNPEEAJ0ZZ_RTROPTP_3_SHIRE-M-A-TAKEDA-FEES.JPG", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T00:00:00+01:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.475387, "label": "negative"}, "text": "Takeda", "relevance": 0.971907, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical of Japan", "relevance": 0.815338, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.720595, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.475387, "label": "negative"}, "text": "Shire", "relevance": 0.569144, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.237643, "label": "negative"}, "text": "Shire", "relevance": 0.510009, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reuters", "relevance": 0.463641, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 2, "sentiment": {"score": -0.102566, "label": "negative"}, "text": "European Commission", "relevance": 0.42408, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alastair Macdonald", "relevance": 0.316201, "type": "Person", "disambiguation": {"subtype": [], "name": "Alastair Macdonald", "dbpedia_resource": "http://dbpedia.org/resource/Alastair_Macdonald"}}, {"count": 1, "sentiment": {"score": -0.475387, "label": "negative"}, "text": "bowel disease", "relevance": 0.264596, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BRUSSELS", "relevance": 0.25104, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "SchoolDistrict", "City"], "name": "Brussels", "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.21514, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.211779, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Entyvio", "relevance": 0.196063, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.189989, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.172389, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.154666, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "48.2 billion pounds", "relevance": 0.154666, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62", "relevance": 0.154666, "type": "Quantity"}], "sentiment": {"document": {"score": -0.597708, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": "BRUSSELS (Reuters) - The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.", "object": {"text": "the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development", "keywords": [{"text": "Shire plc"}, {"text": "Shire drug"}, {"text": "Takeda Pharmaceutical"}, {"text": "divestment"}], "entities": [{"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Company", "text": "Takeda Pharmaceutical of Japan"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "48.2 billion pounds"}, {"type": "Quantity", "text": "$62"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "the Commission", "keywords": [{"text": "Commission"}], "entities": []}, "sentence": " In a statement, the Commission said Takeda had agreed to the sale in order to ensure that the drug in Shire's product pipeline aimed at treating inflammatory bowel disease would continue its way to the market, where it is expected to compete with Entyvio, Takeda's biggest-selling drug.", "object": {"text": "Takeda had agreed to the sale in order to ensure that the drug in Shire's product pipeline aimed at treating inflammatory bowel disease would continue its way to the market, where it is expected to compete with Entyvio, Takeda's biggest-selling drug", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "product pipeline"}, {"text": "Takeda"}, {"text": "biggest-selling drug"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}, {"type": "HealthCondition", "text": "bowel disease"}, {"type": "Company", "text": "Entyvio"}, {"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " In a statement, the Commission said Takeda had agreed to the sale in order to ensure that the drug in Shire's product pipeline aimed at treating inflammatory bowel disease would continue its way to the market, where it is expected to compete with Entyvio, Takeda's biggest-selling drug.", "object": {"text": "that the drug in Shire's product pipeline aimed at treating inflammatory bowel disease would continue its way to the market", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "product pipeline"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "HealthCondition", "text": "bowel disease"}]}, "action": {"verb": {"text": "ensure", "tense": "future"}, "text": "to ensure", "normalized": "to ensure"}}, {"subject": {"text": "Reuters", "keywords": [{"text": "Reuters"}], "entities": [{"type": "Company", "text": "Reuters", "disambiguation": {"subtype": ["Company"], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}]}, "sentence": " Reuters reported the approval was expected on Nov. 9.", "object": {"text": "the approval was expected on Nov. 9", "keywords": [{"text": "approval"}, {"text": "Nov."}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "the approval", "keywords": [{"text": "approval"}]}, "sentence": " Reuters reported the approval was expected on Nov. 9.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was expected", "normalized": "be expect"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "already secured unconditional clearance from regulators in the United States, Japan, China and Brazil", "keywords": [{"text": "unconditional clearance"}, {"text": "United States"}, {"text": "regulators"}, {"text": "Brazil"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "object": {"text": "unconditional clearance", "keywords": [{"text": "unconditional clearance"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "secured", "normalized": "secure"}}, {"subject": {"text": "Stocks", "keywords": [{"text": "Stocks"}]}, "sentence": " Stocks treated in this article : Takeda Pharmaceutical Co Ltd , Shire", "object": {"text": "in this article", "keywords": [{"text": "article"}]}, "action": {"verb": {"text": "treat", "tense": "past"}, "text": "treated", "normalized": "treat"}}], "concepts": [{"text": "European Union", "relevance": 0.961321, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "European Commission", "relevance": 0.554651, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "Brussels", "relevance": 0.505489, "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}, {"text": "European Parliament", "relevance": 0.504703, "dbpedia_resource": "http://dbpedia.org/resource/European_Parliament"}, {"text": "German language", "relevance": 0.491717, "dbpedia_resource": "http://dbpedia.org/resource/German_language"}, {"text": "United States", "relevance": 0.488622, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "European Council", "relevance": 0.478166, "dbpedia_resource": "http://dbpedia.org/resource/European_Council"}, {"text": "Berlaymont building", "relevance": 0.454057, "dbpedia_resource": "http://dbpedia.org/resource/Berlaymont_building"}, {"text": "European Economic Community", "relevance": 0.444611, "dbpedia_resource": "http://dbpedia.org/resource/European_Economic_Community"}, {"text": "Belgium", "relevance": 0.439536, "dbpedia_resource": "http://dbpedia.org/resource/Belgium"}, {"text": "Council of the European Union", "relevance": 0.427206, "dbpedia_resource": "http://dbpedia.org/resource/Council_of_the_European_Union"}, {"text": "Institutions of the European Union", "relevance": 0.42415, "dbpedia_resource": "http://dbpedia.org/resource/Institutions_of_the_European_Union"}, {"text": "Inflammatory bowel disease", "relevance": 0.412965, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Brussels and the European Union", "relevance": 0.406982, "dbpedia_resource": "http://dbpedia.org/resource/Brussels_and_the_European_Union"}], "categories": [{"score": 0.747785, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.741073, "label": "/health and fitness"}, {"score": 0.670369, "label": "/health and fitness/disease"}], "relations": [{"type": "agentOf", "sentence": "BRUSSELS (Reuters) - The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.", "score": 0.961259, "arguments": [{"text": "European Commission", "location": [25, 44], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "said", "location": [45, 49], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "locatedAt", "sentence": "Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.", "score": 0.580836, "arguments": [{"text": "regulators", "location": [637, 647], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "United States", "location": [655, 668], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "BRUSSELS (Reuters) - The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.", "score": 0.97579, "arguments": [{"text": "Tuesday", "location": [53, 60], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "said", "location": [45, 49], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "BRUSSELS (Reuters) - The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.", "score": 0.432994, "arguments": [{"text": "Tuesday", "location": [53, 60], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "takeover", "location": [116, 124], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "locatedAt", "sentence": "BRUSSELS (Reuters) - The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.", "score": 0.307677, "arguments": [{"text": "takeover", "location": [116, 124], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}, {"text": "London", "location": [128, 134], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "basedIn", "sentence": "BRUSSELS (Reuters) - The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.", "score": 0.930553, "arguments": [{"text": "Shire plc", "location": [137, 146], "entities": [{"type": "Organization", "text": "Shire plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "London", "location": [128, 134], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "partOf", "sentence": "BRUSSELS (Reuters) - The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.", "score": 0.378035, "arguments": [{"text": "Shire plc", "location": [137, 146], "entities": [{"type": "Organization", "text": "Shire plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda Pharmaceutical of Japan", "location": [150, 180], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical of Japan", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "BRUSSELS (Reuters) - The European Commission said on Tuesday that it approved the $62-billion (48.2 billion pounds) takeover of London's Shire plc by Takeda Pharmaceutical of Japan, subject to the divestment of a Shire drug in development.", "score": 0.499696, "arguments": [{"text": "drug", "location": [219, 223], "entities": [{"type": "Substance", "text": "drug"}]}, {"text": "Shire", "location": [213, 218], "entities": [{"type": "Facility", "text": "Shire"}]}]}, {"type": "agentOf", "sentence": "In a statement, the Commission said Takeda had agreed to the sale in order to ensure that the drug in Shire's product pipeline aimed at treating inflammatory bowel disease would continue its way to the market, where it is expected to compete with Entyvio, Takeda's biggest-selling drug.", "score": 0.990861, "arguments": [{"text": "Commission", "location": [260, 270], "entities": [{"type": "Organization", "text": "Commission"}]}, {"text": "said", "location": [271, 275], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Reuters reported the approval was expected on Nov. 9.", "score": 0.98091, "arguments": [{"text": "Reuters", "location": [527, 534], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reported", "location": [535, 543], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical of Japan", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.821964, "count": 1}, {"text": "European Commission", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.780496, "count": 1}, {"text": "BRUSSELS", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.742005, "count": 1}, {"text": "Takeda", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.722523, "count": 3}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.71442, "count": 1}, {"text": "Reuters", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.684254, "count": 2}, {"text": "Shire plc", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.66278, "count": 1}, {"text": "Shire's product pipeline", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.628859, "count": 1}, {"text": "Commission", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.628147, "count": 1}, {"text": "divestment of a Shire drug", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.595773, "count": 1}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593331, "count": 1}, {"text": "statement", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.588442, "count": 1}, {"text": "drug", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.579422, "count": 2}, {"text": "Stocks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578479, "count": 1}, {"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567992, "count": 1}, {"text": "order", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.561428, "count": 1}, {"text": "pounds", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.559649, "count": 1}, {"text": "market", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.559345, "count": 1}, {"text": "way", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.557515, "count": 1}, {"text": "sale", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.556332, "count": 1}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552719, "count": 1}, {"text": "article", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54896, "count": 1}, {"text": "takeover of London", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.542553, "count": 1}, {"text": "regulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54055, "count": 1}, {"text": "approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527574, "count": 1}, {"text": "China", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520131, "count": 1}, {"text": "development", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.516605, "count": 1}, {"text": "Brazil", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516605, "count": 1}, {"text": "unconditional clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513854, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513369, "count": 1}, {"text": "Tuesday", "sentiment": {"score": -0.472922, "label": "negative"}, "relevance": 0.44382, "count": 1}, {"text": "Alastair Macdonald", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.434362, "count": 1}, {"text": "Entyvio", "sentiment": {"score": -0.690785, "label": "negative"}, "relevance": 0.424024, "count": 1}, {"text": "Nov.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39437, "count": 1}]}, "extracted_metadata": {"sha1": "00c9dd4e4edb2344eba8e39188f26cd873fb7e46", "filename": "1542740572655.zip-7b4112a328d894f179cb2439d42b80f7.xml", "file_type": "json"}, "title": "Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition", "forum_title": "Stock Market Quotes and News : Equities, Indexes, Commodities, Forex on MarketScreener.com"}, {"id": "JKetHzPRHHD-SBNxdRe4ncV8VUYHRPnIP2ztO8W6AJjr4rqKQ8PXWDzS-_-TONkw", "result_metadata": {"score": 36.564148}, "author": "Allison DeAngelis", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.415876, "label": "positive"}, "text": "EU", "relevance": 0.33, "type": "Organization"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Shire-Takeda deal", "keywords": [{"text": "Shire-Takeda deal"}]}, "sentence": "Shire-Takeda deal gets conditional EU approval, heads to shareholders", "object": {"text": "conditional EU approval", "keywords": [{"text": "conditional EU approval"}], "entities": [{"type": "Organization", "text": "EU"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "gets", "normalized": "get"}}], "concepts": [], "categories": [{"score": 0.82542, "label": "/business and industrial/company"}, {"score": 0.786887, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.686534, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "partOfMany", "sentence": "Shire-Takeda deal gets conditional EU approval, heads to shareholders", "score": 0.703739, "arguments": [{"text": "Shire", "location": [0, 5], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "shareholders", "location": [57, 69], "entities": [{"type": "Person", "text": "shareholders"}]}]}, {"type": "partOfMany", "sentence": "Shire-Takeda deal gets conditional EU approval, heads to shareholders", "score": 0.878769, "arguments": [{"text": "Takeda", "location": [6, 12], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "shareholders", "location": [57, 69], "entities": [{"type": "Person", "text": "shareholders"}]}]}], "keywords": [{"text": "Shire-Takeda deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998378, "count": 1}, {"text": "heads", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.687236, "count": 1}, {"text": "shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.656845, "count": 1}, {"text": "conditional EU approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529769, "count": 1}]}, "crawl_date": "2018-11-20T15:58:54Z", "url": "https://www.bizjournals.com/boston/news/2018/11/20/shire-takeda-deal-gets-conditional-eu-approval.html", "host": "bizjournals.com", "text": "\u2013 Life Sciences Reporter, Boston Business Journal Nov 20, 2018, 10:39am EST European Union antitrust regulators have conditionally approved Takeda Pharmaceutical Co.", "main_image_url": "https://media.bizj.us/view/img/514181/shire-pharmaceuticals-lexington-jacobs*1200xx1500-844-0-121.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T15:39:00Z", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": -0.0893261, "label": "negative"}, "text": "Takeda", "relevance": 0.944077, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.444742, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.43991, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.436651, "label": "positive"}, "text": "Shire", "relevance": 0.334787, "type": "Person"}, {"count": 2, "sentiment": {"score": -0.531883, "label": "negative"}, "text": "Shire", "relevance": 0.311784, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.311484, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.302986, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.0665259, "label": "positive"}, "text": "European Commission", "relevance": 0.295459, "type": "Organization"}, {"count": 3, "sentiment": {"score": -0.222852, "label": "negative"}, "text": "Massachusetts", "relevance": 0.244959, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Life Sciences", "relevance": 0.207564, "type": "Organization", "disambiguation": {"subtype": ["Location", "University"], "name": "University of Florida College of Agricultural and Life Sciences", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Florida_College_of_Agricultural_and_Life_Sciences"}}, {"count": 2, "sentiment": {"score": 0.603779, "label": "positive"}, "text": "Cambridge", "relevance": 0.184354, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Cambridge, Illinois", "dbpedia_resource": "http://dbpedia.org/resource/Cambridge,_Illinois"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Union", "relevance": 0.182204, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston Business Journal", "relevance": 0.170874, "type": "PrintMedia", "disambiguation": {"subtype": [], "name": "Boston Business Journal", "dbpedia_resource": "http://dbpedia.org/resource/Boston_Business_Journal"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.160799, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Reporter", "relevance": 0.149908, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.603779, "label": "positive"}, "text": "Kendall Square", "relevance": 0.147373, "type": "Facility"}, {"count": 1, "sentiment": {"score": -0.383348, "label": "negative"}, "text": "Reuters", "relevance": 0.145191, "type": "Company", "disambiguation": {"subtype": [], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christophe Weber", "relevance": 0.14357, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.142417, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.435885, "label": "positive"}, "text": "Sanofi", "relevance": 0.139006, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Illinois", "relevance": 0.137343, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Illinois", "dbpedia_resource": "http://dbpedia.org/resource/Illinois"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lexington", "relevance": 0.131576, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Lexington, Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Lexington,_Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.12922, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mass", "relevance": 0.115835, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NYSE", "relevance": 0.112422, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62 billion", "relevance": 0.112422, "type": "Quantity"}], "sentiment": {"document": {"score": 0.48622, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "39am EST European Union antitrust regulators", "keywords": [{"text": "Union antitrust regulators"}, {"text": "EST"}], "entities": [{"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": "\u2013 Life Sciences Reporter, Boston Business Journal Nov 20, 2018, 10:39am EST European Union antitrust regulators have conditionally approved Takeda Pharmaceutical Co.", "object": {"text": "conditionally approved Takeda Pharmaceutical Co", "keywords": [{"text": "Takeda Pharmaceutical"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Takeda Pharmaceutical Co", "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "sentence": "\u2013 Life Sciences Reporter, Boston Business Journal Nov 20, 2018, 10:39am EST European Union antitrust regulators have conditionally approved Takeda Pharmaceutical Co.", "object": {"text": "39am EST European Union antitrust regulators", "keywords": [{"text": "Union antitrust regulators"}, {"text": "EST"}], "entities": [{"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "Ltd.", "entities": [{"type": "Location", "text": "Ltd.", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Ltd.'s $62 billion bid to acquire Shire plc, a deal that will likely create the largest life sciences employer in Massachusetts.", "object": {"text": "Shire plc", "keywords": [{"text": "Shire plc"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "acquire", "tense": "future"}, "text": "to acquire", "normalized": "to acquire"}}, {"subject": {"text": "a deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " Ltd.'s $62 billion bid to acquire Shire plc, a deal that will likely create the largest life sciences employer in Massachusetts.", "object": {"text": "the largest life sciences employer in Massachusetts", "keywords": [{"text": "life sciences employer"}, {"text": "Massachusetts"}], "entities": [{"type": "Location", "text": "Massachusetts", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "will likely create", "normalized": "will likely create"}}, {"subject": {"text": "The European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": " The European Commission said Tuesday that it had approved the acquisition subject to Shire selling an inflammatory bowel disease treatment, called SHP647, that could compete with a Takeda drug if it eventually hits the market.", "object": {"text": "that it had approved the acquisition subject to Shire selling an inflammatory bowel disease treatment, called SHP647, that could compete with a Takeda drug if it eventually hits the market", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "Takeda drug"}, {"text": "acquisition subject"}, {"text": "Shire"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "the acquisition subject to Shire selling an inflammatory bowel disease treatment", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "acquisition subject"}, {"text": "Shire"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " The European Commission said Tuesday that it had approved the acquisition subject to Shire selling an inflammatory bowel disease treatment, called SHP647, that could compete with a Takeda drug if it eventually hits the market.", "object": {"text": "SHP647", "keywords": [{"text": "SHP647"}]}, "action": {"verb": {"text": "call", "tense": "past"}, "text": "called", "normalized": "call"}}, {"subject": {"text": "the acquisition subject to Shire selling an inflammatory bowel disease treatment, called SHP647,", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "acquisition subject"}, {"text": "Shire"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": " The European Commission said Tuesday that it had approved the acquisition subject to Shire selling an inflammatory bowel disease treatment, called SHP647, that could compete with a Takeda drug if it eventually hits the market.", "object": {"text": "with a Takeda drug", "keywords": [{"text": "Takeda drug"}]}, "action": {"verb": {"text": "compete", "tense": "future"}, "text": "could compete", "normalized": "could compete"}}, {"subject": {"text": "it"}, "sentence": " The European Commission said Tuesday that it had approved the acquisition subject to Shire selling an inflammatory bowel disease treatment, called SHP647, that could compete with a Takeda drug if it eventually hits the market.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "hit", "tense": "present"}, "text": "hits", "normalized": "hit"}}, {"subject": {"text": "The commission", "keywords": [{"text": "commission"}], "entities": []}, "sentence": " The commission was the last governmental group that needed to sign off on the deal \u2014 regulators in the U.S. and several other countries have already given it their blessing \u2014 meaning that Takeda can now bring the acquisition to its shareholders for a final vote on Dec. 5.", "object": {"text": "the last governmental group that needed to sign off on the deal \u2014 regulators", "keywords": [{"text": "deal \u2014 regulators"}, {"text": "governmental group"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "\u2014 regulators in the U.S. and several other countries", "keywords": [{"text": "regulators"}, {"text": "U.S."}, {"text": "countries"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The commission was the last governmental group that needed to sign off on the deal \u2014 regulators in the U.S. and several other countries have already given it their blessing \u2014 meaning that Takeda can now bring the acquisition to its shareholders for a final vote on Dec. 5.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "several other countries", "keywords": [{"text": "countries"}]}, "sentence": " The commission was the last governmental group that needed to sign off on the deal \u2014 regulators in the U.S. and several other countries have already given it their blessing \u2014 meaning that Takeda can now bring the acquisition to its shareholders for a final vote on Dec. 5.", "object": {"text": "it"}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "given", "normalized": "give"}}, {"subject": {"text": "\u2014"}, "sentence": " The commission was the last governmental group that needed to sign off on the deal \u2014 regulators in the U.S. and several other countries have already given it their blessing \u2014 meaning that Takeda can now bring the acquisition to its shareholders for a final vote on Dec. 5.", "object": {"text": "that Takeda can now bring the acquisition to its shareholders for a final vote on Dec. 5", "keywords": [{"text": "final vote"}, {"text": "Takeda"}, {"text": "shareholders"}, {"text": "acquisition"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "mean", "tense": "present"}, "text": "meaning", "normalized": "mean"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " The commission was the last governmental group that needed to sign off on the deal \u2014 regulators in the U.S. and several other countries have already given it their blessing \u2014 meaning that Takeda can now bring the acquisition to its shareholders for a final vote on Dec. 5.", "object": {"text": "the acquisition", "keywords": [{"text": "acquisition"}]}, "action": {"verb": {"text": "bring", "tense": "future"}, "text": "bring", "normalized": "bring"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda said Tuesday that it expects the deal to be completed on Jan. 8.", "object": {"text": "that it expects the deal to be completed on Jan. 8", "keywords": [{"text": "deal"}, {"text": "Jan."}], "entities": []}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " Takeda said Tuesday that it expects the deal to be completed on Jan. 8.", "action": {"verb": {"text": "complete", "tense": "past"}, "text": "to be completed", "normalized": "to be complete"}}, {"subject": {"text": "Takeda CEO Christophe Weber", "keywords": [{"text": "CEO Christophe Weber"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "JobTitle", "text": "CEO"}, {"type": "Person", "text": "Christophe Weber"}]}, "sentence": " \u201cWe are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,\u201d Takeda CEO Christophe Weber said in a statement.", "object": {"text": "We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire", "keywords": [{"text": "final regulatory approval"}, {"text": "European Commission"}, {"text": "clearance"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d Takeda and Shire (Nasdaq: SHPG) announced the $62 billion agreement in May .", "object": {"text": "another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader,", "keywords": [{"text": "R&D-driven biopharmaceutical leader"}, {"text": "step"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d Takeda and Shire (Nasdaq: SHPG) announced the $62 billion agreement in May .", "object": {"text": "a global, values-based, R&D-driven biopharmaceutical leader,", "keywords": [{"text": "R&D-driven biopharmaceutical leader"}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "creating", "normalized": "create"}}, {"subject": {"text": "we"}, "sentence": " \u201cWe are another step closer to creating a global, values-based, R&D-driven biopharmaceutical leader, and after several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d Takeda and Shire (Nasdaq: SHPG) announced the $62 billion agreement in May .", "object": {"text": "optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination.\u201d Takeda and Shire (Nasdaq: SHPG) announced the $62 billion agreement in May", "keywords": [{"text": "significant long-term value"}, {"text": "powerful combination."}, {"text": "creation potential"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}, {"type": "Quantity", "text": "$62 billion"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "completed \u2014 and subject to possible layoffs locally \u2014 it", "keywords": [{"text": "possible layoffs"}]}, "sentence": " If completed \u2014 and subject to possible layoffs locally \u2014 it would make Takeda the largest life sciences employer in Massachusetts, surpassing Sanofi (NYSE: SNY).", "object": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "would make", "normalized": "would make"}}, {"subject": {"text": "Both Takeda and Shire", "keywords": [{"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}]}, "sentence": " Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass.", "object": {"text": "a large presence", "keywords": [{"text": "large presence"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters", "keywords": [{"text": "large presence"}, {"text": "Shire"}, {"text": "Takeda"}, {"text": "U.S. headquarters"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Shire"}, {"type": "Location", "text": "Cambridge", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Cambridge, Illinois", "dbpedia_resource": "http://dbpedia.org/resource/Cambridge,_Illinois"}}, {"type": "Person", "text": "Shire"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass.", "object": {"text": "located in Lexington, Mass", "keywords": [{"text": "Lexington"}, {"text": "Mass"}], "entities": [{"type": "Location", "text": "Lexington", "disambiguation": {"subtype": ["AdministrativeDivision", "CityTown", "City"], "name": "Lexington, Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Lexington,_Massachusetts"}}, {"type": "Location", "text": "Mass", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Shire's U.S. headquarters", "keywords": [{"text": "Shire"}, {"text": "U.S. headquarters"}], "entities": [{"type": "Person", "text": "Shire"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass.", "action": {"verb": {"text": "locate", "tense": "past"}, "text": "is located", "normalized": "be locate"}}, {"subject": {"text": "Reuters", "keywords": [{"text": "Reuters"}], "entities": [{"type": "Company", "text": "Reuters", "disambiguation": {"subtype": ["Company"], "name": "Reuters", "dbpedia_resource": "http://dbpedia.org/resource/Reuters"}}]}, "sentence": " Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "object": {"text": "that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on", "keywords": [{"text": "Takeda shareholders"}, {"text": "Japanese drug giant"}, {"text": "financial risk"}, {"text": "deal"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "object": {"text": "a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on", "keywords": [{"text": "Takeda shareholders"}, {"text": "Japanese drug giant"}, {"text": "financial risk"}, {"text": "challenge"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "face", "tense": "future"}, "text": "face", "normalized": "face"}}, {"subject": {"text": "a group of Takeda shareholders", "keywords": [{"text": "Takeda shareholders"}, {"text": "group"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "object": {"text": "concerned about the debt", "keywords": [{"text": "debt"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "both Shire and Takeda", "keywords": [{"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}, {"type": "Person", "text": "Takeda"}]}, "sentence": " Even so, both Shire and Takeda have taken steps forward in anticipation of the deal closing.", "object": {"text": "steps", "keywords": [{"text": "steps"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "have taken", "normalized": "have take"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda announced in September that it was closing its Illinois headquarters and moving employees to Massachusetts .", "object": {"text": "that it was closing its Illinois headquarters and moving employees to Massachusetts", "keywords": [{"text": "Illinois headquarters"}, {"text": "employees"}, {"text": "Massachusetts"}], "entities": [{"type": "Location", "text": "Illinois", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Illinois", "dbpedia_resource": "http://dbpedia.org/resource/Illinois"}}, {"type": "Location", "text": "Massachusetts", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "it"}, "sentence": " Takeda announced in September that it was closing its Illinois headquarters and moving employees to Massachusetts .", "object": {"text": "employees", "keywords": [{"text": "employees"}]}, "action": {"verb": {"text": "move", "tense": "present"}, "text": "moving", "normalized": "move"}}, {"subject": {"text": "the iconic Genzyme building", "keywords": [{"text": "iconic Genzyme building"}]}, "sentence": " Shire, meanwhile, backed out of an agreement to lease the iconic Genzyme building in Cambridge's Kendall Square.", "action": {"verb": {"text": "lease", "tense": "future"}, "text": "to lease", "normalized": "to lease"}}], "concepts": [{"text": "European Union", "relevance": 0.97392, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "European Commission", "relevance": 0.71379, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "European Council", "relevance": 0.589259, "dbpedia_resource": "http://dbpedia.org/resource/European_Council"}, {"text": "European Parliament", "relevance": 0.583071, "dbpedia_resource": "http://dbpedia.org/resource/European_Parliament"}], "categories": [{"score": 0.908726, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.829482, "label": "/finance/financial news"}, {"score": 0.665757, "label": "/real estate/buying and selling homes"}], "relations": [{"type": "employedBy", "sentence": "- Life Sciences Reporter, Boston Business Journal Nov 20, 2018, 10:39am EST European Union antitrust regulators have conditionally approved Takeda Pharmaceutical Co. Ltd.'s $62 billion bid to acquire Shire plc, a deal that will likely create the largest life sciences employer in Massachusetts.", "score": 0.428225, "arguments": [{"text": "regulators", "location": [101, 111], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "European Union", "location": [76, 90], "entities": [{"type": "GeopoliticalEntity", "text": "European Union", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "affectedBy", "sentence": "\"We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,\" Takeda CEO Christophe Weber said in a statement.", "score": 0.849184, "arguments": [{"text": "Shire", "location": [1018, 1023], "entities": [{"type": "Organization", "text": "Shire"}]}, {"text": "acquisition", "location": [1003, 1014], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "\" Takeda and Shire (Nasdaq: SHPG) announced the $62 billion agreement in May .", "score": 0.606338, "arguments": [{"text": "Shire", "location": [1370, 1375], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "announced", "location": [1391, 1400], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "timeOf", "sentence": "\" Takeda and Shire (Nasdaq: SHPG) announced the $62 billion agreement in May .", "score": 0.565946, "arguments": [{"text": "May", "location": [1430, 1433], "entities": [{"type": "Date", "text": "May"}]}, {"text": "announced", "location": [1391, 1400], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "If completed \u2014 and subject to possible layoffs locally \u2014 it would make Takeda the largest life sciences employer in Massachusetts, surpassing Sanofi (NYSE: SNY).", "score": 0.48333, "arguments": [{"text": "employer", "location": [1540, 1548], "entities": [{"type": "Organization", "text": "employer"}]}, {"text": "Massachusetts", "location": [1552, 1565], "entities": [{"type": "GeopoliticalEntity", "text": "Massachusetts"}]}]}, {"type": "partOf", "sentence": "If completed \u2014 and subject to possible layoffs locally \u2014 it would make Takeda the largest life sciences employer in Massachusetts, surpassing Sanofi (NYSE: SNY).", "score": 0.388574, "arguments": [{"text": "employer", "location": [1540, 1548], "entities": [{"type": "Organization", "text": "employer"}]}, {"text": "Sanofi", "location": [1578, 1584], "entities": [{"type": "Organization", "text": "Sanofi", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "If completed \u2014 and subject to possible layoffs locally \u2014 it would make Takeda the largest life sciences employer in Massachusetts, surpassing Sanofi (NYSE: SNY).", "score": 0.911201, "arguments": [{"text": "Sanofi", "location": [1578, 1584], "entities": [{"type": "Organization", "text": "Sanofi", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "SNY", "location": [1592, 1595], "entities": [{"type": "Ticker", "text": "SNY"}]}]}, {"type": "locatedAt", "sentence": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass. Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "score": 0.557046, "arguments": [{"text": "Shire", "location": [1614, 1619], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "Cambridge", "location": [1645, 1654], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}]}, {"type": "ownerOf", "sentence": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass. Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "score": 0.527063, "arguments": [{"text": "Shire", "location": [1660, 1665], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "headquarters", "location": [1673, 1685], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "locatedAt", "sentence": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass. Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "score": 0.797817, "arguments": [{"text": "headquarters", "location": [1673, 1685], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "U.S.", "location": [1668, 1672], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass. Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "score": 0.538474, "arguments": [{"text": "headquarters", "location": [1673, 1685], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Lexington", "location": [1700, 1709], "entities": [{"type": "GeopoliticalEntity", "text": "Lexington"}]}]}, {"type": "basedIn", "sentence": "- Life Sciences Reporter, Boston Business Journal Nov 20, 2018, 10:39am EST European Union antitrust regulators have conditionally approved Takeda Pharmaceutical Co. Ltd.'s $62 billion bid to acquire Shire plc, a deal that will likely create the largest life sciences employer in Massachusetts.", "score": 0.569452, "arguments": [{"text": "employer", "location": [268, 276], "entities": [{"type": "Organization", "text": "employer"}]}, {"text": "Massachusetts", "location": [280, 293], "entities": [{"type": "GeopoliticalEntity", "text": "Massachusetts"}]}]}, {"type": "locatedAt", "sentence": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass. Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "score": 0.932916, "arguments": [{"text": "Lexington", "location": [1700, 1709], "entities": [{"type": "GeopoliticalEntity", "text": "Lexington"}]}, {"text": "Mass.", "location": [1711, 1716], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "basedIn", "sentence": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass. Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "score": 0.941112, "arguments": [{"text": "Reuters", "location": [1717, 1724], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Mass.", "location": [1711, 1716], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "agentOf", "sentence": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass. Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "score": 0.882156, "arguments": [{"text": "Reuters", "location": [1717, 1724], "entities": [{"type": "Organization", "text": "Reuters", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reported", "location": [1736, 1744], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "managerOf", "sentence": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass. Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "score": 0.556199, "arguments": [{"text": "Takeda", "location": [1800, 1806], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "group", "location": [1791, 1796], "entities": [{"type": "Organization", "text": "group"}]}]}, {"type": "colleague", "sentence": "Both Takeda and Shire have a large presence in Cambridge, and Shire's U.S. headquarters is located in Lexington, Mass. Reuters previously reported that the deal may yet face a challenge from a group of Takeda shareholders, who are concerned about the debt and financial risk the Japanese drug giant is taking on.", "score": 0.341487, "arguments": [{"text": "Takeda", "location": [1800, 1806], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "shareholders", "location": [1807, 1819], "entities": [{"type": "Person", "text": "shareholders"}]}]}, {"type": "timeOf", "sentence": "Takeda announced in September that it was closing its Illinois headquarters and moving employees to Massachusetts .", "score": 0.961702, "arguments": [{"text": "September", "location": [2024, 2033], "entities": [{"type": "Date", "text": "September"}]}, {"text": "announced", "location": [2011, 2020], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "ownerOf", "sentence": "Takeda announced in September that it was closing its Illinois headquarters and moving employees to Massachusetts .", "score": 0.575806, "arguments": [{"text": "its", "location": [2054, 2057], "entities": [{"type": "Organization", "text": "Sanofi", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "headquarters", "location": [2067, 2079], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "employedBy", "sentence": "Takeda announced in September that it was closing its Illinois headquarters and moving employees to Massachusetts .", "score": 0.791775, "arguments": [{"text": "employees", "location": [2091, 2100], "entities": [{"type": "Person", "text": "employees"}]}, {"text": "its", "location": [2054, 2057], "entities": [{"type": "Organization", "text": "Sanofi", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Takeda announced in September that it was closing its Illinois headquarters and moving employees to Massachusetts .", "score": 0.8992, "arguments": [{"text": "headquarters", "location": [2067, 2079], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Illinois", "location": [2058, 2066], "entities": [{"type": "GeopoliticalEntity", "text": "Illinois"}]}]}, {"type": "locatedAt", "sentence": "Takeda announced in September that it was closing its Illinois headquarters and moving employees to Massachusetts .", "score": 0.791219, "arguments": [{"text": "employees", "location": [2091, 2100], "entities": [{"type": "Person", "text": "employees"}]}, {"text": "Massachusetts", "location": [2104, 2117], "entities": [{"type": "GeopoliticalEntity", "text": "Massachusetts"}]}]}, {"type": "agentOf", "sentence": "The European Commission said Tuesday that it had approved the acquisition subject to Shire selling an inflammatory bowel disease treatment, called SHP647, that could compete with a Takeda drug if it eventually hits the market.", "score": 0.955182, "arguments": [{"text": "European Commission", "location": [299, 318], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "said", "location": [319, 323], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "Shire, meanwhile, backed out of an agreement to lease the iconic Genzyme building in Cambridge's Kendall Square.", "score": 0.972118, "arguments": [{"text": "Kendall Square", "location": [2217, 2231], "entities": [{"type": "Facility", "text": "Kendall Square"}]}, {"text": "Cambridge", "location": [2205, 2214], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}]}, {"type": "timeOf", "sentence": "The European Commission said Tuesday that it had approved the acquisition subject to Shire selling an inflammatory bowel disease treatment, called SHP647, that could compete with a Takeda drug if it eventually hits the market.", "score": 0.987983, "arguments": [{"text": "Tuesday", "location": [324, 331], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "said", "location": [319, 323], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "locatedAt", "sentence": "The commission was the last governmental group that needed to sign off on the deal \u2014 regulators in the U.S. and several other countries have already given it their blessing \u2014 meaning that Takeda can now bring the acquisition to its shareholders for a final vote on Dec. 5.", "score": 0.463915, "arguments": [{"text": "regulators", "location": [607, 617], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "U.S.", "location": [625, 629], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "The commission was the last governmental group that needed to sign off on the deal \u2014 regulators in the U.S. and several other countries have already given it their blessing \u2014 meaning that Takeda can now bring the acquisition to its shareholders for a final vote on Dec. 5.", "score": 0.809478, "arguments": [{"text": "shareholders", "location": [754, 766], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "its", "location": [750, 753], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Takeda said Tuesday that it expects the deal to be completed on Jan. 8.", "score": 0.997652, "arguments": [{"text": "Takeda", "location": [795, 801], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [802, 806], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,\" Takeda CEO Christophe Weber said in a statement.", "score": 0.995004, "arguments": [{"text": "Christophe Weber", "location": [1037, 1053], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "said", "location": [1054, 1058], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Takeda announced in September that it was closing its Illinois headquarters and moving employees to Massachusetts .", "score": 0.995889, "arguments": [{"text": "Takeda", "location": [2004, 2010], "entities": [{"type": "Person", "text": "Christophe Weber"}]}, {"text": "announced", "location": [2011, 2020], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "timeOf", "sentence": "Takeda said Tuesday that it expects the deal to be completed on Jan. 8.", "score": 0.979798, "arguments": [{"text": "Tuesday", "location": [807, 814], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "said", "location": [802, 806], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "\"We are very pleased to have secured clearance from the European Commission, the final regulatory approval required to proceed with our acquisition of Shire,\" Takeda CEO Christophe Weber said in a statement.", "score": 0.492854, "arguments": [{"text": "our", "location": [999, 1002], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "acquisition", "location": [1003, 1014], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Co. Ltd", "sentiment": {"score": 0.730042, "label": "positive"}, "relevance": 0.78423, "count": 1}, {"text": "Shire plc", "sentiment": {"score": 0.684426, "label": "positive"}, "relevance": 0.735201, "count": 1}, {"text": "European Commission", "sentiment": {"score": 0.51365, "mixed": "1", "label": "positive"}, "relevance": 0.704402, "count": 2}, {"text": "European Union", "sentiment": {"score": 0.730042, "label": "positive"}, "relevance": 0.687881, "count": 1}, {"text": "Shire", "sentiment": {"score": -0.537381, "mixed": "1", "label": "negative"}, "relevance": 0.653195, "count": 5}, {"text": "Takeda drug", "sentiment": {"score": -0.797203, "label": "negative"}, "relevance": 0.62711, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0.266652, "mixed": "1", "label": "positive"}, "relevance": 0.626312, "count": 7}, {"text": "Life Sciences Reporter", "sentiment": {"score": 0.730042, "label": "positive"}, "relevance": 0.613843, "count": 1}, {"text": "commission", "sentiment": {"score": 0.756828, "label": "positive"}, "relevance": 0.596279, "count": 1}, {"text": "Boston Business Journal Nov", "sentiment": {"score": 0.730042, "label": "positive"}, "relevance": 0.578863, "count": 1}, {"text": "deal", "sentiment": {"score": 0.391535, "mixed": "1", "label": "positive"}, "relevance": 0.578626, "count": 4}, {"text": "largest life sciences employer", "sentiment": {"score": 0, "mixed": "1", "label": "neutral"}, "relevance": 0.56784, "count": 2}, {"text": "final vote", "sentiment": {"score": 0.756828, "label": "positive"}, "relevance": 0.567719, "count": 1}, {"text": "acquisition", "sentiment": {"score": 0.277174, "mixed": "1", "label": "positive"}, "relevance": 0.56583, "count": 2}, {"text": "large presence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553842, "count": 1}, {"text": "acquisition of Shire", "sentiment": {"score": 0.983326, "label": "positive"}, "relevance": 0.548865, "count": 1}, {"text": "clearance", "sentiment": {"score": 0.983326, "label": "positive"}, "relevance": 0.543121, "count": 1}, {"text": "Reuters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541995, "count": 1}, {"text": "last governmental group", "sentiment": {"score": 0.756828, "label": "positive"}, "relevance": 0.540182, "count": 1}, {"text": "financial risk", "sentiment": {"score": -0.693674, "label": "negative"}, "relevance": 0.539342, "count": 1}, {"text": "regulators", "sentiment": {"score": 0.756828, "label": "positive"}, "relevance": 0.53921, "count": 1}, {"text": "shareholders", "sentiment": {"score": 0.895538, "label": "positive"}, "relevance": 0.5375, "count": 2}, {"text": "step", "sentiment": {"score": 0.994881, "label": "positive"}, "relevance": 0.535773, "count": 1}, {"text": "steps", "sentiment": {"score": 0.29942, "label": "positive"}, "relevance": 0.535773, "count": 1}, {"text": "Takeda CEO Christophe Weber", "sentiment": {"score": 0.983326, "label": "positive"}, "relevance": 0.532754, "count": 1}, {"text": "values", "sentiment": {"score": 0.994881, "label": "positive"}, "relevance": 0.532026, "count": 1}, {"text": "countries", "sentiment": {"score": 0.756828, "label": "positive"}, "relevance": 0.527499, "count": 1}, {"text": "final regulatory approval", "sentiment": {"score": 0.983326, "label": "positive"}, "relevance": 0.526709, "count": 1}, {"text": "inflammatory bowel disease treatment", "sentiment": {"score": -0.797203, "label": "negative"}, "relevance": 0.526527, "count": 1}, {"text": "blessing", "sentiment": {"score": 0.756828, "label": "positive"}, "relevance": 0.525103, "count": 1}, {"text": "antitrust regulators", "sentiment": {"score": 0.730042, "label": "positive"}, "relevance": 0.525098, "count": 1}, {"text": "challenge", "sentiment": {"score": -0.693674, "label": "negative"}, "relevance": 0.522703, "count": 1}, {"text": "Cambridge", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522598, "count": 1}, {"text": "agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518405, "count": 2}, {"text": "September", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517506, "count": 1}, {"text": "Nasdaq", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517438, "count": 1}, {"text": "possible layoffs", "sentiment": {"score": -0.522483, "label": "negative"}, "relevance": 0.516292, "count": 1}, {"text": "debt", "sentiment": {"score": -0.693674, "label": "negative"}, "relevance": 0.514985, "count": 1}, {"text": "Massachusetts", "sentiment": {"score": 0, "mixed": "1", "label": "neutral"}, "relevance": 0.51136, "count": 3}, {"text": "Sanofi", "sentiment": {"score": -0.522483, "label": "negative"}, "relevance": 0.507728, "count": 1}, {"text": "Lexington", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506374, "count": 1}, {"text": "NYSE", "sentiment": {"score": -0.522483, "label": "negative"}, "relevance": 0.506374, "count": 1}, {"text": "employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506061, "count": 1}, {"text": "market", "sentiment": {"score": 0.277174, "mixed": "1", "label": "positive"}, "relevance": 0.505257, "count": 1}, {"text": "statement", "sentiment": {"score": 0.989153, "label": "positive"}, "relevance": 0.505257, "count": 1}, {"text": "Mass", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505257, "count": 1}, {"text": "Jan", "sentiment": {"score": -0.366898, "label": "negative"}, "relevance": 0.505257, "count": 1}, {"text": "months of constructive dialogue", "sentiment": {"score": 0.994881, "label": "positive"}, "relevance": 0.503297, "count": 1}, {"text": "Shire's U.S. headquarters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.501846, "count": 1}, {"text": "biopharmaceutical leader", "sentiment": {"score": 0.994881, "label": "positive"}, "relevance": 0.499507, "count": 1}]}, "extracted_metadata": {"sha1": "be15e82097ea5868a181b06cce1700728a3ddcb9", "filename": "1542729534753.zip-bfcec1d3a34602dcd68cc2ab91dfee95.xml", "file_type": "json"}, "title": "Shire-Takeda deal gets conditional EU approval, heads to shareholders", "forum_title": "National Business News - Local Business News | bizjournals"}, {"id": "8ZJ6SnIopmoAxNcQam3KH_5dG-wz433QBFPHG-7Mxcr7br2yttZt2m2FTXQ4u0bU", "result_metadata": {"score": 36.0832}, "author": "Zacks Equity Research", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Shire-Takeda Deal", "keywords": [{"text": "Shire-Takeda Deal"}]}, "sentence": "Shire-Takeda Deal Gets Phase I Conditional European Approval", "object": {"text": "Phase I Conditional European Approval", "keywords": [{"text": "European Approval"}, {"text": "Phase"}]}, "action": {"verb": {"text": "Gets", "tense": "present"}, "text": "Gets", "normalized": "Gets"}}], "concepts": [], "categories": [{"score": 0.657961, "label": "/business and industrial/construction"}, {"score": 0.60331, "label": "/law, govt and politics"}, {"score": 0.602295, "label": "/law, govt and politics/government/government contracting and procurement"}], "relations": [{"type": "managerOf", "sentence": "Shire-Takeda Deal Gets Phase I Conditional European Approval", "score": 0.607756, "arguments": [{"text": "I", "location": [29, 30], "entities": [{"type": "Person", "text": "I"}]}, {"text": "Conditional European Approval", "location": [31, 60], "entities": [{"type": "Organization", "text": "Conditional European Approval"}]}]}], "keywords": [{"text": "Shire-Takeda Deal Gets Phase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.987458, "count": 1}, {"text": "Conditional European Approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.012542, "count": 1}]}, "crawl_date": "2018-11-21T14:09:54Z", "url": "https://www.zacks.com/stock/news/338822/ShireTakeda-Deal-Gets-Phase-I-Conditional-European-Approval", "host": "zacks.com", "text": "Shire Plc ( SHPG - Free Report ) announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co.", "main_image_url": "https://staticx-tuner.zacks.com/images/articles/main/a1/1542805630.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T00:00:00-06:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.974275, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.890687, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.878494, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc Price", "relevance": 0.788321, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.498811, "label": "negative"}, "text": "Shire", "relevance": 0.67579, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co", "relevance": 0.574593, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.444661, "label": "positive"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.524393, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 2, "sentiment": {"score": -0.324483, "label": "negative"}, "text": "Merck", "relevance": 0.49426, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.498811, "label": "negative"}, "text": "European Commission", "relevance": 0.452776, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Union", "relevance": 0.413758, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers", "relevance": 0.408569, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co.", "relevance": 0.383448, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.357326, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.554136, "label": "positive"}, "text": "marijuana", "relevance": 0.35053, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "JNJ", "relevance": 0.340892, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson", "relevance": 0.339779, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Court", "relevance": 0.337592, "type": "Organization", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "four quarters", "relevance": 0.290294, "type": "Quantity"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "60 days", "relevance": 0.290294, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "36%", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$20.2 billion", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$6.7 billion", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11.99%", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.62", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.82", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$3.84", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.08", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.27", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.34", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.63", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$4.71", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$8.14", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$8.16", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$8.61", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$8.66", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.65%", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10.2%", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "14.5%", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.96%", "relevance": 0.290294, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$62", "relevance": 0.290294, "type": "Quantity"}], "sentiment": {"document": {"score": 0.492399, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Shire Plc ( SHPG - Free Report )", "keywords": [{"text": "Shire Plc"}, {"text": "Free Report"}, {"text": "SHPG"}], "entities": [{"type": "Company", "text": "Shire Plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "sentence": "Shire Plc ( SHPG - Free Report ) announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co.", "object": {"text": "that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co", "keywords": [{"text": "Union antitrust regulators"}, {"text": "conditional approval"}, {"text": "Takeda Pharmaceutical"}, {"text": "phase"}], "entities": [{"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the European Union antitrust regulators", "keywords": [{"text": "Union antitrust regulators"}, {"text": "European"}], "entities": [{"type": "Organization", "text": "European Union", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "sentence": "Shire Plc ( SHPG - Free Report ) announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co.", "object": {"text": "I conditional approval", "keywords": [{"text": "conditional approval"}]}, "action": {"verb": {"text": "grant", "tense": "past"}, "text": "have granted", "normalized": "have grant"}}, {"subject": {"text": "The European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "approved the deal subject to Shire selling an inflammatory bowel disease treatment", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "deal subject"}, {"text": "Shire"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The European Commission", "keywords": [{"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "Takeda-marketed product Entyvio"}, {"text": "deal subject"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "has approved", "normalized": "have approve"}}, {"subject": {"text": "an inflammatory bowel disease treatment", "keywords": [{"text": "inflammatory bowel disease"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "SHP647 that could compete with a Takeda-marketed product Entyvio", "keywords": [{"text": "Takeda-marketed product Entyvio"}]}, "action": {"verb": {"text": "call", "tense": "past"}, "text": "called", "normalized": "call"}}, {"subject": {"text": "an inflammatory bowel disease treatment, called SHP647", "keywords": [{"text": "inflammatory bowel disease"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "with a Takeda-marketed product Entyvio (vedolizumab)", "keywords": [{"text": "Takeda-marketed product Entyvio"}, {"text": "vedolizumab"}]}, "action": {"verb": {"text": "compete", "tense": "future"}, "text": "could compete", "normalized": "could compete"}}, {"subject": {"text": "SHP647", "keywords": [{"text": "SHP647"}]}, "sentence": " The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "hit", "tense": "present"}, "text": "hits", "normalized": "hit"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire.", "object": {"text": "that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire", "keywords": [{"text": "final regulatory approval"}, {"text": "European Commission"}, {"text": "clearance"}, {"text": "Shire"}], "entities": [{"type": "Organization", "text": "European Commission"}, {"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "state", "tense": "past"}, "text": "stated", "normalized": "state"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda had announced the acquisition in May 2018.", "object": {"text": "announced the acquisition", "keywords": [{"text": "acquisition"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda had announced the acquisition in May 2018.", "object": {"text": "the acquisition", "keywords": [{"text": "acquisition"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "had announced", "normalized": "have announce"}}, {"subject": {"text": "The acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " The acquisition is subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court.", "object": {"text": "subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court", "keywords": [{"text": "Scheme Document"}, {"text": "certain other conditions"}, {"text": "Takeda"}, {"text": "shareholders"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "Court", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court", "keywords": [{"text": "Scheme Document"}, {"text": "Takeda"}, {"text": "shareholders"}, {"text": "sanction"}], "entities": [{"type": "Company", "text": "Shire"}, {"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "Court", "disambiguation": {"subtype": ["Sport"], "name": "Volleyball", "dbpedia_resource": "http://dbpedia.org/resource/Volleyball"}}]}, "sentence": " The acquisition is subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court.", "object": {"text": "certain other conditions", "keywords": [{"text": "certain other conditions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the other conditions", "keywords": [{"text": "conditions"}]}, "sentence": " The acquisition is subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court.", "object": {"text": "in the Scheme Document", "keywords": [{"text": "Scheme Document"}]}, "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "Shire and Takeda", "keywords": [{"text": "Takeda"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}, {"type": "Person", "text": "Takeda"}]}, "sentence": " Assuming these conditions are met, Shire and Takeda confirmed that the acquisition will close on Jan 8, 2019.", "object": {"text": "that the acquisition will close on Jan 8", "keywords": [{"text": "acquisition"}, {"text": "Jan"}]}, "action": {"verb": {"text": "confirm", "tense": "past"}, "text": "confirmed", "normalized": "confirm"}}, {"subject": {"text": "the acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " Assuming these conditions are met, Shire and Takeda confirmed that the acquisition will close on Jan 8, 2019.", "action": {"verb": {"text": "close", "tense": "future"}, "text": "will close", "normalized": "will close"}}, {"subject": {"text": "Both the companies", "keywords": [{"text": "companies"}]}, "sentence": " Both the companies are leaders in their therapeutic areas and also have an attractive geographic footprint.", "object": {"text": "an attractive geographic footprint", "keywords": [{"text": "attractive geographic footprint"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "the combined group", "keywords": [{"text": "group"}]}, "sentence": " Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world", "object": {"text": "better positioned to deliver highly-innovative medicines and transformative care", "keywords": [{"text": "transformative care"}, {"text": "highly-innovative medicines"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "the combined group", "keywords": [{"text": "group"}]}, "sentence": " Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world", "object": {"text": "to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world", "keywords": [{"text": "transformative care"}, {"text": "brighter future"}, {"text": "highly-innovative medicines"}, {"text": "better health"}]}, "action": {"verb": {"text": "position", "tense": "future"}, "text": "positioned", "normalized": "position"}}, {"subject": {"text": "the combined group", "keywords": [{"text": "group"}]}, "sentence": " Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world", "object": {"text": "highly-innovative medicines and transformative care", "keywords": [{"text": "transformative care"}, {"text": "highly-innovative medicines"}]}, "action": {"verb": {"text": "deliver", "tense": "future"}, "text": "to deliver", "normalized": "to deliver"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 14.5% year to date, against the industry \u2019s decline of 10.2%.", "object": {"text": "increased 14.5% year", "keywords": [{"text": "14.5"}], "entities": [{"type": "Quantity", "text": "14.5"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " Shire is a Zacks Rank #3 (Hold) stock.", "object": {"text": "a Zacks Rank #3 (Hold) stock", "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Some better-ranked stocks worth considering", "keywords": [{"text": "better-ranked stocks"}]}, "sentence": " Some better-ranked stocks worth considering are Bristol-Myers Squibb Company ( BMY - Free Report ) , Johnson and Johnson ( JNJ - Free Report ) and Merck & Co. ( MRK - Free Report ) .", "object": {"text": "Bristol-Myers Squibb Company ( BMY - Free Report ) , Johnson and Johnson ( JNJ - Free Report ) and Merck & Co. ( MRK - Free Report )", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Free Report"}, {"text": "JNJ"}, {"text": "Merck"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Person", "text": "Johnson"}, {"type": "Person", "text": "Johnson"}, {"type": "Company", "text": "JNJ", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Merck", "keywords": [{"text": "Merck"}], "entities": [{"type": "Company", "text": "Merck"}]}, "sentence": " While Bristol-Myers sports a Zacks Rank #1 (Strong Buy), J&J and Merck carry a Zacks Rank #2 (Buy).", "object": {"text": "a Zacks Rank #2 (Buy)", "keywords": [{"text": "Zacks Rank"}, {"text": "Buy"}]}, "action": {"verb": {"text": "carry", "tense": "present"}, "text": "carry", "normalized": "carry"}}, {"subject": {"text": "You"}, "sentence": " You can see the stocks here .", "object": {"text": "the stocks", "keywords": [{"text": "stocks"}]}, "action": {"verb": {"text": "see", "tense": "future"}, "text": "can see", "normalized": "can see"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company delivered a positive earnings surprise in all of the trailing four quarters with average of 11.99%.", "object": {"text": "a positive earnings surprise", "keywords": [{"text": "positive earnings surprise"}]}, "action": {"verb": {"text": "deliver", "tense": "past"}, "text": "delivered", "normalized": "deliver"}}, {"subject": {"text": "Merck", "keywords": [{"text": "Merck"}], "entities": [{"type": "Company", "text": "Merck"}]}, "sentence": " Merck\u2019s earnings per share estimates have increased from $4.27 to $4.34 for 2018 and from $4.63 to $4.71 for 2019 over the past 60 days.", "object": {"text": "earnings per share estimates", "keywords": [{"text": "earnings"}, {"text": "estimates"}, {"text": "share"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company delivered a positive earnings surprise in all of the trailing four quarters with average of 3.96%.", "object": {"text": "a positive earnings surprise", "keywords": [{"text": "positive earnings surprise"}]}, "action": {"verb": {"text": "deliver", "tense": "past"}, "text": "delivered", "normalized": "deliver"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 36% year to date.", "object": {"text": "increased 36% year to date", "keywords": [{"text": "date"}], "entities": [{"type": "Quantity", "text": "36"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 36% year to date.", "object": {"text": "36% year", "entities": [{"type": "Quantity", "text": "36"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "have increased", "normalized": "have increase"}}, {"subject": {"text": "J&J", "keywords": [{"text": "J&J"}]}, "sentence": " J&J\u2019s earnings per share estimates have increased from $8.14 to $8.16 for 2018 and from $8.61 to $8.66 for 2019 over the past 60 days.", "object": {"text": "earnings per share estimates", "keywords": [{"text": "earnings"}, {"text": "estimates"}, {"text": "share"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company delivered a positive earnings surprise in all of the trailing four quarters with average of 1.65%.", "object": {"text": "a positive earnings surprise", "keywords": [{"text": "positive earnings surprise"}]}, "action": {"verb": {"text": "deliver", "tense": "past"}, "text": "delivered", "normalized": "deliver"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 36% year to date.", "object": {"text": "increased 36% year to date", "keywords": [{"text": "date"}], "entities": [{"type": "Quantity", "text": "36"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Shares of the company", "keywords": [{"text": "Shares"}, {"text": "company"}]}, "sentence": " Shares of the company have increased 36% year to date.", "object": {"text": "36% year", "entities": [{"type": "Quantity", "text": "36"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "have increased", "normalized": "have increase"}}, {"subject": {"text": "Zacks", "keywords": [{"text": "Zacks"}]}, "sentence": " Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.", "object": {"text": "just released a Special Report on the booming investment opportunities of legal marijuana", "keywords": [{"text": "booming investment opportunities"}, {"text": "legal marijuana"}, {"text": "Special Report"}], "entities": [{"type": "Drug", "text": "marijuana"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Zacks", "keywords": [{"text": "Zacks"}]}, "sentence": " Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.", "object": {"text": "a Special Report on the booming investment opportunities of legal marijuana", "keywords": [{"text": "booming investment opportunities"}, {"text": "legal marijuana"}, {"text": "Special Report"}], "entities": [{"type": "Drug", "text": "marijuana"}]}, "action": {"verb": {"text": "release", "tense": "past"}, "text": "has just released", "normalized": "have just release"}}, {"subject": {"text": "by new referendums and legislation", "keywords": [{"text": "new referendums"}, {"text": "legislation"}]}, "sentence": " Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021.", "object": {"text": "this industry", "keywords": [{"text": "industry"}]}, "action": {"verb": {"text": "Ignited", "tense": "past"}, "text": "Ignited", "normalized": "Ignited"}}, {"subject": {"text": "Early investors", "keywords": [{"text": "Early investors"}]}, "sentence": " Early investors stand to make a killing, but you have to be ready to act and know just where to look.", "object": {"text": "to make a killing", "keywords": [{"text": "killing"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stand", "normalized": "stand"}}, {"subject": {"text": "Early investors", "keywords": [{"text": "Early investors"}]}, "sentence": " Early investors stand to make a killing, but you have to be ready to act and know just where to look.", "object": {"text": "a killing", "keywords": [{"text": "killing"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "stand to make", "normalized": "stand to make"}}, {"subject": {"text": "you"}, "sentence": " Early investors stand to make a killing, but you have to be ready to act and know just where to look.", "object": {"text": "just where to look"}, "action": {"verb": {"text": "know", "tense": "present"}, "text": "know", "normalized": "know"}}], "concepts": [{"text": "Bristol-Myers Squibb", "relevance": 0.957254, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "European Union", "relevance": 0.868368, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "European Commission", "relevance": 0.651395, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "Clopidogrel", "relevance": 0.623021, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Paclitaxel", "relevance": 0.595552, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}], "categories": [{"score": 0.798503, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.796728, "label": "/finance/investing/stocks"}, {"score": 0.759267, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "employedBy", "sentence": "Shire Plc ( SHPG - Free Report ) announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co. Ltd.'s $62-billion bid to acquire the former.", "score": 0.446061, "arguments": [{"text": "regulators", "location": [77, 87], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "European Union", "location": [52, 66], "entities": [{"type": "GeopoliticalEntity", "text": "European Union", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "timeOf", "sentence": "Takeda had announced the acquisition in May 2018.", "score": 0.914463, "arguments": [{"text": "May 2018", "location": [636, 644], "entities": [{"type": "Date", "text": "May 2018"}]}, {"text": "acquisition", "location": [621, 632], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "employedBy", "sentence": "The acquisition is subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court.", "score": 0.462823, "arguments": [{"text": "Shire", "location": [757, 762], "entities": [{"type": "Person", "text": "Shire plc Price\nShire plc Price"}]}, {"text": "shareholders", "location": [741, 753], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Assuming these conditions are met, Shire and Takeda confirmed that the acquisition will close on Jan 8, 2019.", "score": 0.990937, "arguments": [{"text": "Takeda", "location": [953, 959], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "confirmed", "location": [960, 969], "entities": [{"type": "EventCommunication", "text": "confirmed"}]}]}, {"type": "timeOf", "sentence": "Assuming these conditions are met, Shire and Takeda confirmed that the acquisition will close on Jan 8, 2019.", "score": 0.596856, "arguments": [{"text": "2019", "location": [1012, 1016], "entities": [{"type": "Date", "text": "2019"}]}, {"text": "acquisition", "location": [979, 990], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "locatedAt", "sentence": "Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world Shares of the company have increased 14.5% year to date, against the industry 's decline of 10.2%.", "score": 0.59425, "arguments": [{"text": "patients", "location": [1290, 1298], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "world", "location": [1310, 1315], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world Shares of the company have increased 14.5% year to date, against the industry 's decline of 10.2%.", "score": 0.627602, "arguments": [{"text": "company", "location": [1330, 1337], "entities": [{"type": "Organization", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "world", "location": [1310, 1315], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Shire plc Price Shire plc Price | Shire plc Quote: Zacks Rank & Stocks to Consider Shire is a Zacks Rank #3 (Hold) stock.", "score": 0.687817, "arguments": [{"text": "Shire plc Price\nShire plc Price", "location": [1415, 1446], "entities": [{"type": "Person", "text": "Shire plc Price\nShire plc Price"}]}, {"text": "Quote", "location": [1459, 1464], "entities": [{"type": "EventCommunication", "text": "Quote"}]}]}, {"type": "employedBy", "sentence": "Some better-ranked stocks worth considering are Bristol-Myers Squibb Company ( BMY - Free Report ) , Johnson and Johnson ( JNJ - Free Report ) and Merck & Co. ( MRK - Free Report ) .", "score": 0.69986, "arguments": [{"text": "Johnson", "location": [1650, 1657], "entities": [{"type": "Person", "text": "Johnson"}]}, {"text": "JNJ - Free Report", "location": [1660, 1677], "entities": [{"type": "Organization", "text": "JNJ - Free Report", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "While Bristol-Myers sports a Zacks Rank #1 (Strong Buy), J&J and Merck carry a Zacks Rank #2 (Buy).", "score": 0.630847, "arguments": [{"text": "Zacks Rank #1", "location": [1749, 1762], "entities": [{"type": "Person", "text": "Zacks Rank #1"}]}, {"text": "Strong Buy", "location": [1764, 1774], "entities": [{"type": "Organization", "text": "Strong Buy", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Merck's earnings per share estimates have increased from $4.27 to $4.34 for 2018 and from $4.63 to $4.71 for 2019 over the past 60 days.", "score": 0.569526, "arguments": [{"text": "Merck", "location": [2106, 2111], "entities": [{"type": "Organization", "text": "MRK - Free Report", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$4.27", "location": [2163, 2168], "entities": [{"type": "Money", "text": "$4.27"}]}]}, {"type": "hasAttribute", "sentence": "The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "score": 0.892727, "arguments": [{"text": "SHP647", "location": [326, 332], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "bowel disease", "location": [294, 307], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}]}, {"type": "hasAttribute", "sentence": "Merck's earnings per share estimates have increased from $4.27 to $4.34 for 2018 and from $4.63 to $4.71 for 2019 over the past 60 days.", "score": 0.644751, "arguments": [{"text": "Merck", "location": [2106, 2111], "entities": [{"type": "Organization", "text": "MRK - Free Report", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$4.34", "location": [2172, 2177], "entities": [{"type": "Money", "text": "$4.34"}]}]}, {"type": "agentOf", "sentence": "Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.", "score": 0.556697, "arguments": [{"text": "Zacks", "location": [2710, 2715], "entities": [{"type": "Person", "text": "Zacks Rank #3"}]}, {"text": "Report", "location": [2744, 2750], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "affectedBy", "sentence": "The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.", "score": 0.54423, "arguments": [{"text": "SHP647", "location": [326, 332], "entities": [{"type": "Person", "text": "SHP647"}]}, {"text": "called", "location": [319, 325], "entities": [{"type": "EventCommunication", "text": "called"}]}]}, {"type": "agentOf", "sentence": "Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire.", "score": 0.946028, "arguments": [{"text": "Takeda", "location": [449, 455], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "stated", "location": [456, 462], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire.", "score": 0.643586, "arguments": [{"text": "its", "location": [570, 573], "entities": [{"type": "Organization", "text": "SHP647"}]}, {"text": "acquisition", "location": [574, 585], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire.", "score": 0.347349, "arguments": [{"text": "Shire", "location": [589, 594], "entities": [{"type": "Person", "text": "Shire plc Price\nShire plc Price"}]}, {"text": "acquisition", "location": [574, 585], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Takeda had announced the acquisition in May 2018.", "score": 0.889706, "arguments": [{"text": "Takeda", "location": [596, 602], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [607, 616], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "Takeda had announced the acquisition in May 2018.", "score": 0.667234, "arguments": [{"text": "Takeda", "location": [596, 602], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [621, 632], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Takeda had announced the acquisition in May 2018.", "score": 0.515256, "arguments": [{"text": "May 2018", "location": [636, 644], "entities": [{"type": "Date", "text": "May 2018"}]}, {"text": "announced", "location": [607, 616], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}], "keywords": [{"text": "Shire Plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.743833, "count": 1}, {"text": "Zacks Rank", "sentiment": {"score": 0.452294, "label": "positive"}, "relevance": 0.696014, "count": 4}, {"text": "Takeda Pharmaceutical Co. Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.683479, "count": 1}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0.852441, "label": "positive"}, "relevance": 0.665765, "count": 1}, {"text": "European Union", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.65817, "count": 1}, {"text": "Shire", "sentiment": {"score": 0.268329, "mixed": "1", "label": "positive"}, "relevance": 0.649582, "count": 3}, {"text": "better health", "sentiment": {"score": 0.991782, "label": "positive"}, "relevance": 0.629155, "count": 1}, {"text": "European Commission", "sentiment": {"score": -0.35261, "label": "negative"}, "relevance": 0.627112, "count": 2}, {"text": "Takeda", "sentiment": {"score": 0.561036, "mixed": "1", "label": "positive"}, "relevance": 0.6244, "count": 5}, {"text": "J&J", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.619349, "count": 1}, {"text": "Free Report", "sentiment": {"score": 0.852441, "label": "positive"}, "relevance": 0.601354, "count": 4}, {"text": "companies", "sentiment": {"score": 0.806758, "label": "positive"}, "relevance": 0.573879, "count": 1}, {"text": "company", "sentiment": {"score": 0.991782, "label": "positive"}, "relevance": 0.573879, "count": 4}, {"text": "acquisition of Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573563, "count": 1}, {"text": "worth considering", "sentiment": {"score": 0.852441, "label": "positive"}, "relevance": 0.565598, "count": 1}, {"text": "Bristol-Myers sports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564786, "count": 1}, {"text": "conditions", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.559289, "count": 3}, {"text": "conditional approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557799, "count": 1}, {"text": "stock", "sentiment": {"score": 0.852441, "label": "positive"}, "relevance": 0.557281, "count": 1}, {"text": "Stocks", "sentiment": {"score": 0.452294, "label": "positive"}, "relevance": 0.557281, "count": 1}, {"text": "Merck", "sentiment": {"score": 0.852441, "label": "positive"}, "relevance": 0.547371, "count": 2}, {"text": "acquisition", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.545765, "count": 3}, {"text": "stocks", "sentiment": {"score": 0.547457, "mixed": "1", "label": "positive"}, "relevance": 0.538281, "count": 2}, {"text": "Special Report", "sentiment": {"score": 0.794147, "label": "positive"}, "relevance": 0.535709, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.852441, "label": "positive"}, "relevance": 0.532251, "count": 2}, {"text": "clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531539, "count": 1}, {"text": "group", "sentiment": {"score": 0.991782, "label": "positive"}, "relevance": 0.531471, "count": 1}, {"text": "inflammatory bowel disease treatment", "sentiment": {"score": -0.35261, "label": "negative"}, "relevance": 0.531268, "count": 1}, {"text": "deal", "sentiment": {"score": -0.35261, "label": "negative"}, "relevance": 0.531262, "count": 1}, {"text": "shareholders of Shire", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.531242, "count": 1}, {"text": "Bristol-Myers\u2019 earnings", "sentiment": {"score": -0.461638, "label": "negative"}, "relevance": 0.531208, "count": 1}, {"text": "share estimates", "sentiment": {"score": -0.528692, "label": "negative"}, "relevance": 0.524561, "count": 3}, {"text": "satisfaction", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.523285, "count": 1}, {"text": "brighter future", "sentiment": {"score": 0.991782, "label": "positive"}, "relevance": 0.521666, "count": 1}, {"text": "phase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520999, "count": 1}, {"text": "market", "sentiment": {"score": -0.35261, "label": "negative"}, "relevance": 0.520787, "count": 1}, {"text": "Strong Buy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520258, "count": 1}, {"text": "waiver", "sentiment": {"score": 0.879501, "label": "positive"}, "relevance": 0.518773, "count": 1}, {"text": "final regulatory approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517575, "count": 1}, {"text": "leaders", "sentiment": {"score": 0.806758, "label": "positive"}, "relevance": 0.515343, "count": 1}, {"text": "Shire plc Quote", "sentiment": {"score": 0.452294, "label": "positive"}, "relevance": 0.514926, "count": 1}, {"text": "Co.", "sentiment": {"score": 0.852441, "label": "positive"}, "relevance": 0.513861, "count": 1}, {"text": "innovative medicines", "sentiment": {"score": 0.991782, "label": "positive"}, "relevance": 0.510953, "count": 1}, {"text": "industry", "sentiment": {"score": 0.415129, "label": "positive"}, "relevance": 0.509358, "count": 1}, {"text": "legislation", "sentiment": {"score": 0.415129, "label": "positive"}, "relevance": 0.509356, "count": 1}, {"text": "year", "sentiment": {"score": 0.72562, "mixed": "1", "label": "positive"}, "relevance": 0.508102, "count": 3}, {"text": "Early investors", "sentiment": {"score": -0.767999, "label": "negative"}, "relevance": 0.507066, "count": 1}, {"text": "date", "sentiment": {"score": 0.72562, "mixed": "1", "label": "positive"}, "relevance": 0.506682, "count": 3}, {"text": "J&J\u2019s earnings", "sentiment": {"score": -0.517636, "label": "negative"}, "relevance": 0.506317, "count": 1}, {"text": "quarters", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505688, "count": 3}]}, "extracted_metadata": {"sha1": "f5c04090f5e7f72fd5310296840f897a9e6463b2", "filename": "1542809394495.zip-3bf1d3ff16d19386d6fe6e32f639ec89.xml", "file_type": "json"}, "title": "Shire-Takeda Deal Gets Phase I Conditional European Approval", "forum_title": "Most Recent Articles - Zacks.com"}, {"id": "go9d4T0hxrutmtGWfO1EAyHjSgSXSszfOFxxzfZYiIBgocufM0x2WDGSE_GguOZN", "result_metadata": {"score": 35.4856}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prurigo", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mn", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$697.9", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0.661392, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Prurigo nodularis", "relevance": 0.932431, "dbpedia_resource": "http://dbpedia.org/resource/Prurigo_nodularis"}], "categories": [{"score": 0.897199, "label": "/health and fitness/therapy"}, {"score": 0.714089, "label": "/finance/investing"}, {"score": 0.714089, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "hasAttribute", "sentence": "Prurigo Nodularis Treatment Market to Reflect a Modest Growth of US $697.9 Mn by 2028", "score": 0.539936, "arguments": [{"text": "US", "location": [65, 67], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "$697.9", "location": [68, 74], "entities": [{"type": "Money", "text": "$697.9", "disambiguation": {"subtype": ["Gainloss"]}}]}]}], "keywords": [{"text": "Prurigo Nodularis Treatment Market", "sentiment": {"score": 0.661392, "label": "positive"}, "relevance": 0.993048, "count": 1}, {"text": "Modest Growth of US", "sentiment": {"score": 0.661392, "label": "positive"}, "relevance": 0.283786, "count": 1}, {"text": "Mn", "sentiment": {"score": 0.661392, "label": "positive"}, "relevance": 0.017363, "count": 1}]}, "crawl_date": "2018-11-21T12:38:23Z", "url": "http://www.sbwire.com/press-releases/prurigo-nodularis-treatment-market-to-reflect-a-modest-growth-of-us-6979-mn-by-2028-1086676.htm", "host": "sbwire.com", "text": "., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co.", "main_image_url": "http://media.releasewire.com/photos/show/?id=79336", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T12:35:00Z", "enriched_text": {"entities": [{"count": 13, "sentiment": {"score": 0.472846, "label": "positive"}, "text": "Global Prurigo Nodularis Treatment Market", "relevance": 0.951767, "type": "Company"}, {"count": 14, "sentiment": {"score": 0.366402, "label": "positive"}, "text": "Prurigo", "relevance": 0.464788, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}, {"count": 4, "sentiment": {"score": 0.521255, "label": "positive"}, "text": "Mn", "relevance": 0.077216, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0.772163, "label": "positive"}, "text": "Orphan Products Development", "relevance": 0.0581088, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.0558752, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NY", "relevance": 0.0526046, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.0484341, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.0481055, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Media Relations Contact", "relevance": 0.0479327, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.702921, "label": "positive"}, "text": "China", "relevance": 0.0472379, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.0470427, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": -0.358157, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.0468441, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.702921, "label": "positive"}, "text": "Asia Pacific", "relevance": 0.0466062, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.0464097, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Western Europe", "relevance": 0.0430174, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer AG", "relevance": 0.0419122, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.A", "relevance": 0.041663, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.0407976, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0407847, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd", "relevance": 0.0404794, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.0402854, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.040147, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson Services Inc.", "relevance": 0.0393894, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.0383886, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": -0.449951, "label": "negative"}, "text": "Sanofi SA", "relevance": 0.0380798, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0380798, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$697.9", "relevance": 0.0380798, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2028", "relevance": 0.0380798, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.4%", "relevance": 0.0380798, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.8%", "relevance": 0.0380798, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "40%", "relevance": 0.0380798, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "45%", "relevance": 0.0380798, "type": "Quantity"}], "sentiment": {"document": {"score": 0.613858, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "by Future Market Insights titled 'Prurigo Nodularis Treatment Market", "keywords": [{"text": "Nodularis Treatment Market"}, {"text": "Future Market Insights"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " New York, NY According to the latest report published by Future Market Insights titled 'Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 \u2013 2017 and Opportunity Assessment 2018 \u2013 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018\u20132028.", "object": {"text": "the latest report", "keywords": [{"text": "latest report"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Future Market Insights", "keywords": [{"text": "Future Market Insights"}]}, "sentence": " New York, NY According to the latest report published by Future Market Insights titled 'Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 \u2013 2017 and Opportunity Assessment 2018 \u2013 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018\u20132028.", "object": {"text": "'Prurigo Nodularis Treatment Market", "keywords": [{"text": "Nodularis Treatment Market"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "title", "tense": "past"}, "text": "titled", "normalized": "title"}}, {"subject": {"text": "The global market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "global market"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018\u20132028.", "object": {"text": "a valuation of US$ 697.9 Mn", "keywords": [{"text": "valuation"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "Factors", "keywords": [{"text": "Factors"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Factors Influencing Growth Favourable regulations and initiatives for orphan drug development in various regions is expected to fuel the market for prurigo nodularis treatment in the near future.", "object": {"text": "Growth Favourable regulations", "keywords": [{"text": "Growth Favourable regulations"}]}, "action": {"verb": {"text": "Influencing", "tense": "present"}, "text": "Influencing", "normalized": "Influencing"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Factors Influencing Growth Favourable regulations and initiatives for orphan drug development in various regions is expected to fuel the market for prurigo nodularis treatment in the near future.", "object": {"text": "Factors Influencing Growth Favourable regulations and initiatives for orphan drug development in various regions", "keywords": [{"text": "Growth Favourable regulations"}, {"text": "orphan drug development"}, {"text": "various regions"}, {"text": "initiatives"}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "is expected to fuel", "normalized": "be expect to fuel"}}, {"subject": {"text": "awareness programmes", "keywords": [{"text": "awareness programmes"}]}, "sentence": " The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China", "keywords": [{"text": "highly populated regions"}, {"text": "rapidly developing healthcare"}, {"text": "awareness programmes"}, {"text": "Asia Pacific"}], "entities": [{"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "sentence": " The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "object": {"text": "an important role", "keywords": [{"text": "important role"}]}, "action": {"verb": {"text": "play", "tense": "future"}, "text": "is expected to play", "normalized": "be expect to play"}}, {"subject": {"text": "Segmental Insights The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "Segmental Insights"}, {"text": "treatment market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "sentence": " Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Segmental Insights The global prurigo nodularis treatment market has been segmented on the basis of product type, distribution channel and region.", "object": {"text": "been segmented on the basis of product type, distribution channel and region", "keywords": [{"text": "product type"}, {"text": "distribution channel"}, {"text": "basis"}, {"text": "region"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Segmental Insights The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "Segmental Insights"}, {"text": "treatment market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "sentence": " Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Segmental Insights The global prurigo nodularis treatment market has been segmented on the basis of product type, distribution channel and region.", "object": {"text": "on the basis of product type, distribution channel and region", "keywords": [{"text": "product type"}, {"text": "distribution channel"}, {"text": "basis"}, {"text": "region"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "Prurigo", "keywords": [{"text": "Prurigo"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.", "object": {"text": "treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others", "keywords": [{"text": "treatment product types"}, {"text": "capsacin cream"}, {"text": "corticosteroids"}, {"text": "antihistamines"}]}, "action": {"verb": {"text": "nodularis", "tense": "present"}, "text": "nodularis", "normalized": "nodularis"}}, {"subject": {"text": "corticosteroids, emollients, capsacin cream, antihistamines and others", "keywords": [{"text": "capsacin cream"}, {"text": "corticosteroids"}, {"text": "antihistamines"}, {"text": "emollients"}]}, "sentence": " Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.", "object": {"text": "Prurigo nodularis treatment product types", "keywords": [{"text": "Prurigo"}, {"text": "treatment product types"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "capsacin cream under the product type segment", "keywords": [{"text": "product type segment"}, {"text": "capsacin cream"}]}, "sentence": " Globally, capsacin cream under the product type segment stands the most attractive product form amongst the different product types.", "object": {"text": "the most attractive product form amongst the different product types", "keywords": [{"text": "attractive product form"}, {"text": "different product types"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stands", "normalized": "stand"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "anticipated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "action": {"verb": {"text": "anticipate", "tense": "past"}, "text": "are anticipated to be", "normalized": "be anticipate to be"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "the most lucrative distribution channel", "keywords": [{"text": "lucrative distribution channel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are anticipated to be", "normalized": "be anticipate to be"}}, {"subject": {"text": "by hospital pharmacies", "keywords": [{"text": "hospital pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "the most lucrative distribution channel", "keywords": [{"text": "lucrative distribution channel"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Regional Highlights With nearly 40% \u2013 45% market share, Western Europe", "keywords": [{"text": "Regional Highlights"}, {"text": "market share"}, {"text": "Western Europe"}], "entities": [{"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Quantity", "text": "40"}, {"type": "Quantity", "text": "45"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% \u2013 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "object": {"text": "the global prurigo nodularis treatment Market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment Market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "action": {"verb": {"text": "dominate", "tense": "past"}, "text": "dominated", "normalized": "dominate"}}, {"subject": {"text": "by governments", "keywords": [{"text": "governments"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% \u2013 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "object": {"text": "key research and development initiatives", "keywords": [{"text": "development initiatives"}, {"text": "key research"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "taken", "normalized": "take"}}, {"subject": {"text": "advanced medical facilities", "keywords": [{"text": "advanced medical facilities"}]}, "sentence": " Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "object": {"text": "the region cope with the current healthcare crisis", "keywords": [{"text": "current healthcare crisis"}, {"text": "region cope"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "are helping", "normalized": "be help"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate.", "object": {"text": "the second largest regional market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "largest regional market"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}, {"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the markets in U.S.A and Canada", "keywords": [{"text": "U.S.A"}, {"text": "markets"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "U.S.A", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "sentence": " North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate.", "object": {"text": "at a faster rate", "keywords": [{"text": "faster rate"}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "Eastern Europe", "keywords": [{"text": "Eastern Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Eastern Europe is projected to be the third largest market for prurigo nodularis treatment.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Key Research Findings The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "Key Research Findings"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Key Research Findings The global prurigo nodularis treatment market is expected to create incremental opportunity of US$ 197.9 Mn between 2018 and 2028 The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.", "object": {"text": "incremental opportunity of US$ 197.9 Mn between 2018 and 2028 The prurigo nodularis treatment market", "keywords": [{"text": "incremental opportunity"}, {"text": "treatment market"}, {"text": "prurigo"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "is expected to create", "normalized": "be expect to create"}}, {"subject": {"text": "US$ 197.9 Mn between 2018 and 2028 The prurigo nodularis treatment market", "keywords": [{"text": "treatment market"}, {"text": "prurigo"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Key Research Findings The global prurigo nodularis treatment market is expected to create incremental opportunity of US$ 197.9 Mn between 2018 and 2028 The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.", "object": {"text": "steady growth", "keywords": [{"text": "steady growth"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is expected to witness", "normalized": "be expect to witness"}}, {"subject": {"text": "Vendor Insights The global market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "Vendor Insights"}, {"text": "global market"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Vendor Insights The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "object": {"text": "highly competitive"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "many players", "keywords": [{"text": "players"}]}, "sentence": " Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Vendor Insights The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Some of the companies", "keywords": [{"text": "companies"}]}, "sentence": " Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "Some of the companies identified in global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "sentence": " Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "object": {"text": "Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others", "keywords": [{"text": "Teva Pharmaceutical Industries"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "GlaxoSmithKline plc"}, {"text": "Sanofi SA"}], "entities": [{"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd"}, {"type": "Company", "text": "Johnson & Johnson Services Inc."}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Sanofi SA"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "companies", "keywords": [{"text": "companies"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.", "object": {"text": "close collaborations", "keywords": [{"text": "close collaborations"}]}, "action": {"verb": {"text": "build", "tense": "future"}, "text": "building", "normalized": "build"}}, {"subject": {"text": "these partnerships", "keywords": [{"text": "partnerships"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.", "object": {"text": "firms to grow and expand in the global market", "keywords": [{"text": "global market"}, {"text": "firms"}], "entities": []}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allow", "normalized": "allow"}}, {"subject": {"text": "firms", "keywords": [{"text": "firms"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.", "action": {"verb": {"text": "expand", "tense": "present"}, "text": "expand", "normalized": "expand"}}], "concepts": [{"text": "Marketing", "relevance": 0.965633, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.872259, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Prurigo nodularis", "relevance": 0.718918, "dbpedia_resource": "http://dbpedia.org/resource/Prurigo_nodularis"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.656022, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Distribution", "relevance": 0.643894, "dbpedia_resource": "http://dbpedia.org/resource/Distribution_(business)"}, {"text": "Pharmacy", "relevance": 0.613682, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmaceutical industry", "relevance": 0.581838, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Drug discovery", "relevance": 0.554861, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Pfizer", "relevance": 0.549336, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Region", "relevance": 0.542809, "dbpedia_resource": "http://dbpedia.org/resource/Region"}, {"text": "GlaxoSmithKline", "relevance": 0.506081, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Economics", "relevance": 0.488063, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}], "categories": [{"score": 0.786519, "label": "/finance/financial news"}, {"score": 0.767503, "label": "/finance/investing"}, {"score": 0.767503, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "hasAttribute", "sentence": "RSS Prurigo Nodularis Treatment Market to Reflect a Modest Growth of US $697.9 Mn by 2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development New York, NY According to the latest report published by Future Market Insights titled 'Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.539936, "arguments": [{"text": "US", "location": [69, 71], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "$697.9", "location": [72, 78], "entities": [{"type": "Money", "text": "$697.9", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.42228, "arguments": [{"text": "& Africa", "location": [714, 722], "entities": [{"type": "Organization", "text": "& Africa"}]}, {"text": "attesting", "location": [665, 674], "entities": [{"type": "EventCommunication", "text": "attesting"}]}]}, {"type": "basedIn", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.611012, "arguments": [{"text": "& Africa", "location": [714, 722], "entities": [{"type": "Organization", "text": "& Africa"}]}, {"text": "Middle East", "location": [702, 713], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.891549, "arguments": [{"text": "regions", "location": [1129, 1136], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Asia", "location": [1140, 1144], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.848801, "arguments": [{"text": "regions", "location": [1129, 1136], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Pacific", "location": [1145, 1152], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.647654, "arguments": [{"text": "regions", "location": [1129, 1136], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "China", "location": [1157, 1162], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.614891, "arguments": [{"text": "Asia", "location": [1140, 1144], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [1145, 1152], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Segmental Insights The global prurigo nodularis treatment market has been segmented on the basis of product type, distribution channel and region.", "score": 0.526304, "arguments": [{"text": "Global Prurigo Nodularis Treatment Market", "location": [1385, 1426], "entities": [{"type": "Organization", "text": "Global Prurigo Nodularis Treatment Market"}]}, {"text": "View Sample of Research Report @", "location": [1288, 1320], "entities": [{"type": "Organization", "text": "View Sample of Research Report @"}]}]}, {"type": "locatedAt", "sentence": "Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "score": 0.875969, "arguments": [{"text": "Western", "location": [2106, 2113], "entities": [{"type": "Location", "text": "Western"}]}, {"text": "Europe", "location": [2114, 2120], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "score": 0.457813, "arguments": [{"text": "governments", "location": [2293, 2304], "entities": [{"type": "GeopoliticalEntity", "text": "Report for Table of Contents @"}]}, {"text": "region", "location": [2312, 2318], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "score": 0.82137, "arguments": [{"text": "regions", "location": [2344, 2351], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [2360, 2373], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "RSS Prurigo Nodularis Treatment Market to Reflect a Modest Growth of US $697.9 Mn by 2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development New York, NY According to the latest report published by Future Market Insights titled 'Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.458814, "arguments": [{"text": "Mn", "location": [79, 81], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "Global Prurigo Nodularis Treatment Market", "location": [90, 131], "entities": [{"type": "Organization", "text": "Global Prurigo Nodularis Treatment Market"}]}]}, {"type": "locatedAt", "sentence": "Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "score": 0.667622, "arguments": [{"text": "facilities", "location": [2392, 2402], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2419, 2425], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "partOf", "sentence": "Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Vendor Insights The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "score": 0.557986, "arguments": [{"text": "Global Prurigo Nodularis Treatment Market", "location": [3230, 3271], "entities": [{"type": "Organization", "text": "Global Prurigo Nodularis Treatment Market", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report for Table of Contents @", "location": [3144, 3174], "entities": [{"type": "Organization", "text": "Report for Table of Contents @"}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.473218, "arguments": [{"text": "Bayer AG", "location": [3493, 3501], "entities": [{"type": "Organization", "text": "Bayer AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3423, 3432], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.671821, "arguments": [{"text": "Pfizer Inc.", "location": [3503, 3514], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3423, 3432], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.607119, "arguments": [{"text": "GlaxoSmithKline plc", "location": [3516, 3535], "entities": [{"type": "Organization", "text": "GlaxoSmithKline plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3423, 3432], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.598112, "arguments": [{"text": "Johnson & Johnson Services Inc.", "location": [3573, 3604], "entities": [{"type": "Organization", "text": "Johnson & Johnson Services Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3423, 3432], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.507685, "arguments": [{"text": "Merck & Co. Inc.", "location": [3606, 3622], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3423, 3432], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.577551, "arguments": [{"text": "Sanofi SA", "location": [3624, 3633], "entities": [{"type": "Organization", "text": "Sanofi SA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3423, 3432], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "RSS Prurigo Nodularis Treatment Market to Reflect a Modest Growth of US $697.9 Mn by 2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development New York, NY According to the latest report published by Future Market Insights titled 'Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.677521, "arguments": [{"text": "Global Prurigo Nodularis Treatment Market", "location": [90, 131], "entities": [{"type": "Organization", "text": "Global Prurigo Nodularis Treatment Market"}]}, {"text": "Gain Traction", "location": [135, 148], "entities": [{"type": "Organization", "text": "Gain Traction"}]}]}, {"type": "partOf", "sentence": "RSS Prurigo Nodularis Treatment Market to Reflect a Modest Growth of US $697.9 Mn by 2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development New York, NY According to the latest report published by Future Market Insights titled 'Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.775308, "arguments": [{"text": "Orphan Products Development\nNew York", "location": [205, 241], "entities": [{"type": "Organization", "text": "Orphan Products Development\nNew York"}]}, {"text": "Favourable Regulations", "location": [178, 200], "entities": [{"type": "Organization", "text": "Favourable Regulations"}]}]}, {"type": "partOf", "sentence": "RSS Prurigo Nodularis Treatment Market to Reflect a Modest Growth of US $697.9 Mn by 2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development New York, NY According to the latest report published by Future Market Insights titled 'Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.436284, "arguments": [{"text": "published", "location": [277, 286], "entities": [{"type": "EventCommunication", "text": "published"}]}, {"text": "report", "location": [270, 276], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "RSS Prurigo Nodularis Treatment Market to Reflect a Modest Growth of US $697.9 Mn by 2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development New York, NY According to the latest report published by Future Market Insights titled 'Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.504257, "arguments": [{"text": "Future Market Insights", "location": [290, 312], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "report", "location": [270, 276], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "RSS Prurigo Nodularis Treatment Market to Reflect a Modest Growth of US $697.9 Mn by 2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development New York, NY According to the latest report published by Future Market Insights titled 'Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.871915, "arguments": [{"text": "Future Market Insights", "location": [290, 312], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "published", "location": [277, 286], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "populationOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.577512, "arguments": [{"text": "697.9", "location": [643, 648], "entities": [{"type": "Cardinal", "text": "697.9"}]}, {"text": "US$", "location": [639, 642], "entities": [{"type": "GeopoliticalEntity", "text": "US$"}]}]}, {"type": "agentOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.516048, "arguments": [{"text": "Mn", "location": [649, 651], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "attesting", "location": [665, 674], "entities": [{"type": "EventCommunication", "text": "attesting"}]}]}], "keywords": [{"text": "RSS Prurigo Nodularis Treatment Market", "sentiment": {"score": 0.930096, "label": "positive"}, "relevance": 0.936124, "count": 1}, {"text": "Global Prurigo Nodularis Treatment Market", "sentiment": {"score": 0.804607, "label": "positive"}, "relevance": 0.81632, "count": 3}, {"text": "Prurigo Nodularis Treatment Market", "sentiment": {"score": 0.930096, "label": "positive"}, "relevance": 0.662587, "count": 1}, {"text": "various regions", "sentiment": {"score": 0.772514, "label": "positive"}, "relevance": 0.631378, "count": 2}, {"text": "global prurigo nodularis treatment market", "sentiment": {"score": 0.411871, "mixed": "1", "label": "positive"}, "relevance": 0.628727, "count": 4}, {"text": "Future Market Insights", "sentiment": {"score": 0.930096, "label": "positive"}, "relevance": 0.599947, "count": 1}, {"text": "global market", "sentiment": {"score": 0.697949, "label": "positive"}, "relevance": 0.589937, "count": 4}, {"text": "Global Industry Analysis", "sentiment": {"score": 0.930096, "label": "positive"}, "relevance": 0.570376, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565353, "count": 1}, {"text": "Modest Growth of US", "sentiment": {"score": 0.930096, "label": "positive"}, "relevance": 0.564502, "count": 1}, {"text": "prurigo nodularis treatment", "sentiment": {"score": 0.686707, "label": "positive"}, "relevance": 0.562978, "count": 6}, {"text": "Western Europe", "sentiment": {"score": 0.534574, "label": "positive"}, "relevance": 0.558577, "count": 1}, {"text": "market", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.553373, "count": 1}, {"text": "Eastern Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546892, "count": 1}, {"text": "North America", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.546687, "count": 1}, {"text": "basis of product type", "sentiment": {"score": -0.952324, "label": "negative"}, "relevance": 0.546523, "count": 1}, {"text": "market share", "sentiment": {"score": 0.534574, "label": "positive"}, "relevance": 0.545443, "count": 1}, {"text": "Request Report", "sentiment": {"score": 0.699043, "label": "positive"}, "relevance": 0.544236, "count": 1}, {"text": "region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542157, "count": 2}, {"text": "Gain Traction", "sentiment": {"score": 0.930096, "label": "positive"}, "relevance": 0.538206, "count": 1}, {"text": "important role", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.537199, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533092, "count": 2}, {"text": "steady growth", "sentiment": {"score": 0.62988, "label": "positive"}, "relevance": 0.532431, "count": 1}, {"text": "faster rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531571, "count": 1}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530305, "count": 1}, {"text": "Growth", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.529531, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528921, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0.69688, "label": "positive"}, "relevance": 0.528354, "count": 1}, {"text": "regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525333, "count": 1}, {"text": "markets", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.525191, "count": 1}, {"text": "US", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.524815, "count": 1}, {"text": "Sample of Research Report", "sentiment": {"score": -0.952324, "label": "negative"}, "relevance": 0.522841, "count": 1}, {"text": "regions of Asia Pacific", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.522735, "count": 1}, {"text": "players", "sentiment": {"score": 0.699043, "label": "positive"}, "relevance": 0.521068, "count": 1}, {"text": "Prurigo nodularis treatment product types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518657, "count": 1}, {"text": "order", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517993, "count": 1}, {"text": "latest report", "sentiment": {"score": 0.930096, "label": "positive"}, "relevance": 0.517733, "count": 1}, {"text": "governments", "sentiment": {"score": 0.534574, "label": "positive"}, "relevance": 0.51765, "count": 1}, {"text": "initiatives", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.517562, "count": 1}, {"text": "presence", "sentiment": {"score": 0.534574, "label": "positive"}, "relevance": 0.51662, "count": 1}, {"text": "near future", "sentiment": {"score": 0.825717, "label": "positive"}, "relevance": 0.515901, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515625, "count": 1}, {"text": "China", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.514463, "count": 1}, {"text": "corticosteroids", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512417, "count": 1}, {"text": "Teva Pharmaceutical Industries Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512189, "count": 1}, {"text": "end", "sentiment": {"score": 0.69688, "label": "positive"}, "relevance": 0.511914, "count": 1}, {"text": "Factors", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.511768, "count": 1}, {"text": "demand", "sentiment": {"score": 0.62988, "label": "positive"}, "relevance": 0.510344, "count": 1}, {"text": "partnerships", "sentiment": {"score": 0.590495, "label": "positive"}, "relevance": 0.510328, "count": 1}, {"text": "firms", "sentiment": {"score": 0.590495, "label": "positive"}, "relevance": 0.50987, "count": 1}]}, "extracted_metadata": {"sha1": "85a1014d9983bba0ef23f8b9a58c83ba673e0d5c", "filename": "1542803903402.zip-e85baa8dd1f81263e0fcfdd3f46f22c7.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/askus/rep-gb-3339", "https://www.futuremarketinsights.com/reports/prurigo-nodularis-treatment-and-management-market", "http://www.releasewire.com/rss/", "https://www.futuremarketinsights.com/reports/sample/rep-gb-3339"], "title": "Prurigo Nodularis Treatment Market to Reflect a Modest Growth of US $697.9 Mn by 2028", "forum_title": "ReleaseWire - Latest Press Releases"}, {"id": "HHBXp__GWm_UGnvOGHDgLas6_pzPJhGidTMPSfEboQhVsrW4CDjrxJY0kN0BGak3", "result_metadata": {"score": 34.68092}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.98", "relevance": 0.01, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.1%", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": -0.825887, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Antidepressant Drugs Market", "keywords": [{"text": "Antidepressant Drugs"}, {"text": "Market"}]}, "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "object": {"text": "$15.98 Bn", "keywords": [{"text": "Bn"}], "entities": [{"type": "Quantity", "text": "$15.98"}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "to Reach", "normalized": "to Reach"}}, {"subject": {"text": "Allied Market Research", "keywords": [{"text": "Market Research"}]}, "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "object": {"text": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR", "keywords": [{"text": "Antidepressant Drugs"}, {"text": "Bn"}, {"text": "Globally"}, {"text": "Market"}], "entities": [{"type": "Quantity", "text": "$15.98"}, {"type": "Quantity", "text": "2.1"}]}, "action": {"verb": {"text": "Says", "tense": "present"}, "text": "Says", "normalized": "Says"}}], "concepts": [{"text": "Antidepressant", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}], "categories": [{"score": 0.937842, "label": "/health and fitness"}, {"score": 0.920755, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.737627, "label": "/health and fitness/drugs"}], "relations": [{"type": "locatedAt", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "score": 0.261322, "arguments": [{"text": "Drugs", "location": [15, 20], "entities": [{"type": "Substance", "text": "Drugs"}]}, {"text": "Market", "location": [21, 27], "entities": [{"type": "Organization", "text": "Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "score": 0.633856, "arguments": [{"text": "Allied Market Research", "location": [84, 106], "entities": [{"type": "Organization", "text": "Allied Market Research"}]}, {"text": "Says", "location": [79, 83], "entities": [{"type": "EventCommunication", "text": "Says"}]}]}], "keywords": [{"text": "Antidepressant Drugs Market", "sentiment": {"score": -0.825887, "label": "negative"}, "relevance": 0.993905, "count": 1}, {"text": "Market Research", "sentiment": {"score": -0.825887, "label": "negative"}, "relevance": 0.933194, "count": 1}, {"text": "CAGR", "sentiment": {"score": -0.825887, "label": "negative"}, "relevance": 0.046361, "count": 1}]}, "crawl_date": "2018-11-21T13:19:26Z", "url": "https://www.wallstreet-online.de/nachricht/11031511-antidepressant-drugs-market-to-reach-15-98-bn-by-2023-globally-at-2-1-cagr-says-allied-market-research/all", "host": "wallstreet-online.de", "text": "Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co.", "main_image_url": "https://assets.wallstreet-online.de/_media/6/nachrichtenfeeds/size_645/logo-pr-newswire-engl.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T13:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.23475, "label": "negative"}, "text": "depression", "relevance": 0.856647, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allied Market Research", "relevance": 0.768327, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.577855, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oregon", "relevance": 0.527711, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PORTLAND", "relevance": 0.513497, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan Plc", "relevance": 0.44637, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.438962, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.427372, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.418961, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc", "relevance": 0.41845, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.407369, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0.347629, "label": "positive"}, "text": "Bristol Myers Squibb Co.", "relevance": 0.400351, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.39204, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly and Co.", "relevance": 0.389515, "type": "Company", "disambiguation": {"subtype": [], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.385225, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "H. Lundbeck", "relevance": 0.384213, "type": "Company", "disambiguation": {"subtype": [], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.375604, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alkermes Plc", "relevance": 0.374534, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.374479, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": -0.23701, "label": "negative"}, "text": "Merck & Co., Inc.", "relevance": 0.336245, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$14.11 billion", "relevance": 0.336245, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.98 billion", "relevance": 0.336245, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1 month", "relevance": 0.336245, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2023", "relevance": 0.336245, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.1%", "relevance": 0.336245, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.7%", "relevance": 0.336245, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.9%", "relevance": 0.336245, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.0%", "relevance": 0.336245, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "40%", "relevance": 0.336245, "type": "Quantity"}], "sentiment": {"document": {"score": -0.600217, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PORTLAND, Oregon , November 21, 2018 /PRNewswire/ --", "keywords": [{"text": "POLAND"}, {"text": "Oregon"}, {"text": "/PRNewswire/"}], "entities": [{"type": "Location", "text": "PORTLAND", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Oregon", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}]}, "sentence": " PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market abspielen", "action": {"verb": {"text": "Increase", "tense": "present"}, "text": "Increase", "normalized": "Increase"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market abspielen", "object": {"text": "from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "novel drug"}, {"text": "emergence"}, {"text": "anxiety"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "novel drug"}, {"text": "emergence"}, {"text": "anxiety"}], "entities": [{"type": "Location", "text": "PORTLAND", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Oregon", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}, {"type": "HealthCondition", "text": "depression"}]}, "sentence": " PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market abspielen", "object": {"text": "the growth of the antidepressant drugs market abspielen", "keywords": [{"text": "antidepressant drugs market"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "are expected to boost", "normalized": "be expect to boost"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers in-depth analyses of the global antidepressant drugs market by closely analyzing the industry trends, top investment pockets, drivers & opportunities, key growth strategies, and competitive landscape.", "object": {"text": "in-depth analyses of the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}, {"text": "in-depth analyses"}, {"text": "market"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "object": {"text": "for $14.11 billion", "entities": [{"type": "Quantity", "text": "$14.11 billion"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "object": {"text": "$15.98 billion by 2023", "entities": [{"type": "Quantity", "text": "$15.98 billion"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "a CAGR of 2.1%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "2.1"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "action": {"verb": {"text": "register", "tense": "present"}, "text": "registering", "normalized": "register"}}, {"subject": {"text": "the development of drugs with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "drugs"}, {"text": "development"}]}, "sentence": " Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "drive", "normalized": "drive"}}, {"subject": {"text": "antidepressants", "keywords": [{"text": "antidepressants"}]}, "sentence": " However, poor efficacy and safety profiles of drugs, inclination toward non-pharmacological therapies, and increase in the number of patent expiration of antidepressants hamper the market growth.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.", "object": {"text": "from stress", "keywords": [{"text": "stress"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "lucrative opportunities for the market players", "keywords": [{"text": "lucrative opportunities"}, {"text": "market players"}]}, "sentence": " On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.", "action": {"verb": {"text": "create", "tense": "future"}, "text": "are expected to create", "normalized": "be expect to create"}}, {"subject": {"text": "Obsessive- compulsive disorder segment", "keywords": [{"text": "Obsessive- compulsive disorder"}, {"text": "segment"}]}, "sentence": " Obsessive- compulsive disorder segment to portray fastest demand through 2023", "object": {"text": "fastest demand", "keywords": [{"text": "fastest demand"}]}, "action": {"verb": {"text": "portray", "tense": "future"}, "text": "to portray", "normalized": "to portray"}}, {"subject": {"text": "The obsessive-compulsive disorder segment", "keywords": [{"text": "obsessive-compulsive disorder segment"}]}, "sentence": " The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life.", "object": {"text": "the fastest CAGR of 2.9%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.9"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "The obsessive-compulsive disorder segment", "keywords": [{"text": "obsessive-compulsive disorder segment"}]}, "sentence": " The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life.", "object": {"text": "for better quality of life", "keywords": [{"text": "better quality"}, {"text": "life"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "need", "normalized": "need"}}, {"subject": {"text": "the major depressive disorder segment", "keywords": [{"text": "depressive disorder segment"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "the largest market share", "keywords": [{"text": "largest market share"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "majority of the patients", "keywords": [{"text": "majority"}, {"text": "patients"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "diagnosed with this disorder", "keywords": [{"text": "disorder"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "majority of the patients", "keywords": [{"text": "majority"}, {"text": "patients"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "with this disorder", "keywords": [{"text": "disorder"}]}, "action": {"verb": {"text": "diagnose", "tense": "past"}, "text": "are diagnosed", "normalized": "be diagnose"}}, {"subject": {"text": "The other segments", "keywords": [{"text": "segments"}]}, "sentence": " The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "generalized anxiety disorder, panic disorder, and others", "keywords": [{"text": "panic disorder"}, {"text": "anxiety disorder"}]}, "sentence": " The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.", "object": {"text": "The other segments analyzed in the report", "keywords": [{"text": "segments"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment to lead the market by 2023", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "to lead", "normalized": "to lead"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "projected to manifest the fastest CAGR of 2.7%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.7"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "the fastest CAGR of 2.7%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.7"}]}, "action": {"verb": {"text": "manifest", "tense": "future"}, "text": "is projected to manifest", "normalized": "be project to manifest"}}, {"subject": {"text": "these"}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "highly effective in treat depression and anxiety due to their minimal side-effects", "keywords": [{"text": "minimal side-effects"}, {"text": "treat depression"}, {"text": "anxiety"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The other antidepressant products", "keywords": [{"text": "antidepressant products"}]}, "sentence": " The other antidepressant products analyzed in the report are tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others.", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " North America to retain the largest market share through 2023", "object": {"text": "the largest market share", "keywords": [{"text": "largest market share"}]}, "action": {"verb": {"text": "retain", "tense": "future"}, "text": "to retain", "normalized": "to retain"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region.", "object": {"text": "for the largest share", "keywords": [{"text": "largest share"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "Asia-Pacific region", "keywords": [{"text": "Asia-Pacific region"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population.", "object": {"text": "the fastest CAGR of 4.0%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "4.0"}]}, "action": {"verb": {"text": "portray", "tense": "future"}, "text": "is expected to portray", "normalized": "be expect to portray"}}, {"subject": {"text": "The other regions", "keywords": [{"text": "regions"}]}, "sentence": " The other regions analyzed in the report include Europe and Latin America , Middle East and Africa (LAMEA).", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "Europe and Latin America , Middle East and Africa (LAMEA)", "keywords": [{"text": "Latin America"}, {"text": "Middle East"}, {"text": "Europe"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The other regions analyzed in the report include Europe and Latin America , Middle East and Africa (LAMEA).", "object": {"text": "The other regions analyzed in the report", "keywords": [{"text": "regions"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.", "object": {"text": "the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd", "keywords": [{"text": "Bristol Myers Squibb"}, {"text": "Allergan Plc"}, {"text": "Teva Pharmaceutical Industries"}, {"text": "GlaxoSmithKline Plc"}], "entities": [{"type": "Company", "text": "Allergan Plc"}, {"type": "Company", "text": "Eli Lilly and Co.", "disambiguation": {"subtype": ["Company"], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"type": "Company", "text": "H. Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Alkermes Plc"}, {"type": "Company", "text": "Bristol Myers Squibb Co.", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "GlaxoSmithKline Plc", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co.", "keywords": [{"text": "Teva Pharmaceutical Industries"}, {"text": "Allergan Plc"}, {"text": "H. Lundbeck"}, {"text": "Bristol Myers"}], "entities": [{"type": "Company", "text": "Allergan Plc"}, {"type": "Company", "text": "Eli Lilly and Co.", "disambiguation": {"subtype": ["Company"], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"type": "Company", "text": "H. Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Alkermes Plc"}, {"type": "Company", "text": "Bristol Myers Squibb Co.", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.", "object": {"text": "the several leading players in the market", "keywords": [{"text": "players"}, {"text": "market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Knowledge tree", "keywords": [{"text": "Knowledge tree"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "a cloud-based intelligence platform that offers more than 2,000 selective", "keywords": [{"text": "cloud-based intelligence platform"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a cloud-based intelligence platform", "keywords": [{"text": "cloud-based intelligence platform"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "more than 2,000 selective, off-the-shelf reports on niche markets", "keywords": [{"text": "off-the-shelf reports"}, {"text": "niche markets"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "our clients", "keywords": [{"text": "clients"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "deep insights on the latest trends, dynamic technologies, and emerging application areas", "keywords": [{"text": "deep insights"}, {"text": "latest trends"}, {"text": "dynamic technologies"}, {"text": "application areas"}]}, "action": {"verb": {"text": "gain", "tense": "present"}, "text": "gain", "normalized": "gain"}}, {"subject": {"text": "Purchase", "keywords": [{"text": "Purchase"}]}, "sentence": " Purchase an enterprise user license and get 1 month complimentary access to our Knowledge Tree subscription.", "object": {"text": "complimentary access to our Knowledge Tree subscription", "keywords": [{"text": "complimentary access"}, {"text": "Knowledge Tree subscription"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "get", "normalized": "get"}}], "concepts": [{"text": "Selective serotonin reuptake inhibitor", "relevance": 0.941245, "dbpedia_resource": "http://dbpedia.org/resource/Selective_serotonin_reuptake_inhibitor"}, {"text": "Tricyclic antidepressant", "relevance": 0.591311, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic_antidepressant"}, {"text": "Serotonin", "relevance": 0.568461, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin"}, {"text": "Sertraline", "relevance": 0.509305, "dbpedia_resource": "http://dbpedia.org/resource/Sertraline"}, {"text": "Antidepressant", "relevance": 0.502284, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}, {"text": "Venlafaxine", "relevance": 0.426167, "dbpedia_resource": "http://dbpedia.org/resource/Venlafaxine"}, {"text": "Paroxetine", "relevance": 0.423735, "dbpedia_resource": "http://dbpedia.org/resource/Paroxetine"}, {"text": "Escitalopram", "relevance": 0.390019, "dbpedia_resource": "http://dbpedia.org/resource/Escitalopram"}, {"text": "Fluoxetine", "relevance": 0.373312, "dbpedia_resource": "http://dbpedia.org/resource/Fluoxetine"}, {"text": "Generalized anxiety disorder", "relevance": 0.338424, "dbpedia_resource": "http://dbpedia.org/resource/Generalized_anxiety_disorder"}, {"text": "Monoamine oxidase inhibitor", "relevance": 0.331377, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase_inhibitor"}, {"text": "Panic disorder", "relevance": 0.325707, "dbpedia_resource": "http://dbpedia.org/resource/Panic_disorder"}, {"text": "Bupropion", "relevance": 0.315166, "dbpedia_resource": "http://dbpedia.org/resource/Bupropion"}, {"text": "Citalopram", "relevance": 0.312377, "dbpedia_resource": "http://dbpedia.org/resource/Citalopram"}, {"text": "Major depressive disorder", "relevance": 0.311394, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Cognitive behavioral therapy", "relevance": 0.297622, "dbpedia_resource": "http://dbpedia.org/resource/Cognitive_behavioral_therapy"}, {"text": "Anxiety disorder", "relevance": 0.296344, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety_disorder"}, {"text": "Norepinephrine reuptake inhibitor", "relevance": 0.291402, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor"}, {"text": "Bipolar disorder", "relevance": 0.291142, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Imipramine", "relevance": 0.284097, "dbpedia_resource": "http://dbpedia.org/resource/Imipramine"}, {"text": "Social anxiety disorder", "relevance": 0.271537, "dbpedia_resource": "http://dbpedia.org/resource/Social_anxiety_disorder"}, {"text": "Fluvoxamine", "relevance": 0.254963, "dbpedia_resource": "http://dbpedia.org/resource/Fluvoxamine"}, {"text": "Buspirone", "relevance": 0.243158, "dbpedia_resource": "http://dbpedia.org/resource/Buspirone"}, {"text": "Anxiety disorders", "relevance": 0.239728, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety_disorders"}, {"text": "Tranylcypromine", "relevance": 0.232049, "dbpedia_resource": "http://dbpedia.org/resource/Tranylcypromine"}, {"text": "Antidepressants", "relevance": 0.230713, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressants"}, {"text": "Serotonin syndrome", "relevance": 0.230149, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin_syndrome"}, {"text": "Norepinephrine", "relevance": 0.217809, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine"}, {"text": "Mood disorder", "relevance": 0.215666, "dbpedia_resource": "http://dbpedia.org/resource/Mood_disorder"}, {"text": "Phenelzine", "relevance": 0.206059, "dbpedia_resource": "http://dbpedia.org/resource/Phenelzine"}, {"text": "Monoamine oxidase", "relevance": 0.201485, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.200179, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Dysthymia", "relevance": 0.198679, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}, {"text": "Neurotic, stress-related and somatoform disorders", "relevance": 0.198342, "dbpedia_resource": "http://dbpedia.org/resource/Neurotic,_stress-related_and_somatoform_disorders"}, {"text": "Tricyclic", "relevance": 0.192408, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic"}, {"text": "Insomnia", "relevance": 0.187561, "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}, {"text": "Bristol-Myers Squibb", "relevance": 0.183938, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Alprazolam", "relevance": 0.183494, "dbpedia_resource": "http://dbpedia.org/resource/Alprazolam"}, {"text": "Reuptake inhibitor", "relevance": 0.182119, "dbpedia_resource": "http://dbpedia.org/resource/Reuptake_inhibitor"}, {"text": "Trimipramine", "relevance": 0.180488, "dbpedia_resource": "http://dbpedia.org/resource/Trimipramine"}, {"text": "Suicide", "relevance": 0.180218, "dbpedia_resource": "http://dbpedia.org/resource/Suicide"}, {"text": "Primary care", "relevance": 0.180137, "dbpedia_resource": "http://dbpedia.org/resource/Primary_care"}, {"text": "Abnormal psychology", "relevance": 0.178683, "dbpedia_resource": "http://dbpedia.org/resource/Abnormal_psychology"}, {"text": "Anxiety", "relevance": 0.173993, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety"}, {"text": "Depression", "relevance": 0.169396, "dbpedia_resource": "http://dbpedia.org/resource/Depression_(mood)"}], "categories": [{"score": 0.997116, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}, {"score": 0.99005, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.921657, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}], "relations": [{"type": "locatedAt", "sentence": "| 21.11.2018, 14:00 | 29 | 0 | 0 PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market abspielen Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.986487, "arguments": [{"text": "PORTLAND", "location": [33, 41], "entities": [{"type": "GeopoliticalEntity", "text": "PORTLAND"}]}, {"text": "Oregon", "location": [43, 49], "entities": [{"type": "GeopoliticalEntity", "text": "Oregon"}]}]}, {"type": "hasAttribute", "sentence": "| 21.11.2018, 14:00 | 29 | 0 | 0 PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market abspielen Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.86762, "arguments": [{"text": "patients", "location": [112, 120], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "depression", "location": [136, 146], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "partOfMany", "sentence": "| 21.11.2018, 14:00 | 29 | 0 | 0 PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market abspielen Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.766854, "arguments": [{"text": "Antagonist", "location": [708, 718], "entities": [{"type": "Person", "text": "Antagonist"}]}, {"text": "Others", "location": [748, 754], "entities": [{"type": "Person", "text": "Others"}]}]}, {"type": "partOfMany", "sentence": "| 21.11.2018, 14:00 | 29 | 0 | 0 PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market abspielen Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.8176, "arguments": [{"text": "Reuptake Inhibitors", "location": [723, 742], "entities": [{"type": "Person", "text": "Reuptake Inhibitors"}]}, {"text": "Others", "location": [748, 754], "entities": [{"type": "Person", "text": "Others"}]}]}, {"type": "hasAttribute", "sentence": "(Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg ) Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market.", "score": 0.786356, "arguments": [{"text": "population", "location": [1393, 1403], "entities": [{"type": "Person", "text": "population"}]}, {"text": "depression", "location": [1363, 1373], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "partOfMany", "sentence": "However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "score": 0.978264, "arguments": [{"text": "majority", "location": [2405, 2413], "entities": [{"type": "Cardinal", "text": "majority"}]}, {"text": "patients", "location": [2421, 2429], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "residesIn", "sentence": "For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/2593 North America to retain the largest market share through 2023 North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region.", "score": 0.77241, "arguments": [{"text": "population", "location": [3512, 3522], "entities": [{"type": "Person", "text": "population"}]}, {"text": "region", "location": [3530, 3536], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "residesIn", "sentence": "However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population.", "score": 0.571592, "arguments": [{"text": "population", "location": [3756, 3766], "entities": [{"type": "Person", "text": "population"}]}, {"text": "region", "location": [3709, 3715], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "employedBy", "sentence": "Torchbearers of the market The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "score": 0.657339, "arguments": [{"text": "clients", "location": [4468, 4475], "entities": [{"type": "Person", "text": "players"}]}, {"text": "our", "location": [4464, 4467], "entities": [{"type": "Organization", "text": "Asia-Pacific region"}]}]}], "keywords": [{"text": "Depressive Disorder", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.718615, "count": 1}, {"text": "Selective Serotonin Reuptake Inhibitors", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.702794, "count": 1}, {"text": "growth of the antidepressant drugs market", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.682933, "count": 1}, {"text": "Major Depressive Disorder", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.627605, "count": 1}, {"text": "Obsessive-Compulsive Disorder", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.60524, "count": 1}, {"text": "Market Research", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.595995, "count": 1}, {"text": "Purchase Enquiry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.580738, "count": 1}, {"text": "report", "sentiment": {"score": -0.782636, "label": "negative"}, "relevance": 0.580116, "count": 6}, {"text": "Generalized Anxiety Disorder", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.575565, "count": 1}, {"text": "emergence of novel drug s", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.574442, "count": 1}, {"text": "Access KNOWLEDGE TREE", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.573042, "count": 1}, {"text": "report offers", "sentiment": {"score": -0.437462, "label": "negative"}, "relevance": 0.570191, "count": 1}, {"text": "Monoamine Oxidase Inhibitors", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.568567, "count": 1}, {"text": "Serotonin-Norepinephrine Reuptake Inhibitors", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.566133, "count": 1}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560741, "count": 1}, {"text": "Tricyclic Antidepressants", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.559996, "count": 1}, {"text": "Selective serotonin reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559074, "count": 1}, {"text": "total revenue", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.558833, "count": 1}, {"text": "Panic Disorder", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.558279, "count": 1}, {"text": "enterprise user license", "sentiment": {"score": 0.697558, "label": "positive"}, "relevance": 0.556284, "count": 1}, {"text": "Others", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.555167, "count": 2}, {"text": "Antidepressant Drugs Market", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.55457, "count": 1}, {"text": "compulsive disorder segment", "sentiment": {"score": -0.882245, "label": "negative"}, "relevance": 0.548873, "count": 1}, {"text": "Reuptake Inhibitors", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.547537, "count": 1}, {"text": "Asia-Pacific region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.545292, "count": 1}, {"text": "side-effects", "sentiment": {"score": -0.915829, "label": "negative"}, "relevance": 0.537593, "count": 2}, {"text": "Global Opportunity Analysis", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.537184, "count": 1}, {"text": "others", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536861, "count": 2}, {"text": "anxiety", "sentiment": {"score": -0.853969, "label": "negative"}, "relevance": 0.536364, "count": 3}, {"text": "anxiety disorder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532805, "count": 1}, {"text": "monoamine oxidase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531328, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529423, "count": 1}, {"text": "Co.", "sentiment": {"score": 0.543486, "label": "positive"}, "relevance": 0.528622, "count": 2}, {"text": "poor efficacy", "sentiment": {"score": -0.747675, "label": "negative"}, "relevance": 0.528331, "count": 1}, {"text": "study period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528317, "count": 1}, {"text": "niche markets", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.528176, "count": 1}, {"text": "panic disorder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527755, "count": 1}, {"text": "stress", "sentiment": {"score": -0.886045, "label": "negative"}, "relevance": 0.527065, "count": 3}, {"text": "tricyclic antidepressants", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526612, "count": 1}, {"text": "largest market share", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.526105, "count": 2}, {"text": "region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525518, "count": 2}, {"text": "Product", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.52459, "count": 1}, {"text": "disorder", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.524562, "count": 1}, {"text": "latest trends", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.524168, "count": 1}, {"text": "number of patients", "sentiment": {"score": -0.943918, "label": "negative"}, "relevance": 0.523998, "count": 2}, {"text": "PORTLAND", "sentiment": {"score": -0.94312, "label": "negative"}, "relevance": 0.523098, "count": 1}, {"text": "cloud", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.521467, "count": 1}, {"text": "largest share", "sentiment": {"score": -0.750848, "label": "negative"}, "relevance": 0.521331, "count": 1}, {"text": "Allergan Plc", "sentiment": {"score": 0.543486, "label": "positive"}, "relevance": 0.521074, "count": 1}, {"text": "reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520779, "count": 1}]}, "extracted_metadata": {"sha1": "9dd0e3dbb6e0fd1641455a5781a197891896ce35", "filename": "1542806366442.zip-2f0fefb929c21a3a5705bc40f7c41bfe.xml", "file_type": "json"}, "external_links": ["https://www.alliedmarketresearch.com/knowledgetree", "https://www.alliedmarketresearch.com/purchase-enquiry/2593", "https://www.alliedmarketresearch.com/request-sample/2593", "https://www.alliedmarketresearch.com/checkout/394361"], "title": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "forum_title": "Nachrichten Ticker  - Kategorie: Aktien &amp; Indizes - www.wallstreet-online.de"}, {"id": "yHjXRIg7wh0r6JJjijbeylAn0WYezKP2s0gRDIojBJfXxwfbYjKnkqt_StJ83P5J", "result_metadata": {"score": 33.973743}, "author": "mylubbocktv.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.98", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Antidepressant Drugs Market", "keywords": [{"text": "Antidepressant Drugs"}, {"text": "Market"}]}, "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally", "object": {"text": "$15.98 Bn", "keywords": [{"text": "Bn"}], "entities": [{"type": "Quantity", "text": "$15.98"}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "to Reach", "normalized": "to Reach"}}], "concepts": [{"text": "Antidepressant", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}], "categories": [{"score": 0.946718, "label": "/health and fitness"}, {"score": 0.928503, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.729746, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}], "relations": [{"type": "locatedAt", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally", "score": 0.266372, "arguments": [{"text": "Drugs", "location": [15, 20], "entities": [{"type": "Substance", "text": "Drugs"}]}, {"text": "Market", "location": [21, 27], "entities": [{"type": "Organization", "text": "Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Antidepressant Drugs Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5, "count": 1}]}, "crawl_date": "2018-11-21T14:30:42Z", "url": "http://www.mylubbocktv.com/story/39519750/antidepressant-drugs-market-to-reach-1598-bn-by-2023-globally-at-21-cagr-says-allied-market-research", "host": "mylubbocktv.com", "text": "Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T00:00:00-05:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0.60317, "label": "positive"}, "text": "Allied Market Research", "relevance": 0.886577, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.284698, "label": "negative"}, "text": "depression", "relevance": 0.466978, "type": "HealthCondition"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "PORTLAND", "relevance": 0.450013, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oregon", "relevance": 0.36331, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.323353, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.285684, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.263956, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allied Analytics LLP", "relevance": 0.259745, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.548973, "label": "positive"}, "text": "Hong Kong", "relevance": 0.257556, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.257099, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan Plc", "relevance": 0.253181, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.251177, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.251144, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.25039, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.247939, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Correa", "relevance": 0.246291, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc", "relevance": 0.238319, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.233448, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0.347629, "label": "positive"}, "text": "Bristol Myers Squibb Co.", "relevance": 0.230748, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.227792, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly and Co.", "relevance": 0.226368, "type": "Company", "disambiguation": {"subtype": [], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "H. Lundbeck", "relevance": 0.224421, "type": "Company", "disambiguation": {"subtype": [], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.223747, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.220141, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.217086, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alkermes Plc", "relevance": 0.21449, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.23701, "label": "negative"}, "text": "Merck & Co., Inc.", "relevance": 0.198028, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.197675, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "help@alliedmarketresearch.com", "relevance": 0.197675, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$14.11 billion", "relevance": 0.197675, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.98 billion", "relevance": 0.197675, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1 month", "relevance": 0.197675, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2023", "relevance": 0.197675, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.1%", "relevance": 0.197675, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.7%", "relevance": 0.197675, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.9%", "relevance": 0.197675, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.0%", "relevance": 0.197675, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "40%", "relevance": 0.197675, "type": "Quantity"}], "sentiment": {"document": {"score": 0.291404, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market", "object": {"text": "from depression", "keywords": [{"text": "depression"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "anxiety", "keywords": [{"text": "anxiety"}]}, "sentence": " Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market", "object": {"text": "with emergence of novel drug s with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "emergence"}, {"text": "novel drug"}]}, "action": {"verb": {"text": "couple", "tense": "past"}, "text": "coupled", "normalized": "couple"}}, {"subject": {"text": "stress , and anxiety coupled with emergence of novel drug s with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "novel drug"}, {"text": "emergence"}, {"text": "anxiety"}]}, "sentence": " Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market", "object": {"text": "the growth of the antidepressant drugs market", "keywords": [{"text": "antidepressant drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "are expected to boost", "normalized": "be expect to boost"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers in-depth analyses of the global antidepressant drugs market by closely analyzing the industry trends, top investment pockets, drivers & opportunities, key growth strategies, and competitive landscape.", "object": {"text": "in-depth analyses of the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}, {"text": "in-depth analyses"}, {"text": "market"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "object": {"text": "for $14.11 billion", "entities": [{"type": "Quantity", "text": "$14.11 billion"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "object": {"text": "$15.98 billion by 2023", "entities": [{"type": "Quantity", "text": "$15.98 billion"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "a CAGR of 2.1%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "2.1"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "action": {"verb": {"text": "register", "tense": "present"}, "text": "registering", "normalized": "register"}}, {"subject": {"text": "the development of drugs with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "drugs"}, {"text": "development"}]}, "sentence": " Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "drive", "normalized": "drive"}}, {"subject": {"text": "antidepressants", "keywords": [{"text": "antidepressants"}]}, "sentence": " However, poor efficacy and safety profiles of drugs, inclination toward non-pharmacological therapies, and increase in the number of patent expiration of antidepressants hamper the market growth.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.", "object": {"text": "from stress", "keywords": [{"text": "stress"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "lucrative opportunities for the market players", "keywords": [{"text": "lucrative opportunities"}, {"text": "market players"}]}, "sentence": " On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.", "action": {"verb": {"text": "create", "tense": "future"}, "text": "are expected to create", "normalized": "be expect to create"}}, {"subject": {"text": "Obsessive- compulsive disorder segment", "keywords": [{"text": "Obsessive- compulsive disorder"}, {"text": "segment"}]}, "sentence": " Obsessive- compulsive disorder segment to portray fastest demand through 2023", "object": {"text": "fastest demand", "keywords": [{"text": "fastest demand"}]}, "action": {"verb": {"text": "portray", "tense": "future"}, "text": "to portray", "normalized": "to portray"}}, {"subject": {"text": "The obsessive-compulsive disorder segment", "keywords": [{"text": "obsessive-compulsive disorder segment"}]}, "sentence": " The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life.", "object": {"text": "the fastest CAGR of 2.9%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.9"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "The obsessive-compulsive disorder segment", "keywords": [{"text": "obsessive-compulsive disorder segment"}]}, "sentence": " The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life.", "object": {"text": "for better quality of life", "keywords": [{"text": "better quality"}, {"text": "life"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "need", "normalized": "need"}}, {"subject": {"text": "the major depressive disorder segment", "keywords": [{"text": "depressive disorder segment"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "the largest market share", "keywords": [{"text": "largest market share"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "majority of the patients", "keywords": [{"text": "majority"}, {"text": "patients"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "diagnosed with this disorder", "keywords": [{"text": "disorder"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "majority of the patients", "keywords": [{"text": "majority"}, {"text": "patients"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "with this disorder", "keywords": [{"text": "disorder"}]}, "action": {"verb": {"text": "diagnose", "tense": "past"}, "text": "are diagnosed", "normalized": "be diagnose"}}, {"subject": {"text": "The other segments", "keywords": [{"text": "segments"}]}, "sentence": " The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "generalized anxiety disorder, panic disorder, and others", "keywords": [{"text": "panic disorder"}, {"text": "anxiety disorder"}]}, "sentence": " The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.", "object": {"text": "The other segments analyzed in the report", "keywords": [{"text": "segments"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment to lead the market by 2023", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "to lead", "normalized": "to lead"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "projected to manifest the fastest CAGR of 2.7%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.7"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "the fastest CAGR of 2.7%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.7"}]}, "action": {"verb": {"text": "manifest", "tense": "future"}, "text": "is projected to manifest", "normalized": "be project to manifest"}}, {"subject": {"text": "these"}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "highly effective in treat depression and anxiety due to their minimal side-effects", "keywords": [{"text": "minimal side-effects"}, {"text": "treat depression"}, {"text": "anxiety"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The other antidepressant products", "keywords": [{"text": "antidepressant products"}]}, "sentence": " The other antidepressant products analyzed in the report are tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others.", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " North America to retain the largest market share through 2023", "object": {"text": "the largest market share", "keywords": [{"text": "largest market share"}]}, "action": {"verb": {"text": "retain", "tense": "future"}, "text": "to retain", "normalized": "to retain"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region.", "object": {"text": "for the largest share", "keywords": [{"text": "largest share"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "Asia-Pacific region", "keywords": [{"text": "Asia-Pacific region"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population.", "object": {"text": "the fastest CAGR of 4.0%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "4.0"}]}, "action": {"verb": {"text": "portray", "tense": "future"}, "text": "is expected to portray", "normalized": "be expect to portray"}}, {"subject": {"text": "The other regions", "keywords": [{"text": "regions"}]}, "sentence": " The other regions analyzed in the report include Europe and Latin America , Middle East and Africa (LAMEA).", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "Europe and Latin America , Middle East and Africa (LAMEA)", "keywords": [{"text": "Latin America"}, {"text": "Middle East"}, {"text": "Europe"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The other regions analyzed in the report include Europe and Latin America , Middle East and Africa (LAMEA).", "object": {"text": "The other regions analyzed in the report", "keywords": [{"text": "regions"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.", "object": {"text": "the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd", "keywords": [{"text": "Bristol Myers Squibb"}, {"text": "Allergan Plc"}, {"text": "Teva Pharmaceutical Industries"}, {"text": "GlaxoSmithKline Plc"}], "entities": [{"type": "Company", "text": "Allergan Plc"}, {"type": "Company", "text": "Eli Lilly and Co.", "disambiguation": {"subtype": ["Company"], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"type": "Company", "text": "H. Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Alkermes Plc"}, {"type": "Company", "text": "Bristol Myers Squibb Co.", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "GlaxoSmithKline Plc", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co.", "keywords": [{"text": "Teva Pharmaceutical Industries"}, {"text": "Allergan Plc"}, {"text": "H. Lundbeck"}, {"text": "Bristol Myers"}], "entities": [{"type": "Company", "text": "Allergan Plc"}, {"type": "Company", "text": "Eli Lilly and Co.", "disambiguation": {"subtype": ["Company"], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"type": "Company", "text": "H. Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Alkermes Plc"}, {"type": "Company", "text": "Bristol Myers Squibb Co.", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.", "object": {"text": "the several leading players in the market", "keywords": [{"text": "players"}, {"text": "market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Knowledge tree", "keywords": [{"text": "Knowledge tree"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "a cloud-based intelligence platform that offers more than 2,000 selective", "keywords": [{"text": "cloud-based intelligence platform"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a cloud-based intelligence platform", "keywords": [{"text": "cloud-based intelligence platform"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "more than 2,000 selective, off-the-shelf reports on niche markets", "keywords": [{"text": "off-the-shelf reports"}, {"text": "niche markets"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "our clients", "keywords": [{"text": "clients"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "deep insights on the latest trends, dynamic technologies, and emerging application areas", "keywords": [{"text": "deep insights"}, {"text": "latest trends"}, {"text": "dynamic technologies"}, {"text": "application areas"}]}, "action": {"verb": {"text": "gain", "tense": "present"}, "text": "gain", "normalized": "gain"}}, {"subject": {"text": "Purchase", "keywords": [{"text": "Purchase"}]}, "sentence": " Purchase an enterprise user license and get 1 month complimentary access to our Knowledge Tree subscription.", "object": {"text": "complimentary access to our Knowledge Tree subscription", "keywords": [{"text": "complimentary access"}, {"text": "Knowledge Tree subscription"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "get", "normalized": "get"}}, {"subject": {"text": "Allied Market Research (AMR)", "keywords": [{"text": "Market Research"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "object": {"text": "a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon ", "keywords": [{"text": "Allied Analytics LLP"}, {"text": "full-service market research"}, {"text": "business-consulting wing"}, {"text": "Portland"}], "entities": [{"type": "Company", "text": "Allied Market Research"}, {"type": "Company", "text": "Allied Analytics LLP"}, {"type": "Location", "text": "PORTLAND", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Portland, Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Portland,_Oregon"}}, {"type": "Location", "text": "Oregon", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a full-service market research and business-consulting wing of Allied Analytics LLP", "keywords": [{"text": "Allied Analytics LLP"}, {"text": "full-service market research"}, {"text": "business-consulting wing"}], "entities": [{"type": "Company", "text": "Allied Market Research"}, {"type": "Company", "text": "Allied Analytics LLP"}]}, "sentence": " Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "Allied Market Research", "keywords": [{"text": "Market Research"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of \"Market Research Reports\" and \"Business Intelligence Solutions.\"", "object": {"text": "global enterprises", "keywords": [{"text": "global enterprises"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "AMR", "keywords": [{"text": "AMR"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.", "object": {"text": "a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain", "keywords": [{"text": "respective market domain"}, {"text": "strategic business decisions"}, {"text": "targeted view"}, {"text": "business insights"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "AMR", "keywords": [{"text": "AMR"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.", "object": {"text": "business insights and consulting", "keywords": [{"text": "business insights"}, {"text": "consulting"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "AMR", "keywords": [{"text": "AMR"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.", "object": {"text": "its clients", "keywords": [{"text": "clients"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "consulting to assist", "normalized": "consult to assist"}}, {"subject": {"text": "We"}, "sentence": " We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting.", "object": {"text": "in professional corporate relations with various companies", "keywords": [{"text": "professional corporate relations"}, {"text": "various companies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "this"}, "sentence": " We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting.", "object": {"text": "us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting", "keywords": [{"text": "confirms utmost accuracy"}, {"text": "accurate research data"}, {"text": "market forecasting"}, {"text": "market data"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "us"}, "sentence": " We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting.", "object": {"text": "market data", "keywords": [{"text": "market data"}]}, "action": {"verb": {"text": "dig", "tense": "present"}, "text": "digging", "normalized": "dig"}}, {"subject": {"text": "Each and every data", "keywords": [{"text": "data"}]}, "sentence": " Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "by us"}, "sentence": " Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "object": {"text": "the reports", "keywords": [{"text": "reports"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Each and every data presented in the reports published by us", "keywords": [{"text": "data"}, {"text": "reports"}]}, "sentence": " Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "object": {"text": "extracted through primary interviews", "keywords": [{"text": "primary interviews"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Each and every data presented in the reports published by us", "keywords": [{"text": "data"}, {"text": "reports"}]}, "sentence": " Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "object": {"text": "from leading companies of domain concerned", "keywords": [{"text": "companies"}, {"text": "domain"}]}, "action": {"verb": {"text": "extract", "tense": "past"}, "text": "is extracted", "normalized": "be extract"}}, {"subject": {"text": "deep online and offline research and discussion with knowledgeable professionals and analysts in the industry", "keywords": [{"text": "knowledgeable professionals"}, {"text": "offline research"}, {"text": "deep online"}, {"text": "analysts"}]}, "sentence": " Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.", "object": {"text": "Our secondary data procurement methodology", "keywords": [{"text": "data procurement methodology"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}], "concepts": [{"text": "Selective serotonin reuptake inhibitor", "relevance": 0.962459, "dbpedia_resource": "http://dbpedia.org/resource/Selective_serotonin_reuptake_inhibitor"}, {"text": "Tricyclic antidepressant", "relevance": 0.589304, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic_antidepressant"}, {"text": "Serotonin", "relevance": 0.563637, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin"}, {"text": "Antidepressant", "relevance": 0.531106, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}, {"text": "Sertraline", "relevance": 0.472372, "dbpedia_resource": "http://dbpedia.org/resource/Sertraline"}, {"text": "Venlafaxine", "relevance": 0.412614, "dbpedia_resource": "http://dbpedia.org/resource/Venlafaxine"}, {"text": "Paroxetine", "relevance": 0.39968, "dbpedia_resource": "http://dbpedia.org/resource/Paroxetine"}, {"text": "Escitalopram", "relevance": 0.368693, "dbpedia_resource": "http://dbpedia.org/resource/Escitalopram"}, {"text": "Fluoxetine", "relevance": 0.357768, "dbpedia_resource": "http://dbpedia.org/resource/Fluoxetine"}, {"text": "Generalized anxiety disorder", "relevance": 0.3316, "dbpedia_resource": "http://dbpedia.org/resource/Generalized_anxiety_disorder"}, {"text": "Monoamine oxidase inhibitor", "relevance": 0.323135, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase_inhibitor"}, {"text": "Panic disorder", "relevance": 0.320915, "dbpedia_resource": "http://dbpedia.org/resource/Panic_disorder"}, {"text": "Major depressive disorder", "relevance": 0.30838, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Cognitive behavioral therapy", "relevance": 0.307449, "dbpedia_resource": "http://dbpedia.org/resource/Cognitive_behavioral_therapy"}, {"text": "Citalopram", "relevance": 0.304331, "dbpedia_resource": "http://dbpedia.org/resource/Citalopram"}, {"text": "Anxiety disorder", "relevance": 0.297479, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety_disorder"}, {"text": "Bupropion", "relevance": 0.289683, "dbpedia_resource": "http://dbpedia.org/resource/Bupropion"}, {"text": "Bipolar disorder", "relevance": 0.279954, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Norepinephrine reuptake inhibitor", "relevance": 0.274773, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor"}, {"text": "Social anxiety disorder", "relevance": 0.273719, "dbpedia_resource": "http://dbpedia.org/resource/Social_anxiety_disorder"}, {"text": "Imipramine", "relevance": 0.268878, "dbpedia_resource": "http://dbpedia.org/resource/Imipramine"}, {"text": "Fluvoxamine", "relevance": 0.238543, "dbpedia_resource": "http://dbpedia.org/resource/Fluvoxamine"}, {"text": "Anxiety disorders", "relevance": 0.23623, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety_disorders"}, {"text": "Antidepressants", "relevance": 0.235311, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressants"}, {"text": "Buspirone", "relevance": 0.229483, "dbpedia_resource": "http://dbpedia.org/resource/Buspirone"}, {"text": "Tranylcypromine", "relevance": 0.216673, "dbpedia_resource": "http://dbpedia.org/resource/Tranylcypromine"}, {"text": "Serotonin syndrome", "relevance": 0.206256, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin_syndrome"}, {"text": "Mood disorder", "relevance": 0.203649, "dbpedia_resource": "http://dbpedia.org/resource/Mood_disorder"}, {"text": "Neurotic, stress-related and somatoform disorders", "relevance": 0.199986, "dbpedia_resource": "http://dbpedia.org/resource/Neurotic,_stress-related_and_somatoform_disorders"}, {"text": "Phenelzine", "relevance": 0.195528, "dbpedia_resource": "http://dbpedia.org/resource/Phenelzine"}, {"text": "Monoamine oxidase", "relevance": 0.19457, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase"}, {"text": "Norepinephrine", "relevance": 0.188404, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine"}, {"text": "Dysthymia", "relevance": 0.187434, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}, {"text": "Reuptake inhibitor", "relevance": 0.186986, "dbpedia_resource": "http://dbpedia.org/resource/Reuptake_inhibitor"}, {"text": "Insomnia", "relevance": 0.180723, "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}, {"text": "Tricyclic", "relevance": 0.18035, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic"}, {"text": "Anxiety", "relevance": 0.17816, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety"}, {"text": "Primary care", "relevance": 0.176055, "dbpedia_resource": "http://dbpedia.org/resource/Primary_care"}, {"text": "Abnormal psychology", "relevance": 0.173884, "dbpedia_resource": "http://dbpedia.org/resource/Abnormal_psychology"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.171714, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Economics", "relevance": 0.168373, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Alprazolam", "relevance": 0.168352, "dbpedia_resource": "http://dbpedia.org/resource/Alprazolam"}, {"text": "Trimipramine", "relevance": 0.165455, "dbpedia_resource": "http://dbpedia.org/resource/Trimipramine"}, {"text": "Fear", "relevance": 0.165286, "dbpedia_resource": "http://dbpedia.org/resource/Fear"}, {"text": "Bristol-Myers Squibb", "relevance": 0.163357, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Alcoholism", "relevance": 0.163288, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholism"}, {"text": "Suicide", "relevance": 0.161797, "dbpedia_resource": "http://dbpedia.org/resource/Suicide"}, {"text": "Depression", "relevance": 0.157103, "dbpedia_resource": "http://dbpedia.org/resource/Depression_(mood)"}, {"text": "Duloxetine", "relevance": 0.155261, "dbpedia_resource": "http://dbpedia.org/resource/Duloxetine"}, {"text": "Obsessive\u2013compulsive disorder", "relevance": 0.155003, "dbpedia_resource": "http://dbpedia.org/resource/Obsessive\u2013compulsive_disorder"}], "categories": [{"score": 0.996722, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}, {"score": 0.988635, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.91353, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}], "relations": [{"type": "locatedAt", "sentence": "Allied Market Research PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.950179, "arguments": [{"text": "PORTLAND", "location": [23, 31], "entities": [{"type": "GeopoliticalEntity", "text": "PORTLAND"}]}, {"text": "Oregon", "location": [33, 39], "entities": [{"type": "GeopoliticalEntity", "text": "Oregon"}]}]}, {"type": "locatedAt", "sentence": "(*Terms and Conditions apply) Get subscription : https://www.alliedmarketresearch.com/checkout/394361 Trending Reports of Medical Devices Market: Immunoglobulin Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 Antibiotics Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "score": 0.95042, "arguments": [{"text": "Portland", "location": [5150, 5158], "entities": [{"type": "GeopoliticalEntity", "text": "PORTLAND"}]}, {"text": "Oregon", "location": [5160, 5166], "entities": [{"type": "GeopoliticalEntity", "text": "Oregon"}]}]}, {"type": "locatedAt", "sentence": "(*Terms and Conditions apply) Get subscription : https://www.alliedmarketresearch.com/checkout/394361 Trending Reports of Medical Devices Market: Immunoglobulin Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 Antibiotics Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "score": 0.504914, "arguments": [{"text": "Allied Analytics LLP", "location": [5120, 5140], "entities": [{"type": "Organization", "text": "Allied Analytics LLP"}]}, {"text": "Oregon", "location": [5160, 5166], "entities": [{"type": "GeopoliticalEntity", "text": "Oregon"}]}]}, {"type": "partOf", "sentence": "Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of \"Market Research Reports\" and \"Business Intelligence Solutions.", "score": 0.53894, "arguments": [{"text": "businesses", "location": [5248, 5258], "entities": [{"type": "Organization", "text": "businesses", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Market Research Reports", "location": [5286, 5309], "entities": [{"type": "Organization", "text": "Market Research Reports"}]}]}, {"type": "employedBy", "sentence": "\" AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.", "score": 0.608865, "arguments": [{"text": "clients", "location": [5432, 5439], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "its", "location": [5428, 5431], "entities": [{"type": "Organization", "text": "Allied Market Research"}]}]}, {"type": "participantIn", "sentence": "Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "score": 0.682026, "arguments": [{"text": "us", "location": [5821, 5823], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "interviews", "location": [5853, 5863], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "participantIn", "sentence": "Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "score": 0.955083, "arguments": [{"text": "officials", "location": [5873, 5882], "entities": [{"type": "Person", "text": "officials"}]}, {"text": "interviews", "location": [5853, 5863], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "participantIn", "sentence": "Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "score": 0.665484, "arguments": [{"text": "companies", "location": [5896, 5905], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "interviews", "location": [5853, 5863], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "participantIn", "sentence": "Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.", "score": 0.681537, "arguments": [{"text": "professionals", "location": [6046, 6059], "entities": [{"type": "Person", "text": "professionals"}]}, {"text": "discussion", "location": [6016, 6026], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "participantIn", "sentence": "Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.", "score": 0.911449, "arguments": [{"text": "analysts", "location": [6064, 6072], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "discussion", "location": [6016, 6026], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "residesIn", "sentence": "Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA / Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong : +852-301-84916 India ( Pune ): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com", "score": 0.471563, "arguments": [{"text": "NE Win Sivers Drive\n#205", "location": [6117, 6141], "entities": [{"type": "Person", "text": "NE Win Sivers Drive\n#205"}]}, {"text": "Portland", "location": [6143, 6151], "entities": [{"type": "GeopoliticalEntity", "text": "PORTLAND"}]}]}, {"type": "locatedAt", "sentence": "Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA / Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong : +852-301-84916 India ( Pune ): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com", "score": 0.33793, "arguments": [{"text": "United States", "location": [6162, 6175], "entities": [{"type": "GeopoliticalEntity", "text": "United States", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "USA", "location": [6176, 6179], "entities": [{"type": "GeopoliticalEntity", "text": "USA", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Allied Market Research PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.805375, "arguments": [{"text": "patients", "location": [102, 110], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "depression", "location": [126, 136], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "locatedAt", "sentence": "Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA / Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141 UK: +44-845-528-1300 Hong Kong : +852-301-84916 India ( Pune ): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com", "score": 0.752719, "arguments": [{"text": "Fax", "location": [6332, 6335], "entities": [{"type": "Facility", "text": "Fax"}]}, {"text": "Pune", "location": [6308, 6312], "entities": [{"type": "GeopoliticalEntity", "text": "Pune"}]}]}, {"type": "partOfMany", "sentence": "Allied Market Research PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.837031, "arguments": [{"text": "Antagonist", "location": [688, 698], "entities": [{"type": "Person", "text": "Antagonist"}]}, {"text": "Others", "location": [728, 734], "entities": [{"type": "Person", "text": "Others"}]}]}, {"type": "partOfMany", "sentence": "Allied Market Research PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.848678, "arguments": [{"text": "Reuptake Inhibitors", "location": [703, 722], "entities": [{"type": "Person", "text": "Reuptake Inhibitors"}]}, {"text": "Others", "location": [728, 734], "entities": [{"type": "Person", "text": "Others"}]}]}, {"type": "hasAttribute", "sentence": "(Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg ) Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market.", "score": 0.786356, "arguments": [{"text": "population", "location": [1373, 1383], "entities": [{"type": "Person", "text": "population"}]}, {"text": "depression", "location": [1343, 1353], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "partOfMany", "sentence": "However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "score": 0.978264, "arguments": [{"text": "majority", "location": [2385, 2393], "entities": [{"type": "Cardinal", "text": "majority"}]}, {"text": "patients", "location": [2401, 2409], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "residesIn", "sentence": "For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/2593 North America to retain the largest market share through 2023 North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region.", "score": 0.77241, "arguments": [{"text": "population", "location": [3492, 3502], "entities": [{"type": "Person", "text": "population"}]}, {"text": "region", "location": [3510, 3516], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "residesIn", "sentence": "However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population.", "score": 0.571592, "arguments": [{"text": "population", "location": [3736, 3746], "entities": [{"type": "Person", "text": "population"}]}, {"text": "region", "location": [3689, 3695], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "employedBy", "sentence": "Torchbearers of the market The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "score": 0.657339, "arguments": [{"text": "clients", "location": [4448, 4455], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "our", "location": [4444, 4447], "entities": [{"type": "Organization", "text": "Asia-Pacific region"}]}]}, {"type": "basedIn", "sentence": "(*Terms and Conditions apply) Get subscription : https://www.alliedmarketresearch.com/checkout/394361 Trending Reports of Medical Devices Market: Immunoglobulin Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 Antibiotics Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "score": 0.766956, "arguments": [{"text": "Allied Analytics LLP", "location": [5120, 5140], "entities": [{"type": "Organization", "text": "Allied Analytics LLP"}]}, {"text": "Portland", "location": [5150, 5158], "entities": [{"type": "GeopoliticalEntity", "text": "PORTLAND"}]}]}], "keywords": [{"text": "growth of the antidepressant drugs market", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.746651, "count": 1}, {"text": "Market Research", "sentiment": {"score": -0.370854, "mixed": "1", "label": "negative"}, "relevance": 0.704148, "count": 3}, {"text": "Depressive Disorder", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.667025, "count": 1}, {"text": "Selective Serotonin Reuptake Inhibitors", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.650553, "count": 1}, {"text": "Major Depressive Disorder", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.595616, "count": 1}, {"text": "Obsessive-Compulsive Disorder", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.578477, "count": 1}, {"text": "Antidepressant Drugs Market", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.576687, "count": 1}, {"text": "report", "sentiment": {"score": -0.615715, "label": "negative"}, "relevance": 0.575341, "count": 6}, {"text": "wing of Allied Analytics LLP", "sentiment": {"score": 0.359503, "mixed": "1", "label": "positive"}, "relevance": 0.567037, "count": 1}, {"text": "market data", "sentiment": {"score": 0.998435, "label": "positive"}, "relevance": 0.566574, "count": 1}, {"text": "emergence of novel drug s", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.558675, "count": 1}, {"text": "report offers", "sentiment": {"score": -0.437462, "label": "negative"}, "relevance": 0.558214, "count": 1}, {"text": "Global Opportunity Analysis", "sentiment": {"score": -0.719363, "label": "negative"}, "relevance": 0.55606, "count": 3}, {"text": "Generalized Anxiety Disorder", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.555966, "count": 1}, {"text": "Monoamine Oxidase Inhibitors", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.549404, "count": 1}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548552, "count": 1}, {"text": "total revenue", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.547193, "count": 1}, {"text": "small businesses", "sentiment": {"score": 0.742034, "label": "positive"}, "relevance": 0.546455, "count": 1}, {"text": "Serotonin-Norepinephrine Reuptake Inhibitors", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.545169, "count": 1}, {"text": "Tricyclic Antidepressants", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.544643, "count": 1}, {"text": "Selective serotonin reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543133, "count": 1}, {"text": "Panic Disorder", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.542915, "count": 1}, {"text": "business", "sentiment": {"score": -0.749271, "label": "negative"}, "relevance": 0.542701, "count": 1}, {"text": "enterprise user license", "sentiment": {"score": 0.697558, "label": "positive"}, "relevance": 0.540884, "count": 1}, {"text": "Others", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.539573, "count": 2}, {"text": "various companies", "sentiment": {"score": 0.998435, "label": "positive"}, "relevance": 0.538819, "count": 1}, {"text": "professional corporate relations", "sentiment": {"score": 0.998435, "label": "positive"}, "relevance": 0.538313, "count": 1}, {"text": "compulsive disorder segment", "sentiment": {"score": -0.882245, "label": "negative"}, "relevance": 0.535696, "count": 1}, {"text": "AMR", "sentiment": {"score": 0.579018, "mixed": "1", "label": "positive"}, "relevance": 0.535509, "count": 2}, {"text": "global antidepressant drugs market", "sentiment": {"score": -0.559456, "label": "negative"}, "relevance": 0.535199, "count": 1}, {"text": "Reuptake Inhibitors", "sentiment": {"score": -0.666666, "label": "negative"}, "relevance": 0.53428, "count": 1}, {"text": "Access KNOWLEDGE TREE", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.533725, "count": 1}, {"text": "Asia-Pacific region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533626, "count": 1}, {"text": "data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532774, "count": 1}, {"text": "full-service market research", "sentiment": {"score": -0.749271, "label": "negative"}, "relevance": 0.532757, "count": 1}, {"text": "accurate research data tables", "sentiment": {"score": 0.998435, "label": "positive"}, "relevance": 0.531584, "count": 1}, {"text": "side-effects", "sentiment": {"score": -0.785636, "label": "negative"}, "relevance": 0.528736, "count": 2}, {"text": "market", "sentiment": {"score": -0.750848, "label": "negative"}, "relevance": 0.528196, "count": 4}, {"text": "largest market share", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.52792, "count": 2}, {"text": "niche markets", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.527254, "count": 1}, {"text": "secondary data procurement methodology", "sentiment": {"score": 0.991689, "label": "positive"}, "relevance": 0.526863, "count": 1}, {"text": "anxiety", "sentiment": {"score": -0.710081, "label": "negative"}, "relevance": 0.526826, "count": 3}, {"text": "others", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526413, "count": 2}, {"text": "anxiety disorder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524243, "count": 1}, {"text": "poor efficacy", "sentiment": {"score": -0.747675, "label": "negative"}, "relevance": 0.523623, "count": 1}, {"text": "latest trends", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.523276, "count": 1}, {"text": "study period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522985, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522843, "count": 1}, {"text": "monoamine oxidase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522534, "count": 1}, {"text": "Purchase Enquiry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52136, "count": 1}]}, "extracted_metadata": {"sha1": "ce1d0b52b2d8bde21542d4ad9fb811bca71c6d45", "filename": "1542810642997.zip-8b1152aa7338d01c382618f09c5894bb.xml", "file_type": "json"}, "external_links": ["https://www.alliedmarketresearch.com/antidepressants-drugs-market", "https://www.alliedmarketresearch.com/purchase-enquiry/2593", "https://www.alliedmarketresearch.com/knowledgetree", "http://www.xmlnews.org/ns/", "https://www.alliedmarketresearch.com/checkout/394361", "https://www.alliedmarketresearch.com/immunoglobulin-market", "https://www.alliedmarketresearch.com/antibiotics-market", "https://www.alliedmarketresearch.com/request-sample/2593"], "title": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally", "forum_title": "Health Care"}, {"id": "R08TSjCU0M3C0QeyyZ9g-52uua17aN4kHrB79D71BLjkSqYxmKM--zFozb0VK2dv", "result_metadata": {"score": 33.89238}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.98", "relevance": 0.01, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.1%", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": -0.825887, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Antidepressant Drugs Market", "keywords": [{"text": "Antidepressant Drugs"}, {"text": "Market"}]}, "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "object": {"text": "$15.98 Bn", "keywords": [{"text": "Bn"}], "entities": [{"type": "Quantity", "text": "$15.98"}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "to Reach", "normalized": "to Reach"}}, {"subject": {"text": "Allied Market Research", "keywords": [{"text": "Market Research"}]}, "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "object": {"text": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR", "keywords": [{"text": "Antidepressant Drugs"}, {"text": "Bn"}, {"text": "Globally"}, {"text": "Market"}], "entities": [{"type": "Quantity", "text": "$15.98"}, {"type": "Quantity", "text": "2.1"}]}, "action": {"verb": {"text": "Says", "tense": "present"}, "text": "Says", "normalized": "Says"}}], "concepts": [{"text": "Antidepressant", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}], "categories": [{"score": 0.937842, "label": "/health and fitness"}, {"score": 0.920755, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.737627, "label": "/health and fitness/drugs"}], "relations": [{"type": "locatedAt", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "score": 0.261322, "arguments": [{"text": "Drugs", "location": [15, 20], "entities": [{"type": "Substance", "text": "Drugs"}]}, {"text": "Market", "location": [21, 27], "entities": [{"type": "Organization", "text": "Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "score": 0.633856, "arguments": [{"text": "Allied Market Research", "location": [84, 106], "entities": [{"type": "Organization", "text": "Allied Market Research"}]}, {"text": "Says", "location": [79, 83], "entities": [{"type": "EventCommunication", "text": "Says"}]}]}], "keywords": [{"text": "Antidepressant Drugs Market", "sentiment": {"score": -0.825887, "label": "negative"}, "relevance": 0.993905, "count": 1}, {"text": "Market Research", "sentiment": {"score": -0.825887, "label": "negative"}, "relevance": 0.933194, "count": 1}, {"text": "CAGR", "sentiment": {"score": -0.825887, "label": "negative"}, "relevance": 0.046361, "count": 1}]}, "crawl_date": "2018-11-21T13:31:20Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45336421-antidepressant-drugs-market-to-reach-dollar-15-98-bn-by-2023-globally-at-2-1-cagr-says-allied-market-research-008.htm", "host": "finanznachrichten.de", "text": "Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co.", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-21T13:01:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0.156494, "label": "positive"}, "text": "Allied Market Research", "relevance": 0.830113, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.23475, "label": "negative"}, "text": "depression", "relevance": 0.460452, "type": "HealthCondition"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "PORTLAND", "relevance": 0.410545, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oregon", "relevance": 0.358993, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.283595, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.261681, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allied Analytics LLP", "relevance": 0.255515, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.254434, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allergan Plc", "relevance": 0.250402, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.248354, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.245037, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc", "relevance": 0.235451, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd.", "relevance": 0.230537, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0.347629, "label": "positive"}, "text": "Bristol Myers Squibb Co.", "relevance": 0.227775, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.224881, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly and Co.", "relevance": 0.223329, "type": "Company", "disambiguation": {"subtype": [], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "H. Lundbeck", "relevance": 0.221329, "type": "Company", "disambiguation": {"subtype": [], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.220837, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.216999, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.214362, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Alkermes Plc", "relevance": 0.21148, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.23701, "label": "negative"}, "text": "Merck & Co., Inc.", "relevance": 0.194859, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.1%", "relevance": 0.194859, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$14.11 billion", "relevance": 0.194859, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.98 billion", "relevance": 0.194859, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1 month", "relevance": 0.194859, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$15.98", "relevance": 0.194859, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2023", "relevance": 0.194859, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.7%", "relevance": 0.194859, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2.9%", "relevance": 0.194859, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.0%", "relevance": 0.194859, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "40%", "relevance": 0.194859, "type": "Quantity"}], "sentiment": {"document": {"score": -0.341127, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Antidepressant Drugs Market", "keywords": [{"text": "Antidepressant Drugs"}, {"text": "Market"}]}, "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "object": {"text": "$15.98 Bn", "keywords": [{"text": "Bn"}], "entities": [{"type": "Quantity", "text": "$15.98"}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "to Reach", "normalized": "to Reach"}}, {"subject": {"text": "Allied Market Research", "keywords": [{"text": "Market Research"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "object": {"text": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR", "keywords": [{"text": "Antidepressant Drugs"}, {"text": "Bn"}, {"text": "Globally"}, {"text": "Market"}], "entities": [{"type": "Quantity", "text": "$15.98"}, {"type": "Quantity", "text": "2.1"}]}, "action": {"verb": {"text": "Says", "tense": "present"}, "text": "Says", "normalized": "Says"}}, {"subject": {"text": "PORTLAND, Oregon , November 21, 2018 /PRNewswire/ --", "keywords": [{"text": "POLAND"}, {"text": "Oregon"}, {"text": "/PRNewswire/"}], "entities": [{"type": "Location", "text": "PORTLAND", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Oregon", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}]}, "sentence": " PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market", "action": {"verb": {"text": "Increase", "tense": "present"}, "text": "Increase", "normalized": "Increase"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market", "object": {"text": "from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "novel drug"}, {"text": "emergence"}, {"text": "anxiety"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "novel drug"}, {"text": "emergence"}, {"text": "anxiety"}], "entities": [{"type": "Location", "text": "PORTLAND", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Oregon", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}, {"type": "HealthCondition", "text": "depression"}]}, "sentence": " PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market", "object": {"text": "the growth of the antidepressant drugs market", "keywords": [{"text": "antidepressant drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "are expected to boost", "normalized": "be expect to boost"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers in-depth analyses of the global antidepressant drugs market by closely analyzing the industry trends, top investment pockets, drivers & opportunities, key growth strategies, and competitive landscape.", "object": {"text": "in-depth analyses of the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}, {"text": "in-depth analyses"}, {"text": "market"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "object": {"text": "for $14.11 billion", "entities": [{"type": "Quantity", "text": "$14.11 billion"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "the global antidepressant drugs market", "keywords": [{"text": "global antidepressant drugs"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "object": {"text": "$15.98 billion by 2023", "entities": [{"type": "Quantity", "text": "$15.98 billion"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "a CAGR of 2.1%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "2.1"}]}, "sentence": " According to the report, the global antidepressant drugs market accounted for $14.11 billion in 2017 and is expected to reach $15.98 billion by 2023, registering a CAGR of 2.1% during the forecast period.", "action": {"verb": {"text": "register", "tense": "present"}, "text": "registering", "normalized": "register"}}, {"subject": {"text": "the development of drugs with fewer side-effects", "keywords": [{"text": "fewer side-effects"}, {"text": "drugs"}, {"text": "development"}]}, "sentence": " Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "drive", "normalized": "drive"}}, {"subject": {"text": "antidepressants", "keywords": [{"text": "antidepressants"}]}, "sentence": " However, poor efficacy and safety profiles of drugs, inclination toward non-pharmacological therapies, and increase in the number of patent expiration of antidepressants hamper the market growth.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "patients", "keywords": [{"text": "patients"}]}, "sentence": " On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.", "object": {"text": "from stress", "keywords": [{"text": "stress"}]}, "action": {"verb": {"text": "suffer", "tense": "present"}, "text": "suffering", "normalized": "suffer"}}, {"subject": {"text": "lucrative opportunities for the market players", "keywords": [{"text": "lucrative opportunities"}, {"text": "market players"}]}, "sentence": " On the contrary, increase in awareness regarding the disease state and rise in number of patients suffering from stress are expected to create lucrative opportunities for the market players in future.", "action": {"verb": {"text": "create", "tense": "future"}, "text": "are expected to create", "normalized": "be expect to create"}}, {"subject": {"text": "Obsessive- compulsive disorder segment", "keywords": [{"text": "Obsessive- compulsive disorder"}, {"text": "segment"}]}, "sentence": " Obsessive- compulsive disorder segment to portray fastest demand through 2023", "object": {"text": "fastest demand", "keywords": [{"text": "fastest demand"}]}, "action": {"verb": {"text": "portray", "tense": "future"}, "text": "to portray", "normalized": "to portray"}}, {"subject": {"text": "The obsessive-compulsive disorder segment", "keywords": [{"text": "obsessive-compulsive disorder segment"}]}, "sentence": " The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life.", "object": {"text": "the fastest CAGR of 2.9%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.9"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "The obsessive-compulsive disorder segment", "keywords": [{"text": "obsessive-compulsive disorder segment"}]}, "sentence": " The obsessive-compulsive disorder segment is expected to register the fastest CAGR of 2.9% during the forecast period, owing to changing lifestyle and need for better quality of life.", "object": {"text": "for better quality of life", "keywords": [{"text": "better quality"}, {"text": "life"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "need", "normalized": "need"}}, {"subject": {"text": "the major depressive disorder segment", "keywords": [{"text": "depressive disorder segment"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "the largest market share", "keywords": [{"text": "largest market share"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "majority of the patients", "keywords": [{"text": "majority"}, {"text": "patients"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "diagnosed with this disorder", "keywords": [{"text": "disorder"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "majority of the patients", "keywords": [{"text": "majority"}, {"text": "patients"}]}, "sentence": " However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "object": {"text": "with this disorder", "keywords": [{"text": "disorder"}]}, "action": {"verb": {"text": "diagnose", "tense": "past"}, "text": "are diagnosed", "normalized": "be diagnose"}}, {"subject": {"text": "The other segments", "keywords": [{"text": "segments"}]}, "sentence": " The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "generalized anxiety disorder, panic disorder, and others", "keywords": [{"text": "panic disorder"}, {"text": "anxiety disorder"}]}, "sentence": " The other segments analyzed in the report include generalized anxiety disorder, panic disorder, and others.", "object": {"text": "The other segments analyzed in the report", "keywords": [{"text": "segments"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment to lead the market by 2023", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "lead", "tense": "future"}, "text": "to lead", "normalized": "to lead"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "projected to manifest the fastest CAGR of 2.7%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.7"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Selective serotonin reuptake inhibitors segment", "keywords": [{"text": "serotonin reuptake inhibitors"}, {"text": "segment"}]}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "the fastest CAGR of 2.7%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "2.7"}]}, "action": {"verb": {"text": "manifest", "tense": "future"}, "text": "is projected to manifest", "normalized": "be project to manifest"}}, {"subject": {"text": "these"}, "sentence": " Selective serotonin reuptake inhibitors segment is projected to manifest the fastest CAGR of 2.7% during the forecast period, as these are highly effective in treat depression and anxiety due to their minimal side-effects.", "object": {"text": "highly effective in treat depression and anxiety due to their minimal side-effects", "keywords": [{"text": "minimal side-effects"}, {"text": "treat depression"}, {"text": "anxiety"}], "entities": [{"type": "HealthCondition", "text": "depression"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The other antidepressant products", "keywords": [{"text": "antidepressant products"}]}, "sentence": " The other antidepressant products analyzed in the report are tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others.", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " North America to retain the largest market share through 2023", "object": {"text": "the largest market share", "keywords": [{"text": "largest market share"}]}, "action": {"verb": {"text": "retain", "tense": "future"}, "text": "to retain", "normalized": "to retain"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region.", "object": {"text": "for the largest share", "keywords": [{"text": "largest share"}]}, "action": {"verb": {"text": "account", "tense": "past"}, "text": "accounted", "normalized": "account"}}, {"subject": {"text": "Asia-Pacific region", "keywords": [{"text": "Asia-Pacific region"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population.", "object": {"text": "the fastest CAGR of 4.0%", "keywords": [{"text": "fastest CAGR"}], "entities": [{"type": "Quantity", "text": "4.0"}]}, "action": {"verb": {"text": "portray", "tense": "future"}, "text": "is expected to portray", "normalized": "be expect to portray"}}, {"subject": {"text": "The other regions", "keywords": [{"text": "regions"}]}, "sentence": " The other regions analyzed in the report include Europe and Latin America , Middle East and Africa (LAMEA).", "action": {"verb": {"text": "analyze", "tense": "past"}, "text": "analyzed", "normalized": "analyze"}}, {"subject": {"text": "Europe and Latin America , Middle East and Africa (LAMEA)", "keywords": [{"text": "Latin America"}, {"text": "Middle East"}, {"text": "Europe"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The other regions analyzed in the report include Europe and Latin America , Middle East and Africa (LAMEA).", "object": {"text": "The other regions analyzed in the report", "keywords": [{"text": "regions"}, {"text": "report"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.", "object": {"text": "the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd", "keywords": [{"text": "Bristol Myers Squibb"}, {"text": "Allergan Plc"}, {"text": "Teva Pharmaceutical Industries"}, {"text": "GlaxoSmithKline Plc"}], "entities": [{"type": "Company", "text": "Allergan Plc"}, {"type": "Company", "text": "Eli Lilly and Co.", "disambiguation": {"subtype": ["Company"], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"type": "Company", "text": "H. Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Alkermes Plc"}, {"type": "Company", "text": "Bristol Myers Squibb Co.", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "GlaxoSmithKline Plc", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co.", "keywords": [{"text": "Teva Pharmaceutical Industries"}, {"text": "Allergan Plc"}, {"text": "H. Lundbeck"}, {"text": "Bristol Myers"}], "entities": [{"type": "Company", "text": "Allergan Plc"}, {"type": "Company", "text": "Eli Lilly and Co.", "disambiguation": {"subtype": ["Company"], "name": "Eli Lilly and Company", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}}, {"type": "Company", "text": "H. Lundbeck", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Lundbeck", "dbpedia_resource": "http://dbpedia.org/resource/Lundbeck"}}, {"type": "Company", "text": "Merck & Co., Inc."}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Alkermes Plc"}, {"type": "Company", "text": "Bristol Myers Squibb Co.", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}]}, "sentence": " The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.", "object": {"text": "the several leading players in the market", "keywords": [{"text": "players"}, {"text": "market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Knowledge tree", "keywords": [{"text": "Knowledge tree"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "a cloud-based intelligence platform that offers more than 2,000 selective", "keywords": [{"text": "cloud-based intelligence platform"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a cloud-based intelligence platform", "keywords": [{"text": "cloud-based intelligence platform"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "more than 2,000 selective, off-the-shelf reports on niche markets", "keywords": [{"text": "off-the-shelf reports"}, {"text": "niche markets"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "our clients", "keywords": [{"text": "clients"}]}, "sentence": " Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "object": {"text": "deep insights on the latest trends, dynamic technologies, and emerging application areas", "keywords": [{"text": "deep insights"}, {"text": "latest trends"}, {"text": "dynamic technologies"}, {"text": "application areas"}]}, "action": {"verb": {"text": "gain", "tense": "present"}, "text": "gain", "normalized": "gain"}}, {"subject": {"text": "Purchase", "keywords": [{"text": "Purchase"}]}, "sentence": " Purchase an enterprise user license and get 1 month complimentary access to our Knowledge Tree subscription.", "object": {"text": "complimentary access to our Knowledge Tree subscription", "keywords": [{"text": "complimentary access"}, {"text": "Knowledge Tree subscription"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "get", "normalized": "get"}}, {"subject": {"text": "Allied Market Research (AMR)", "keywords": [{"text": "Market Research"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "object": {"text": "a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon ", "keywords": [{"text": "Allied Analytics LLP"}, {"text": "full-service market research"}, {"text": "business-consulting wing"}, {"text": "Portland"}], "entities": [{"type": "Company", "text": "Allied Market Research"}, {"type": "Company", "text": "Allied Analytics LLP"}, {"type": "Location", "text": "PORTLAND", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "Portland, Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Portland,_Oregon"}}, {"type": "Location", "text": "Oregon", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "WineRegion", "StateOrCounty"], "name": "Oregon", "dbpedia_resource": "http://dbpedia.org/resource/Oregon"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a full-service market research and business-consulting wing of Allied Analytics LLP", "keywords": [{"text": "Allied Analytics LLP"}, {"text": "full-service market research"}, {"text": "business-consulting wing"}], "entities": [{"type": "Company", "text": "Allied Market Research"}, {"type": "Company", "text": "Allied Analytics LLP"}]}, "sentence": " Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "Allied Market Research", "keywords": [{"text": "Market Research"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of \"Market Research Reports\" and \"Business Intelligence Solutions.\"", "object": {"text": "global enterprises", "keywords": [{"text": "global enterprises"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "AMR", "keywords": [{"text": "AMR"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.", "object": {"text": "a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain", "keywords": [{"text": "respective market domain"}, {"text": "strategic business decisions"}, {"text": "targeted view"}, {"text": "business insights"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "AMR", "keywords": [{"text": "AMR"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.", "object": {"text": "business insights and consulting", "keywords": [{"text": "business insights"}, {"text": "consulting"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "AMR", "keywords": [{"text": "AMR"}], "entities": [{"type": "Company", "text": "Allied Market Research"}]}, "sentence": " AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.", "object": {"text": "its clients", "keywords": [{"text": "clients"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "consulting to assist", "normalized": "consult to assist"}}, {"subject": {"text": "We"}, "sentence": " We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting.", "object": {"text": "in professional corporate relations with various companies", "keywords": [{"text": "professional corporate relations"}, {"text": "various companies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "this"}, "sentence": " We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting.", "object": {"text": "us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting", "keywords": [{"text": "confirms utmost accuracy"}, {"text": "accurate research data"}, {"text": "market forecasting"}, {"text": "market data"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "us"}, "sentence": " We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting.", "object": {"text": "market data", "keywords": [{"text": "market data"}]}, "action": {"verb": {"text": "dig", "tense": "present"}, "text": "digging", "normalized": "dig"}}, {"subject": {"text": "Each and every data", "keywords": [{"text": "data"}]}, "sentence": " Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "by us"}, "sentence": " Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "object": {"text": "the reports", "keywords": [{"text": "reports"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Each and every data presented in the reports published by us", "keywords": [{"text": "data"}, {"text": "reports"}]}, "sentence": " Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "object": {"text": "extracted through primary interviews", "keywords": [{"text": "primary interviews"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Each and every data presented in the reports published by us", "keywords": [{"text": "data"}, {"text": "reports"}]}, "sentence": " Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "object": {"text": "from leading companies of domain concerned", "keywords": [{"text": "companies"}, {"text": "domain"}]}, "action": {"verb": {"text": "extract", "tense": "past"}, "text": "is extracted", "normalized": "be extract"}}], "concepts": [{"text": "Selective serotonin reuptake inhibitor", "relevance": 0.970606, "dbpedia_resource": "http://dbpedia.org/resource/Selective_serotonin_reuptake_inhibitor"}, {"text": "Tricyclic antidepressant", "relevance": 0.596594, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic_antidepressant"}, {"text": "Serotonin", "relevance": 0.577574, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin"}, {"text": "Antidepressant", "relevance": 0.533254, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressant"}, {"text": "Sertraline", "relevance": 0.4926, "dbpedia_resource": "http://dbpedia.org/resource/Sertraline"}, {"text": "Venlafaxine", "relevance": 0.424663, "dbpedia_resource": "http://dbpedia.org/resource/Venlafaxine"}, {"text": "Paroxetine", "relevance": 0.411526, "dbpedia_resource": "http://dbpedia.org/resource/Paroxetine"}, {"text": "Escitalopram", "relevance": 0.379881, "dbpedia_resource": "http://dbpedia.org/resource/Escitalopram"}, {"text": "Fluoxetine", "relevance": 0.369641, "dbpedia_resource": "http://dbpedia.org/resource/Fluoxetine"}, {"text": "Generalized anxiety disorder", "relevance": 0.334527, "dbpedia_resource": "http://dbpedia.org/resource/Generalized_anxiety_disorder"}, {"text": "Monoamine oxidase inhibitor", "relevance": 0.334424, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase_inhibitor"}, {"text": "Panic disorder", "relevance": 0.324066, "dbpedia_resource": "http://dbpedia.org/resource/Panic_disorder"}, {"text": "Citalopram", "relevance": 0.314172, "dbpedia_resource": "http://dbpedia.org/resource/Citalopram"}, {"text": "Major depressive disorder", "relevance": 0.310584, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Cognitive behavioral therapy", "relevance": 0.308406, "dbpedia_resource": "http://dbpedia.org/resource/Cognitive_behavioral_therapy"}, {"text": "Anxiety disorder", "relevance": 0.306618, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety_disorder"}, {"text": "Bupropion", "relevance": 0.302442, "dbpedia_resource": "http://dbpedia.org/resource/Bupropion"}, {"text": "Bipolar disorder", "relevance": 0.289904, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Norepinephrine reuptake inhibitor", "relevance": 0.285424, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine_reuptake_inhibitor"}, {"text": "Imipramine", "relevance": 0.281298, "dbpedia_resource": "http://dbpedia.org/resource/Imipramine"}, {"text": "Social anxiety disorder", "relevance": 0.275309, "dbpedia_resource": "http://dbpedia.org/resource/Social_anxiety_disorder"}, {"text": "Fluvoxamine", "relevance": 0.248119, "dbpedia_resource": "http://dbpedia.org/resource/Fluvoxamine"}, {"text": "Antidepressants", "relevance": 0.243768, "dbpedia_resource": "http://dbpedia.org/resource/Antidepressants"}, {"text": "Buspirone", "relevance": 0.239567, "dbpedia_resource": "http://dbpedia.org/resource/Buspirone"}, {"text": "Anxiety disorders", "relevance": 0.238012, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety_disorders"}, {"text": "Tranylcypromine", "relevance": 0.225854, "dbpedia_resource": "http://dbpedia.org/resource/Tranylcypromine"}, {"text": "Serotonin syndrome", "relevance": 0.215744, "dbpedia_resource": "http://dbpedia.org/resource/Serotonin_syndrome"}, {"text": "Mood disorder", "relevance": 0.211975, "dbpedia_resource": "http://dbpedia.org/resource/Mood_disorder"}, {"text": "Phenelzine", "relevance": 0.204217, "dbpedia_resource": "http://dbpedia.org/resource/Phenelzine"}, {"text": "Neurotic, stress-related and somatoform disorders", "relevance": 0.20116, "dbpedia_resource": "http://dbpedia.org/resource/Neurotic,_stress-related_and_somatoform_disorders"}, {"text": "Norepinephrine", "relevance": 0.20086, "dbpedia_resource": "http://dbpedia.org/resource/Norepinephrine"}, {"text": "Monoamine oxidase", "relevance": 0.196807, "dbpedia_resource": "http://dbpedia.org/resource/Monoamine_oxidase"}, {"text": "Dysthymia", "relevance": 0.189663, "dbpedia_resource": "http://dbpedia.org/resource/Dysthymia"}, {"text": "Tricyclic", "relevance": 0.189375, "dbpedia_resource": "http://dbpedia.org/resource/Tricyclic"}, {"text": "Reuptake inhibitor", "relevance": 0.18784, "dbpedia_resource": "http://dbpedia.org/resource/Reuptake_inhibitor"}, {"text": "Insomnia", "relevance": 0.182937, "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}, {"text": "Anxiety", "relevance": 0.178832, "dbpedia_resource": "http://dbpedia.org/resource/Anxiety"}, {"text": "Primary care", "relevance": 0.177364, "dbpedia_resource": "http://dbpedia.org/resource/Primary_care"}, {"text": "Abnormal psychology", "relevance": 0.175226, "dbpedia_resource": "http://dbpedia.org/resource/Abnormal_psychology"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.175128, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Trimipramine", "relevance": 0.174711, "dbpedia_resource": "http://dbpedia.org/resource/Trimipramine"}, {"text": "Alprazolam", "relevance": 0.17003, "dbpedia_resource": "http://dbpedia.org/resource/Alprazolam"}, {"text": "Economics", "relevance": 0.168639, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Bristol-Myers Squibb", "relevance": 0.168109, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Fear", "relevance": 0.165649, "dbpedia_resource": "http://dbpedia.org/resource/Fear"}, {"text": "Alcoholism", "relevance": 0.164037, "dbpedia_resource": "http://dbpedia.org/resource/Alcoholism"}, {"text": "Suicide", "relevance": 0.163502, "dbpedia_resource": "http://dbpedia.org/resource/Suicide"}, {"text": "Depression", "relevance": 0.159048, "dbpedia_resource": "http://dbpedia.org/resource/Depression_(mood)"}, {"text": "Trazodone", "relevance": 0.157883, "dbpedia_resource": "http://dbpedia.org/resource/Trazodone"}, {"text": "Duloxetine", "relevance": 0.156941, "dbpedia_resource": "http://dbpedia.org/resource/Duloxetine"}], "categories": [{"score": 0.996728, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}, {"score": 0.988712, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.913934, "label": "/health and fitness/disorders/mental disorder/bipolar disorder"}], "relations": [{"type": "hasAttribute", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.814292, "arguments": [{"text": "patients", "location": [186, 194], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "depression", "location": [210, 220], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "locatedAt", "sentence": "(*Terms and Conditions apply) Get subscription : https://www.alliedmarketresearch.com/checkout/394361 Trending Reports of Medical Devices Market: Immunoglobulin Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 Antibiotics Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "score": 0.504914, "arguments": [{"text": "Allied Analytics LLP", "location": [5204, 5224], "entities": [{"type": "Organization", "text": "Allied Analytics LLP"}]}, {"text": "Oregon", "location": [5244, 5250], "entities": [{"type": "GeopoliticalEntity", "text": "Oregon"}]}]}, {"type": "locatedAt", "sentence": "(*Terms and Conditions apply) Get subscription : https://www.alliedmarketresearch.com/checkout/394361 Trending Reports of Medical Devices Market: Immunoglobulin Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 Antibiotics Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "score": 0.95042, "arguments": [{"text": "Portland", "location": [5234, 5242], "entities": [{"type": "GeopoliticalEntity", "text": "Portland"}]}, {"text": "Oregon", "location": [5244, 5250], "entities": [{"type": "GeopoliticalEntity", "text": "Oregon"}]}]}, {"type": "partOf", "sentence": "Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of \"Market Research Reports\" and \"Business Intelligence Solutions.", "score": 0.53894, "arguments": [{"text": "businesses", "location": [5332, 5342], "entities": [{"type": "Organization", "text": "businesses", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Market Research Reports", "location": [5370, 5393], "entities": [{"type": "Organization", "text": "Market Research Reports"}]}]}, {"type": "employedBy", "sentence": "\" AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.", "score": 0.608865, "arguments": [{"text": "clients", "location": [5516, 5523], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "its", "location": [5512, 5515], "entities": [{"type": "Organization", "text": "Allied Market Research\nPORTLAND"}]}]}, {"type": "participantIn", "sentence": "Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "score": 0.682026, "arguments": [{"text": "us", "location": [5905, 5907], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "interviews", "location": [5937, 5947], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "participantIn", "sentence": "Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "score": 0.955083, "arguments": [{"text": "officials", "location": [5957, 5966], "entities": [{"type": "Person", "text": "officials"}]}, {"text": "interviews", "location": [5937, 5947], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "participantIn", "sentence": "Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned.", "score": 0.665484, "arguments": [{"text": "companies", "location": [5980, 5989], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "interviews", "location": [5937, 5947], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "participantIn", "sentence": "Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.", "score": 0.681537, "arguments": [{"text": "professionals", "location": [6130, 6143], "entities": [{"type": "Person", "text": "professionals"}]}, {"text": "discussion", "location": [6100, 6110], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "participantIn", "sentence": "Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.", "score": 0.911449, "arguments": [{"text": "analysts", "location": [6148, 6156], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "discussion", "location": [6100, 6110], "entities": [{"type": "EventMeeting", "text": "interviews"}]}]}, {"type": "residesIn", "sentence": "Contact: 5933 NE Win Sivers Drive#205, Portland, OR 97220", "score": 0.780098, "arguments": [{"text": "NE Win Sivers Drive#", "location": [6188, 6208], "entities": [{"type": "Person", "text": "NE Win Sivers Drive#"}]}, {"text": "Portland", "location": [6213, 6221], "entities": [{"type": "GeopoliticalEntity", "text": "Portland"}]}]}, {"type": "partOf", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.342671, "arguments": [{"text": "Depressive Disorder", "location": [468, 487], "entities": [{"type": "Organization", "text": "Depressive Disorder"}]}, {"text": "Antidepressant Drugs Market", "location": [437, 464], "entities": [{"type": "Organization", "text": "Antidepressant Drugs Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.863471, "arguments": [{"text": "Antagonist", "location": [772, 782], "entities": [{"type": "Person", "text": "Antagonist"}]}, {"text": "Others", "location": [812, 818], "entities": [{"type": "Person", "text": "Others"}]}]}, {"type": "partOfMany", "sentence": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research PORTLAND, Oregon , November 21, 2018 /PRNewswire/ -- Increase in the number of patients suffering from depression , stress , and anxiety coupled with emergence of novel drug s with fewer side-effects are expected to boost the growth of the antidepressant drugs market Allied Market Research recently published a report, titled, \" Antidepressant Drugs Market by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Others) and Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, and Others) : Global Opportunity Analysis and Industry Forecast, 2017-2023 \" .", "score": 0.857429, "arguments": [{"text": "Reuptake Inhibitors", "location": [787, 806], "entities": [{"type": "Person", "text": "Reuptake Inhibitors"}]}, {"text": "Others", "location": [812, 818], "entities": [{"type": "Person", "text": "Others"}]}]}, {"type": "hasAttribute", "sentence": "(Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg ) Increased global disease burden of depression, rise in geriatric population, and emergence of innovative techniques for the development of drugs with fewer side-effects drive the growth of the market.", "score": 0.786356, "arguments": [{"text": "population", "location": [1457, 1467], "entities": [{"type": "Person", "text": "population"}]}, {"text": "depression", "location": [1427, 1437], "entities": [{"type": "HealthCondition", "text": "depression"}]}]}, {"type": "partOfMany", "sentence": "However, the major depressive disorder segment held the largest market share in 2017, contributing about 40% of the total revenue, as majority of the patients are diagnosed with this disorder due to high stress levels.", "score": 0.978264, "arguments": [{"text": "majority", "location": [2469, 2477], "entities": [{"type": "Cardinal", "text": "majority"}]}, {"text": "patients", "location": [2485, 2493], "entities": [{"type": "Person", "text": "patients"}]}]}, {"type": "residesIn", "sentence": "For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/2593 North America to retain the largest market share through 2023 North America accounted for the largest share in the market, contributing more than half of the total revenue, owing to increase in incidence of disorders such as stress, suicidal feelings, serious psychological disorders, and anxiety among the adult population in the region.", "score": 0.77241, "arguments": [{"text": "population", "location": [3576, 3586], "entities": [{"type": "Person", "text": "population"}]}, {"text": "region", "location": [3594, 3600], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "residesIn", "sentence": "However, Asia-Pacific region is expected to portray the fastest CAGR of 4.0% during the study period, owing to the increase in marketing approval for new medicines in the region and presence of large pool of geriatric population.", "score": 0.571592, "arguments": [{"text": "population", "location": [3820, 3830], "entities": [{"type": "Person", "text": "population"}]}, {"text": "region", "location": [3773, 3779], "entities": [{"type": "GeopoliticalEntity", "text": "CAGR of"}]}]}, {"type": "employedBy", "sentence": "Torchbearers of the market The report analyzes the several leading players in the market, which include Allergan Plc, Eli Lilly and Co., H. Lundbeck, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Alkermes Plc, Bristol Myers Squibb Co., GlaxoSmithKline Plc, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.", "score": 0.657339, "arguments": [{"text": "clients", "location": [4532, 4539], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "our", "location": [4528, 4531], "entities": [{"type": "Organization", "text": "Asia-Pacific region"}]}]}, {"type": "basedIn", "sentence": "(*Terms and Conditions apply) Get subscription : https://www.alliedmarketresearch.com/checkout/394361 Trending Reports of Medical Devices Market: Immunoglobulin Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 Antibiotics Market - Global Opportunity Analysis and Industry Forecast, 2018 - 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon .", "score": 0.766956, "arguments": [{"text": "Allied Analytics LLP", "location": [5204, 5224], "entities": [{"type": "Organization", "text": "Allied Analytics LLP"}]}, {"text": "Portland", "location": [5234, 5242], "entities": [{"type": "GeopoliticalEntity", "text": "Portland"}]}]}], "keywords": [{"text": "Antidepressant Drugs Market", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.762423, "count": 2}, {"text": "Depressive Disorder", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.670377, "count": 1}, {"text": "Market Research", "sentiment": {"score": -0.529012, "mixed": "1", "label": "negative"}, "relevance": 0.668929, "count": 3}, {"text": "Selective Serotonin Reuptake Inhibitors", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.652503, "count": 1}, {"text": "growth of the antidepressant drugs market", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.624263, "count": 1}, {"text": "Major Depressive Disorder", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.597519, "count": 1}, {"text": "Obsessive-Compulsive Disorder", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.580194, "count": 1}, {"text": "report", "sentiment": {"score": -0.792039, "label": "negative"}, "relevance": 0.576835, "count": 6}, {"text": "market data", "sentiment": {"score": 0.998435, "label": "positive"}, "relevance": 0.562561, "count": 1}, {"text": "report offers", "sentiment": {"score": -0.437462, "label": "negative"}, "relevance": 0.561936, "count": 1}, {"text": "wing of Allied Analytics LLP", "sentiment": {"score": 0.359503, "mixed": "1", "label": "positive"}, "relevance": 0.560105, "count": 1}, {"text": "Generalized Anxiety Disorder", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.557335, "count": 1}, {"text": "Global Opportunity Analysis", "sentiment": {"score": -0.834936, "label": "negative"}, "relevance": 0.555344, "count": 3}, {"text": "Monoamine Oxidase Inhibitors", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.550099, "count": 1}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548174, "count": 1}, {"text": "Serotonin-Norepinephrine Reuptake Inhibitors", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.544941, "count": 1}, {"text": "total revenue", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.54413, "count": 1}, {"text": "Panic Disorder", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.543954, "count": 1}, {"text": "Selective serotonin reuptake inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543665, "count": 1}, {"text": "Tricyclic Antidepressants", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.542475, "count": 1}, {"text": "enterprise user license", "sentiment": {"score": 0.697558, "label": "positive"}, "relevance": 0.540647, "count": 1}, {"text": "Others", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.540608, "count": 2}, {"text": "small businesses", "sentiment": {"score": 0.742034, "label": "positive"}, "relevance": 0.538987, "count": 1}, {"text": "various companies", "sentiment": {"score": 0.998435, "label": "positive"}, "relevance": 0.537873, "count": 1}, {"text": "Access KNOWLEDGE TREE", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.535973, "count": 1}, {"text": "compulsive disorder segment", "sentiment": {"score": -0.882245, "label": "negative"}, "relevance": 0.535655, "count": 1}, {"text": "professional corporate relations", "sentiment": {"score": 0.998435, "label": "positive"}, "relevance": 0.535539, "count": 1}, {"text": "business", "sentiment": {"score": -0.749271, "label": "negative"}, "relevance": 0.534981, "count": 1}, {"text": "Reuptake Inhibitors", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.534755, "count": 1}, {"text": "Asia-Pacific region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534328, "count": 1}, {"text": "AMR", "sentiment": {"score": 0.579018, "mixed": "1", "label": "positive"}, "relevance": 0.532592, "count": 2}, {"text": "data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531865, "count": 1}, {"text": "side-effects", "sentiment": {"score": -0.921248, "label": "negative"}, "relevance": 0.529765, "count": 2}, {"text": "anxiety", "sentiment": {"score": -0.861156, "label": "negative"}, "relevance": 0.527663, "count": 3}, {"text": "accurate research data tables", "sentiment": {"score": 0.998435, "label": "positive"}, "relevance": 0.527449, "count": 1}, {"text": "others", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527105, "count": 2}, {"text": "global antidepressant drugs market", "sentiment": {"score": -0.559456, "label": "negative"}, "relevance": 0.526772, "count": 1}, {"text": "niche markets", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.526592, "count": 1}, {"text": "market", "sentiment": {"score": -0.750848, "label": "negative"}, "relevance": 0.526273, "count": 4}, {"text": "emergence of novel drug s", "sentiment": {"score": -0.952093, "label": "negative"}, "relevance": 0.525762, "count": 1}, {"text": "anxiety disorder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524906, "count": 1}, {"text": "full-service market research", "sentiment": {"score": -0.749271, "label": "negative"}, "relevance": 0.52463, "count": 1}, {"text": "largest market share", "sentiment": {"score": -0.959746, "label": "negative"}, "relevance": 0.523821, "count": 2}, {"text": "latest trends", "sentiment": {"score": 0.975831, "label": "positive"}, "relevance": 0.523433, "count": 1}, {"text": "secondary data procurement methodology", "sentiment": {"score": 0.991689, "label": "positive"}, "relevance": 0.523049, "count": 1}, {"text": "monoamine oxidase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522853, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52277, "count": 1}, {"text": "study period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521363, "count": 1}, {"text": "Purchase Enquiry", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521307, "count": 1}, {"text": "panic disorder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520888, "count": 1}]}, "extracted_metadata": {"sha1": "276ed304405837a02943c191d405fe527e2ce610", "filename": "1542807080224.zip-a432830a206122d4a4c8f0c233971185.xml", "file_type": "json"}, "external_links": ["https://www.alliedmarketresearch.com/knowledgetree", "https://www.alliedmarketresearch.com/purchase-enquiry/2593", "https://www.alliedmarketresearch.com/request-sample/2593", "https://www.alliedmarketresearch.com/checkout/394361"], "title": "Antidepressant Drugs Market to Reach $15.98 Bn by 2023, Globally at 2.1% CAGR, Says Allied Market Research", "forum_title": "FinanzNachrichten.de: News"}, {"id": "JTyMdwLopZBEpuOEmXOQZKvrpUfFsREqNNnyJCgSqvxoK_KK4bNq2JUi_6ZFU1e-", "result_metadata": {"score": 33.757027}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.33, "type": "Organization"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Takeda's proposed takeover of Shire", "keywords": [{"text": "Takeda"}, {"text": "takeover"}, {"text": "Shire"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "Shire"}]}, "sentence": "Takeda's proposed takeover of Shire receives conditional EU clearance", "object": {"text": "conditional EU clearance", "keywords": [{"text": "conditional EU clearance"}], "entities": [{"type": "Organization", "text": "EU"}]}, "action": {"verb": {"text": "receive", "tense": "present"}, "text": "receives", "normalized": "receive"}}], "concepts": [{"text": "Scottish Gaelic", "relevance": 0.859165, "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Gaelic"}], "categories": [{"score": 0.63005, "label": "/law, govt and politics"}, {"score": 0.595452, "label": "/law, govt and politics/immigration"}, {"score": 0.560092, "label": "/finance/financial news"}], "relations": [{"type": "affectedBy", "sentence": "Takeda's proposed takeover of Shire receives conditional EU clearance", "score": 0.449973, "arguments": [{"text": "Takeda", "location": [0, 6], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "takeover", "location": [18, 26], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}, {"type": "employedBy", "sentence": "Takeda's proposed takeover of Shire receives conditional EU clearance", "score": 0.538786, "arguments": [{"text": "Takeda", "location": [0, 6], "entities": [{"type": "Person", "text": "Takeda"}]}, {"text": "Shire", "location": [30, 35], "entities": [{"type": "Organization", "text": "Shire", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Takeda's proposed takeover of Shire receives conditional EU clearance", "score": 0.388145, "arguments": [{"text": "Shire", "location": [30, 35], "entities": [{"type": "Organization", "text": "Shire", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "takeover", "location": [18, 26], "entities": [{"type": "EventPersonnel", "text": "takeover"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.989818, "count": 1}, {"text": "takeover of Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.690587, "count": 1}, {"text": "conditional EU clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261527, "count": 1}]}, "crawl_date": "2018-11-20T16:41:36Z", "url": "https://www.proactiveinvestors.co.uk/companies/news/209603/takeda-s-proposed-takeover-of-shire-receives-conditional-eu-clearance-209603.html", "host": "proactiveinvestors.co.uk", "text": "The acquisition is expected to be completed on January 8, subject to shareholder approval The US, Japan, China and Brazil have already approved the deal The proposed takeover of Shire PLC ( LON:SHP ) by Japan\u2019s Takeda Pharmaceutical Company Ltd has received conditional clearance from the European Commission.", "main_image_url": "https://www.proactiveinvestors.co.uk/thumbs/upload/Article/Image/2018_11/757x468_1542727265_shire.jpg", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-20T15:16:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.866543, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd", "relevance": 0.670065, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.208431, "label": "positive"}, "text": "Japan", "relevance": 0.545321, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 5, "sentiment": {"score": 0.539447, "label": "positive"}, "text": "US", "relevance": 0.455992, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.444439, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "EU", "relevance": 0.404437, "type": "Organization", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}, {"count": 2, "sentiment": {"score": 0.427802, "label": "positive"}, "text": "Brazil", "relevance": 0.354451, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.341705, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": 0.427802, "label": "positive"}, "text": "China", "relevance": 0.319398, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Commission", "relevance": 0.261658, "type": "Organization"}], "sentiment": {"document": {"score": 0.655608, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": "The acquisition is expected to be completed on January 8, subject to shareholder approval The US, Japan, China and Brazil have already approved the deal", "object": {"text": "completed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "China and Brazil", "keywords": [{"text": "Brazil"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": "The acquisition is expected to be completed on January 8, subject to shareholder approval The US, Japan, China and Brazil have already approved the deal", "object": {"text": "the deal", "keywords": [{"text": "deal"}], "entities": []}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "Japan\u2019s Takeda Pharmaceutical Company Ltd", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " The proposed takeover of Shire PLC ( LON:SHP ) by Japan\u2019s Takeda Pharmaceutical Company Ltd has received conditional clearance from the European Commission.", "object": {"text": "received conditional clearance from the European Commission", "keywords": [{"text": "conditional clearance"}, {"text": "European Commission"}], "entities": [{"type": "Organization", "text": "European Commission"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "SHP ) by Japan\u2019s Takeda Pharmaceutical Company Ltd", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "SHP"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd"}]}, "sentence": " The proposed takeover of Shire PLC ( LON:SHP ) by Japan\u2019s Takeda Pharmaceutical Company Ltd has received conditional clearance from the European Commission.", "object": {"text": "conditional clearance", "keywords": [{"text": "conditional clearance"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "has received", "normalized": "have receive"}}, {"subject": {"text": "The companies", "keywords": [{"text": "companies"}]}, "sentence": " The companies have agreed to sell SHP647 \u2013 an inflammatory bowel disease treatment Shire is developing \u2013 along with some associated rights to help ease concerns about an overlap in similar drugs, including Takeda\u2019s biggest-seller Entyvio.", "object": {"text": "to sell SHP647 \u2013 an inflammatory bowel disease treatment Shire", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "treatment Shire"}]}, "action": {"verb": {"text": "agree", "tense": "past"}, "text": "agreed", "normalized": "agree"}}, {"subject": {"text": "The companies", "keywords": [{"text": "companies"}]}, "sentence": " The companies have agreed to sell SHP647 \u2013 an inflammatory bowel disease treatment Shire is developing \u2013 along with some associated rights to help ease concerns about an overlap in similar drugs, including Takeda\u2019s biggest-seller Entyvio.", "object": {"text": "SHP647 \u2013"}, "action": {"verb": {"text": "sell", "tense": "future"}, "text": "have agreed to sell", "normalized": "have agree to sell"}}, {"subject": {"text": "an inflammatory bowel disease treatment Shire", "keywords": [{"text": "inflammatory bowel disease"}, {"text": "treatment Shire"}]}, "sentence": " The companies have agreed to sell SHP647 \u2013 an inflammatory bowel disease treatment Shire is developing \u2013 along with some associated rights to help ease concerns about an overlap in similar drugs, including Takeda\u2019s biggest-seller Entyvio.", "object": {"text": "\u2013"}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "is developing", "normalized": "be develop"}}, {"subject": {"text": "Takeda\u2019s biggest-seller Entyvio", "keywords": [{"text": "Takeda"}, {"text": "biggest-seller Entyvio"}]}, "sentence": " The companies have agreed to sell SHP647 \u2013 an inflammatory bowel disease treatment Shire is developing \u2013 along with some associated rights to help ease concerns about an overlap in similar drugs, including Takeda\u2019s biggest-seller Entyvio.", "object": {"text": "similar drugs", "keywords": [{"text": "similar drugs"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " READ: Takeda proposes sale of Shire drug to gain EU clearance for US$62bn merger", "object": {"text": "sale of Shire drug to gain EU clearance for US$62bn merger", "keywords": [{"text": "EU clearance"}, {"text": "Shire drug"}, {"text": "merger"}, {"text": "sale"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "propose", "tense": "present"}, "text": "proposes", "normalized": "propose"}}, {"subject": {"text": "the divestment", "keywords": [{"text": "divestment"}]}, "sentence": " However, the divestment is not a condition to completing the deal.", "object": {"text": "not a condition", "keywords": [{"text": "condition"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The sale of the drug", "keywords": [{"text": "sale"}, {"text": "drug"}]}, "sentence": " The sale of the drug was proposed by Takeda in talks with the EU, as announced in October.", "object": {"text": "proposed by Takeda in talks with the EU", "keywords": [{"text": "Takeda"}, {"text": "EU"}, {"text": "talks"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Organization", "text": "EU", "disambiguation": {"subtype": ["Location", "Country", "GovernmentalJurisdiction", "MembershipOrganization", "AwardWinner"], "name": "European Union", "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " The sale of the drug was proposed by Takeda in talks with the EU, as announced in October.", "object": {"text": "The sale of the drug", "keywords": [{"text": "sale"}, {"text": "drug"}]}, "action": {"verb": {"text": "propose", "tense": "past"}, "text": "was proposed", "normalized": "be propose"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the US, Japan, China and Brazil for the US$62bn deal to buy the British drugmaker.", "object": {"text": "already secured unconditional clearance from regulators in the US, Japan, China and Brazil", "keywords": [{"text": "unconditional clearance"}, {"text": "regulators"}, {"text": "Brazil"}, {"text": "Japan"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the US, Japan, China and Brazil for the US$62bn deal to buy the British drugmaker.", "object": {"text": "unconditional clearance", "keywords": [{"text": "unconditional clearance"}]}, "action": {"verb": {"text": "secure", "tense": "past"}, "text": "secured", "normalized": "secure"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda has already secured unconditional clearance from regulators in the US, Japan, China and Brazil for the US$62bn deal to buy the British drugmaker.", "object": {"text": "the British drugmaker", "keywords": [{"text": "British drugmaker"}]}, "action": {"verb": {"text": "buy", "tense": "future"}, "text": "to buy", "normalized": "to buy"}}, {"subject": {"text": "The acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " The acquisition is expected to be completed on January 8, subject to shareholder approval.", "action": {"verb": {"text": "complete", "tense": "past"}, "text": "is expected to be completed", "normalized": "be expect to be complete"}}], "concepts": [{"text": "European Union", "relevance": 0.977284, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "European Commission", "relevance": 0.608538, "dbpedia_resource": "http://dbpedia.org/resource/European_Commission"}, {"text": "German language", "relevance": 0.550989, "dbpedia_resource": "http://dbpedia.org/resource/German_language"}, {"text": "Brussels", "relevance": 0.498459, "dbpedia_resource": "http://dbpedia.org/resource/Brussels"}, {"text": "European Council", "relevance": 0.497167, "dbpedia_resource": "http://dbpedia.org/resource/European_Council"}, {"text": "European Parliament", "relevance": 0.483851, "dbpedia_resource": "http://dbpedia.org/resource/European_Parliament"}, {"text": "European Coal and Steel Community", "relevance": 0.477984, "dbpedia_resource": "http://dbpedia.org/resource/European_Coal_and_Steel_Community"}], "categories": [{"score": 0.919653, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.74627, "label": "/health and fitness"}, {"score": 0.64647, "label": "/finance/financial news"}], "relations": [{"type": "timeOf", "sentence": "The acquisition is expected to be completed on January 8, subject to shareholder approval The US, Japan, China and Brazil have already approved the deal The proposed takeover of Shire PLC ( LON:SHP ) by Japan's Takeda Pharmaceutical Company Ltd has received conditional clearance from the European Commission.", "score": 0.613893, "arguments": [{"text": "January 8", "location": [47, 56], "entities": [{"type": "Date", "text": "January 8"}]}, {"text": "acquisition", "location": [4, 15], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "basedIn", "sentence": "Takeda has already secured unconditional clearance from regulators in the US, Japan, China and Brazil for the US$62bn deal to buy the British drugmaker.", "score": 0.980778, "arguments": [{"text": "drugmaker", "location": [930, 939], "entities": [{"type": "Organization", "text": "drugmaker", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "British", "location": [922, 929], "entities": [{"type": "GeopoliticalEntity", "text": "British", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "The acquisition is expected to be completed on January 8, subject to shareholder approval.", "score": 0.593072, "arguments": [{"text": "January 8", "location": [988, 997], "entities": [{"type": "Date", "text": "January 8"}]}, {"text": "acquisition", "location": [945, 956], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "The acquisition is expected to be completed on January 8, subject to shareholder approval The US, Japan, China and Brazil have already approved the deal The proposed takeover of Shire PLC ( LON:SHP ) by Japan's Takeda Pharmaceutical Company Ltd has received conditional clearance from the European Commission.", "score": 0.7907, "arguments": [{"text": "Takeda Pharmaceutical Company Ltd", "location": [211, 244], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [203, 208], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "READ: Takeda proposes sale of Shire drug to gain EU clearance for US$62bn merger However, the divestment is not a condition to completing the deal.", "score": 0.466669, "arguments": [{"text": "US$62bn", "location": [615, 622], "entities": [{"type": "Person", "text": "US$62bn"}]}, {"text": "merger", "location": [623, 629], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "The sale of the drug was proposed by Takeda in talks with the EU, as announced in October.", "score": 0.558584, "arguments": [{"text": "Takeda", "location": [734, 740], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "sale", "location": [701, 705], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "The sale of the drug was proposed by Takeda in talks with the EU, as announced in October.", "score": 0.494392, "arguments": [{"text": "October", "location": [779, 786], "entities": [{"type": "Date", "text": "October"}]}, {"text": "sale", "location": [701, 705], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "participantIn", "sentence": "The sale of the drug was proposed by Takeda in talks with the EU, as announced in October.", "score": 0.599331, "arguments": [{"text": "Takeda", "location": [734, 740], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "talks", "location": [744, 749], "entities": [{"type": "EventMeeting", "text": "talks"}]}]}, {"type": "participantIn", "sentence": "The sale of the drug was proposed by Takeda in talks with the EU, as announced in October.", "score": 0.475369, "arguments": [{"text": "EU", "location": [759, 761], "entities": [{"type": "GeopoliticalEntity", "text": "EU", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "talks", "location": [744, 749], "entities": [{"type": "EventMeeting", "text": "talks"}]}]}, {"type": "timeOf", "sentence": "The sale of the drug was proposed by Takeda in talks with the EU, as announced in October.", "score": 0.888351, "arguments": [{"text": "October", "location": [779, 786], "entities": [{"type": "Date", "text": "October"}]}, {"text": "announced", "location": [766, 775], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "clientOf", "sentence": "Takeda has already secured unconditional clearance from regulators in the US, Japan, China and Brazil for the US$62bn deal to buy the British drugmaker.", "score": 0.285355, "arguments": [{"text": "regulators", "location": [844, 854], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "Takeda", "location": [788, 794], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Japan\u2019s Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.89579, "count": 1}, {"text": "takeover of Shire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.734256, "count": 1}, {"text": "inflammatory bowel disease treatment Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.684404, "count": 1}, {"text": "sale of Shire drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.682254, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.669263, "count": 3}, {"text": "similar drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.66718, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.66591, "count": 1}, {"text": "Takeda\u2019s biggest-seller Entyvio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.64656, "count": 1}, {"text": "SHP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.642928, "count": 1}, {"text": "Japan", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.608281, "count": 2}, {"text": "acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585094, "count": 2}, {"text": "LON", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569992, "count": 1}, {"text": "rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565089, "count": 1}, {"text": "overlap", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563914, "count": 1}, {"text": "US", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.560454, "count": 4}, {"text": "concerns", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558922, "count": 1}, {"text": "sale of the drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539172, "count": 1}, {"text": "European Commission", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538412, "count": 1}, {"text": "divestment", "sentiment": {"score": 0.62049, "label": "positive"}, "relevance": 0.537592, "count": 1}, {"text": "China", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.531703, "count": 2}, {"text": "regulators", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.529662, "count": 1}, {"text": "Brazil", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.528753, "count": 2}, {"text": "SHP647", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528459, "count": 1}, {"text": "deal", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.521812, "count": 3}, {"text": "talks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520886, "count": 1}, {"text": "condition", "sentiment": {"score": 0.62049, "label": "positive"}, "relevance": 0.520347, "count": 1}, {"text": "October", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.512242, "count": 1}, {"text": "merger", "sentiment": {"score": 0.62049, "label": "positive"}, "relevance": 0.512242, "count": 1}, {"text": "conditional clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.480331, "count": 1}, {"text": "shareholder approval", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470214, "count": 2}, {"text": "unconditional clearance", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.453998, "count": 1}, {"text": "EU clearance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452028, "count": 1}, {"text": "Top stories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433362, "count": 1}, {"text": "British drugmaker", "sentiment": {"score": 0.687222, "label": "positive"}, "relevance": 0.42063, "count": 1}, {"text": "January", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.418749, "count": 2}, {"text": "EU", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.409737, "count": 1}]}, "extracted_metadata": {"sha1": "4e30bff00fdfe91e6dd808ad54102e38cfb9cca2", "filename": "1542732096708.zip-c5bcf3636456dadc7ff2ac8c3fc3835e.xml", "file_type": "json"}, "title": "Takeda's proposed takeover of Shire receives conditional EU clearance", "forum_title": "Proactiveinvestors United Kingdom Companies"}]}